var title_f36_62_37856="Stool sample 3";
var content_f36_62_37856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stool sample 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37856=[""].join("\n");
var outline_f36_62_37856=null;
var title_f36_62_37857="Benign tumor of femoral neck";
var content_f36_62_37857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bone tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 372px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF0AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5c3O9wV8wjLYyTx1rQfR71JCplTPtIaypP9a/+8a61GL28Dt1eMEn8KAMQaVeHP71OP8AbNT/ANg6htDebHg/9ND/AIVqJzntWnZsZYiO44oA5l9A1BMZlj5/6aH/AApk2iX8ShmkTB9HP+Fdmy7k55qKdPNgZQPmAoA4z+y7zGfMX/vs1LBod/OPkmj/ABkP+FaiswYA/SpoJTGcqcUAZf8Awjmo4J82LA/6aH/Cj/hHNRwD50X/AH8P+FdPb3AcCpHkUsBwKAOS/wCEd1HBPmR4H/TQ/wCFM/sLUP8Anon/AH2f8K6xpsKRnIPpSFieBQByD6ReocGRf++zUY0277SL/wB9mutmQYas9gEI+tAGD/Z91n/WL/32acumXjZxIvH+2a2VUNnjvT87E2+tAGF/Zt3n/Wr/AN9mj+zbz/nov/fZrbxuOQOBQTk4oAyIdIvZn2LKgOM8uanPh7UevnRf9/D/AIVvaX80jcfdGK0MZjyfrQByX/CO6jtB82Ln/pof8KT/AIR7UcA+bFz/ANND/hXYLzGoFDcgL60Ach/wjmpY/wBbF/38P+FOTw1qTqSJYse8h/wrrsgKc9hUqZEYGetAHIp4T1RxkT24+sp/wpx8I6oELfaLbA/6an/Cuzt3DuEJwKW4dI1Zs8CgDiD4V1QAnzoP+/h/wpG8LampwZoP+/h/wq/d+KVheREt2Lg4BJwKrDxbK7ZmgU/7poAgPhjUh/y3g/7+H/CkHhnUv+e8H/fw/wCFRTeJLx3cpsCnpkdKR9d1BrcIODnO4L1oAtL4U1RmAE0GT/01P+FTN4L1lSB5kBzyMSnn9KzBrWqMCVdjxjISrlr4h16LZIHlkROMMtAEo8HaxyS8SgdSZDx+lVv+Eb1HnE0Rx6SH/Cu30nWb2/0tnuY9hfjGMZqGDb5pUH60AcOuiX5dk8xAR1y5qQeH9RYcSxf9/D/hXXzxqJyQOppEwMg9etAHIr4e1FgcSxcf9ND/AIUf8I/qH/PWL/v4f8K64cSHjrQoAbBHbNAHI/8ACPaj/wA9Yv8Av4f8Kjk0S/jVmMiYXg4c/wCFdnnk5HFRsofcpHDdaAOJXTbtuPNUfVzU39i33/PaP/v4f8K1JE2yMnTBqVZTtYCgDDbSb1esqf8AfZpn9m3f/PRf++zW4xLN1oIBX3oAwxpt2c4kX/vs0v8AZl5j/WL/AN9mtbJUZHepVbpx2oAw/wCzbv8A56L/AN9ml/sy8/56L/32a2ieefTFOxwcHtQBgnTrsf8ALRf++zTv7MvP+ei/99mtnHHNOBy3A4oAxP7MvP8Anov/AH2acuk3jHHmoPq5rZ2ksTmlzwMmgDJOiXwIHnRc+kh/wpj6ReoSDLH+Dn/CtoSN0zSOxZgB+NAGMukXp/5ap/32asDw7qJAPmxf9/D/AIVvaem+U5H3a0sAvkUAcf8A8I5qX/PWL/v4f8KP+Ed1H/nrF/38P+FdgxOwmo1b5CeuKAONbRb5c5lTjr85/wAKi/sy8xnzF/77NdM8gDEHvVYDOfSgDEXSrwxSyeYu2NSzfOelZhkf++3512b4TSb9v+mRFcUaAJIpH81PnbqO9FNi/wBan+8KKACT/Wv9TXXxYOnWbf8ATECuQl/1r/U102lOZdHh9Y2Kn2oAsR8uPWrenv8AvCPU4qoVwQynkVJEfLG73oA2gcNjt1qOUlXVux60ROJEU98c0sgBRlP4UAZd5EI5s/wnkGqsY5JzkZrUG3YI5+SOhqN7PaTtPXmgCpFJjgcYpWlcnGalWxfP402a2kjOSOO9AEayNyc9KmE7EgdutVgw/MU0E44oAsG5Y8VXkO4ZPWgnDZ96Mbj15oAltkDjBOCadcIqrx1zioUOwiiSQtzQAKR0FMHBp4IBzTerYFAF/SfvSemKvu2cjpmqGl4xJzwDV+QjCkeuaAJORGPXpTMbuvUU7cWPFBHAHc0AN25yfepbKVWuWhlOAOlIq/w54rMvmaG9LKeQARQBs20LPd4PyqM8+1aBtIJTJidcAce9Z2lXYuQCT+8TOR6iiZtk+wcEdaAGPp8BYF44yfUjNV5tIsHkJMMe76UshbaCrE4OKcxwu/260ANXT7FTgxICO20VKkVsrYKDB6cVHMQzAr028/WmzJ+5iY9etAFhY7dJdm0Yz6VIHtw0gKDgdKosuZAc8gc03J8pZPfaaANV9QjZ1jSIKvQCnGC2UI6S/M55X0NULWPfOsknCR8t+FUL+8Z5GMfyqTwBQBoXTKLlVRg2eeKYOSCe9ZdpJ/pCls8cVpqflX0oAc5HymlYkj/dox8pyaC3yk4oAQfw5ofAYEUEHoKONgJ7UAZuqQFW3qOO5qkpxgVs3ieZbyY9MisVFBUGgAPBFOUU0g0pyAM0AAAD4PalHBJHehTwSaXsMUAIBkDihRzyetCnPTtSnsewoARulCfKBz1ppJIGOlKVyARQAufmpD97ntTlwvB5IpOrcdKAE75p6sFJ45pApOSelKkZlk2qOpFAGlpygKzZ5NXI87cnvUTLsRY0wD61LECAFPagBScZWq7nbCxFSvyXb0FV7s7LYZPU0AUJl3EEdai3FRjHWnTtgL1zTEPzfN0zQAt9JjQLtjxnCj86489a6zXyIdDCD/lpMMfQc1ydADov9an+8KKIv9an+8KKACX/AFr/AO8a3PDLl0urfPJXeB9OtYcv+tf/AHjV/wAPTeVqsGTgOSh/GgDe+7kn/wDVTs8UrptldWFIVAIHXigCzYTBXKnoa0SdwA7VkRnJOePSrdncEIA5zg0AF1xxVdJHRWGSfStCQRvkEDkZqrLCoTKmgAtrliQHyTV2aGaW3YrGc9BxWp4a0uO4tmuXUHZzUl5qAgzsUfL2oA4x4yrYYEGmKMNiumje1v5AsyhGPQ1n6jpL2zFl5Q9KAMpjge4oAwfrQUO75hyKTOMmgBx+/ijGfpmmM/PHen5AUKD9aAEP3/btQB3pDyOaACBweKALdgGIO3vWmR1HoKo6dhVz/tZrRHOWPfigBp+RQfWnggkDvjNRT5PA6CnqMMpoAepJPToKzL0b7wg+laCt8zD3rPn+e9fB4AoALeQ27+bGCGWuh1hA9vBfIMLOo6evesOOIspCfMXFdO8P2fwrbwzYLgFhntQBzTy+WCFGSTUkR8y2CHhhk0MgKM56cU4Y8tQg+bp+FAEA3NCFXgsSfwpzSHyhnn5jipApT/gIpJEH3R9aAI9xMIYfeXrSbj9l2/7WacpUQlOm4Zp9ugfO7gYoAtXbCDRYpT1nb9BWHO4diQMV0EyreaU0a/egO5R7VzmCkh3jAJxQAsXBOPrWtAMwisl4WRWAOQOQfatSzOYEz1xQBL/CRQn+r96c39KSMcD8qAFJxnH40ijOPTGaU/KpIpobKA+lAC53DkdawJQEmdR2Nb8fzj6ViXyf6XJt6ZoAib5j+NOYZIzTVzup56DNAEbA8gU4Zx70p68dKADigADfLgetDfdNL39qQj5aAGqOOelOPQEdKTqDjvRnacigAYcmgYBUH1oBOT70+CJpJlIBIoA1Vt4zEoxToYFhbKY6VLlVUZ7CqjXGScdKAJoSZJi3pU5kwCe+ahh2quR6UpGOe5oARnzJtH1NV9ROdiL0qyUAyxqm58y4yOgGKAKc+NwXvTRhiqjrmlkYl2NSWEZln56LzQBm+L5QDa2wP3F3n6mubq/rVx9q1KeTqN20fQcVQoAfF/rU/wB4UURf61P94UUAEv8ArX/3jSwOY5kcdVYN+VJL/rX/AN400daAO4viryK69JFDD8ahjyWAxkgUyybz9FtXz8yAofwNSREq4ORmgAUZUsTwO1EZyGApjZzjuaVDsGO5oAkSVlOT2p/n5PA4PFQMOgJ/CnRkmZAPWgDvfDsq2+hMCfmbOBXKXjsXfryc81egu3j+QHgDpSMkd2HKnD+lAGIrMXXGQR3rotLuDewG1m5dRlTWTJEYhtcYY1HbzNBfRzAkAHmgB2oWxySn3gcGsro2D24NdVfBTcFlHDANWBqEJjmLKOG5oAp4yvHrShf3hozgY7A0o4Oe9ADTy30o6ijOT6UvUcdaANOxQGHJq2GwpDVFY8WqDHJqRlyMd6AHkBvxpW5Ix25FNwQAO/eng7gB7UARoMyt9Kozja07/RRWgBhmPoKoalkRKB1ds0AamlW6xW6TvyvetbUZRe2yqpwgUDFYujzs1v5ZPTsa0knCRhVQE80AVWjZcxKm5SBTFtJll6DANaKzncCigMRg1Ve6LF+xoAjNpIXH3SG68+9LJZSfNtxyevtT1ZsDk0vnNng8UAVZ7ZoxEu3gY5ppiKqyKuC2AKvefufnntg095FIQMoO3vQBV01vst0WkHyY2kHvUOraclwzPZnpyRV+Qwu4JTgdqvRXlvDbiNYgM/eY0AcXESQsbcFDtOavWRPlFf7pxmq10FGoyFTlH4NTWashZe+c0AWs7k9xSqfmPtThjpiozncD2HWgBsjHmmWuTuyeDUk3zD2pIRgUAOhBVcA1lX64umNaoOCSO9ZWoH/SGzQBUIyTil6ilx1pQoGeetACqBtNDk5wPrSjrwOBSsOAx+lADVB2896aT2p4ORio2oAF+X3pxAbBFNQEtjBq9aWbFQW79BQBTCtn5QTW3Y2zLAvyEE96tNax2cYLAM+Oh7U77XvVecEDtQBj3xlDFMdDUScRgP1rrdJsF1OOTABZRn3rndS06a1u8up8snrQAWgcoS/TtVk/M1NRwF29hUczDI2HigCK8lKqVXpVaJgFz+tPnO7aD602UKIOOM8UAVsgsTUssv2LSZ7nozAov1NQxqS6j3qh4ru/nisYz8kXzPjuxoA540lFFAD4v9an+8KKIv8AWp/vCigAl/1r/wC8abTpf9a/+8aZQB0vhx9+l3Kf883DD8avnAO76Cs7wgcrfoenlhv1q+xyMdqAHthnyD0pLhQG+XninjCqGxUTtyKAEA3OCTUtpzdKO4qD+IEH3q5p8Z8zeTjtmgC+AWYMPoaVQY3DJ1BzTVzhwP4aeh49c0AXtSjFzpiXEY+eM4fFYLkMMD0rd0qUec9u+PLm4xWTqFq1pfSRHop4+lAGgWD2kDDk7cGq1wnmxsuOgp+nAy2csf8AEPmWnKPlyaAOdZCkhV6UjkgdSK2LmBJBkjmsq4iML8ZoAjHTB70HOeO9LwevUUEHigDX09v3Ce3FWBjk1XtVCxKp6jmpdwBJzxQBKvIYH1pSMkgdqihkLKfUVIjHBPc0AN5PHc8VQ1Dm4jTPAFXiSrlj05rJlk8yZmzyaALWmSbZWXPU10EEREW/rycVycD+W+/PJrf0+9MpVNwye1AGlFF8zuSAcVB9nAbeBwOtTrauWYlxz71JHC+NquDnNAFRHXedwBJqueWJHQmrz2bsTjHHpTBYS5Y4yM0AVEUZB5xnmlwWYhTknoK0EtHFu8ZTk/dNMt7OSKcPMhAXnpQBEkO0qZgV9Kiu/nnIjHy9BWpqcEk+1yNkfG0e1VNRubfT5vlw5A6fhQBylwGWWQHqrZrRX+Bx0ZazZpd90ztwHbP51esWLwFTyUOPwoAt9VHrQMEEetIoHJ96QjDcdzQANyv4U0DG70p+3gjsaaB8rD3oAaMpnNZd6wNwe/vWtIMqx9aytglaQHr60AVjxj3pQePahkIyPQUg4HFADkb5SPU1KDvjIPbmoAOSe5pfm59KAE5zxSjDNinHPbrViztDv3Sd6ALNjbAKGfrWtYRqWeVyNkYzVRRtUipbp/s+lhecynP4UAUb27M1xIwPB7U2F85JPaqsykEMPpSoxwB6d6ANnSb17ScvCxHYj2rrpLOOSCGa4Xfazjk9ShrhLPqM9TXd+G9TQwPYzYZduVB9aAOQ1zT3068aI52Ebkb+8KzI265PSul8QXP2uFEk/wBdE20H2rmJVIdsdDQAzcQNxGSegqK4Y5A7AVIu5UDd8VWG6Rh/ePFAFi2dbaCa7m+5GuR7muMuJWnmeV+Wdixrd8TXgUJYRn5U+aQju3pXO0AFFFFAD4v9an+8KKIv9an+8KKACX/Wv/vGmU+X/Wv/ALxplAHQeD/+Pq69PIP8xWnn5RwKzfCC/vLxu3lbc/U1pIhLbQaAFLZVQOgqMkdOtSBSrEH0qFeMsaAHHk8fSrtn8qqM/KWql2yK0I12hAPrQBPHJuZwO1SK3yD3qK2QnzD3p4HyjNABI+xAU4cHIrW1gR6hpUF/F/rAAsg9CKxZQRg1Y8N3YiuZbW4J8mY4IPY0AR2UxgkR16dxVueMI4KnKPyKp6nayWV2Yj9zOVPqK1LDbf6dJAp/0iE71HqO9AFKQZxgVn30L5+XkVfBJ4Ix1zQwyvtigDDeMqRx1qVVBADAg4zmtJoQ7ggcU8xoUAK9KAM2R2BG3o1XoUO35+QBUFxCfMXb9zFWLRt8ZU9RQAoQK5wOvSph0wKZIdqqfU0o4PtQBDfybbbjqelZap3I5rQmdGnRGPC80yBRLNu7A0AQ21rvUF+OOKmkiMK+ZGcMtWyBt/wqK5wLaQ+goAl0jWXLkXHK45rchlgILI/XoM1xEWAsp7npVy2lZD8xI4oA68sUlUqQc1PGxWF/McAHOOe9cct/JE5+ckelF1fTbEOThh60AdUL2CJSfMLNTpdeYRvHGoIbABNcjZz73Kt+Gauc9PxoAn1PUbydeG6DbisKWWRmHmk7hxmtbP5VFcQLLggc4oAyCQQcjpWhpjgllz94VT8vD4bg96faN5Nyp/hoA14zmPA7Uq5J+hpFABJB607pxQAg4FNI+b2NPGMUxjjHrQAjHHyjmq8MGFJ7mrBHzZHWlPyLgCgDIvE2TDJ5xVc8DGa09UiDKrr16VmNwoPtQA5CBj86s2+0o27HBqpHh1OKu2kOX55U0APtot8hYjgVeA24IpFQRjAHUU8r6ewoAfEjTOEA+Y1Hqzb7gQr92IBRV/TcRxzXLdEBUH3rFclpMluSc5oAicZbGenJp0UfG3v3owPmKnknFamlWD3VyAikgc0ARQxbRuA56AVraDBKtz9ql+WNTkk9qsvbW9oCZ5ANuWwO5rLu9Se4Ty4vkh9B3oAdqk0VxqE7wY2FuKw5T87Keoq1A2J8dM1UuvluGJ6igCrKTkAHiprPESy3Eg+SJS35VGyhJeR15qPxFL5OhgRnHnOFOPTrQByM8jTTPI5yzksfxqOlpKACiiigB8X+tT/eFFEX+tT/AHhRQAS/61/940yny/61/wDeNNHWgDqfC0ezTLmQ/wAbhQfoKvIVBBHXNQ6Sgj8PW/8AtMzUofaAAO9AEkp+8c8mqx9qlc5PPem8KTj0oAaFLMgHrWqE2BScE4qhaAeYzN0FaAO5EoAkhDKeO/WpcDKj1pAdo570rD5x6gUAQ3LAc44FV1IfEifeBxVmRcg7vSqdtIsbMh9aAOulhXWNCDKAbu3GfdhWBp87Wd0s0fDjg+9avha9EGqxK5HkyfKw+tU9fszY6vNDghScoT3BoAsavCF23cI/cTjPHY+lUl5Ucc+tXtCuVlV9PujiGTG1j/C1VbqJ7O6eCQEFTge4oAiDgZ9qQHilAyjHvmgfyoAjk4UflUYISTK5AHWrBG449KbMqsjcdRQBSuLrLIO1SG7UREjrWdcZ80qegqOJi2R2oAkLM8pfOSTWtbJtiGB71Rto1aZccgDJrRBxkdqAFHbiobkYgfPTFTNlSB1yKpajKdqoDkUAVJ1CqhB5I7UjMcDNRl/n56U533dKAEb/AFZ9akUmRVQngVE3A/CrdlGshIY84oArEmOXA6g1rxSh1XkdKypx5cm3rimK7DBU45oA2hypFOxgfSs+0uskrJ07GtBSCM5oAqahDhd69R1qrcrhVKdStajr5iMD6VkhW37eeTigDQsZfNhGT8wqyefx4rMt1a3uApPDVpnHagAIyOKRfQjrSk4OB1ocYAxQAxD87DvTtwPDdhVSWXypAwI5JyKI2eUgrwKAJLrBj4rOaIGQDsela2zcuDTWt1LDPYUAZ8cASUDg5rRhTYNoHSoTDsbeMkg1aGMHPWgBBywpxJJCgEsTgUm0jnNW9NVY83kozFFnr3NAEOsS/Y4YrNTyw3Pj1rHjOUHOSadeXDXdzJM/3nP5CnIAiZxnFAEtnbvNOkSAl3bAAru7kweG9L2KAbt1x7ijwFpMcdpda9fqFt7dSI93G41ymq6k+rX8t3IcIWwo9BQBRvrh5dzSuSzVHaqRHz+FMmXzJwAcjFWyAsfHYUARsuF3Z5FQ3yfv1I6MBUw5Rs1Hdk+TG3oaAKU5O8A9xVbxGM+H4Dj7sv8AQ1PMcueabrA87w7LjrGyn9aAONooooAKKKKAHxf61P8AeFFEX+tT/eFFABL/AK1/9400U6X/AFr/AO8aaoywA78UAdrDlNHsIh/cyfxpu3hQepNT3ieUsKj+GML+lV0zwWoAZIMNt9KQqRj1p0hy31oI5z37UAT28f7lmPersKFoxjtUZXy4lXvip4cngelAEgyyhW/SlJO5SPpTIgQeT71I5B2ketACMMqfWsecbZmPQ5rYZuSB6ZrLnjEju2eR+tAF6yz5aODgqc11/iWJdT0Cx1NBh41Eb1yFnwgB6YruPBaf2no2qaWeXEZkjHuKAOBkfBKqTgHOfpXVwr/b2kh/lF5bjp3da5nyTFK6yDG3IP1qbTL57G8FxGTtUdPWgCVlIyCMEHpTHByCOmK6bXNNjvrOHVdNAKyrmSMdVNc4RgUANUHk0p5XFCjjFGfkyPWgDL1CBlkaRehODVSBRuC5rbnAZDnnHNZKgPd/Lx3oAuWEeC5Bx2+tW9pxmobYYjU+5qZsj6UATWMEl3cCKFGZyDwBVPXtHvdOjgnuYWSGUkIxHBI61u+ENWXRtXF06CRDEyFT711HxY8W6b4h8G+H7Kxg8qW1Z3l479KAPITzin7SATTQeKee/pQAYJXJ6DirNqiq5bOMVWJwKXJVgc0ALK2+Uk+tNZPallJ83NOYZf0GBQAznJx3qeO4aM46giqxyrEHtT0UMpPtQBtQuJRkelUrxPLOR94HNb/wu0OTxN4zttHjYDzULknsBUHirSX0rxFqemyfftZmjz7ZoAxbiQSxLJnBWprS5Eo2nqKjltSYsKelUVZoZuRzQBuAZB9eoqG5l2p15oW4DLkdhis+5ZmcEZxQAqRGWRsnIrTiTZGq4HFMtkWNPc1OD0PagBOQDSAAryfenHrg02XAxQAgPUe9HzD6UqkHOOtJKxxgd6AJrWN7mdIIgS7cVb8SvHapFptuwIQbpGHdqv6YU0PSJr64A+1yqViB7e9chNI8pLyMS7HJJoAYAACR2rQ0WyfUdRitUBYysBgVmQ/ebNexfCjRILDSr3xLfgBLWMmPd/exxQBT+KV9Fpem6f4Zsjt8tQ8231x3rzJyEtwvSrmo302qa1eXtyS0krlgT2FUL7gKvpQAWHMr98CrjZxtAzmqenAgtkYBFXl++PagBka4dgaZON9u4GcqeKkkbDtimoCNyn+IUAZsi5+Y8ZFSRx+dp91b9S8ZxSr80cinqpp1kcXCHt0NAHBmkq1qcP2fULiLGNrkD6ZqrQAUUUUAPi/1qf7wooi/1qf7wooAJf8AWv8A7xp1qu65iX1cD9abL/rX/wB41PpS79StV9ZF/nQB2epnN1tH0quf9XgHoKs6lt+0SEHkcVTAYL15PFACgbgDj2FOt8vOufujk007kUAdRU0Q2Qs397igCwRvfP5VbRDs4qvCv7hcjkVZjBDD0PNACKD8wI5pUG5cdxQzHf6VI2FzigCNjgMT6VUWJWiLHg9asTN+6JNUJGYfczsoAvQqRCuORnFdZ8N7oWni223HCTExsPXNcmmRGoFaGk3BtdUtZs4KSKQaAJ/H1kbHxDfWyDb+8JH0NYCKSrA9K9L+MVmBr0F4FG2aFXJH0rzOcOgcKepyDQB0HhrVm0u4VJMvA3ysp6YNafiDSRJAuoaeMwMcuB/DXG2rkj5+qjqe9dj4R1mS2uBFdLvs5BtdT/OgDmlfYfxzTgRgmuz8YeFBHEmqaSvmWci5IH8NcXEByO/cUAI/LYHtWVEm2/IHTJrTuZDCyMo6nBrMDFdRJPTeaANC1AAZTzhs1MSTkntVN5fKu2XswzT55x5LkHnFAEMU7NeHtGOKhu7hpWKj7uaa+5bWNxxuNRnAGe5oAYq7iBjvUzfNnAyMirFlblwGPetBLVFBAGTQBgnO7BBHpTo1aTK4yaztV1dotQdIoxtjbBz3rprREaJJEGN6hsUAUBbyM3Sqt5dRWcuy4cBvQcmna5rJsbjyLcBpAAWJ6A1ylzNJcTPLK252OSaAN9NTtXON5B9WFW1IdcqwI7EVyFXdNvGtZgSSYjwy0Aeu/BXV49A+JekX1y+y3yYpGPZWBFJ451BNX8aa3qUPMNzcsyfTPFcduaNo5UbKn5lI9Kna7LkL0yc0AXTnJqhqEJK717da0ARtGOaGXcu09+KAMe3yeN3vU9oQ07Iw+XnFV44yLkIexxWhHbbWVv4gaALRUYpf4T7UpJpSvGc9KAEbGwetMYZI70HlguMCnthQQKAIzgMSK1/Dmm/bp2ubgbbS3XcxPc+lUdMtJNQvEt4Ry3U+grR8R6jHa2S6VpxxGn+tcfxGgDG1/UH1G7LDiFThF9BWfnjrTWb5sUoRgpY9M0AXNJsnvL+JIxkMwGBXr/xKkPhvwLpuhI22e9/eSgdlrmvgnpC6n4phVlyiNvY46Ac1W+LWtHXvHt5JG+ba2Agjx0AFAHHOMTJjoRiqt/xKB61dZcsp9DiqGoczj0FAFyBV8oY6jmnQEsT6VHbqQpJ6YqWMFeBQA11A3E0MwEqc8U6TDRn1qGZCArZ5B5oAj2hLiT0NVd2x9y9j0q1eqfMyvRlrPRiS2eooAyvFkW3UEmHSWMN+I4rDrqfFcW7TrKbuCUNctQAUUUUAPi/1qf7wooi/1qf7wooAJf8AWv8A7xq5oS79YtF/6aCqcv8ArX/3jWj4aBOt2pHYk/oaAOnvSDdSc96rorN1PFPuMtcOx4yaQ8cg8CgCNsq3XrVqY/u40A56moFAaVPfrVt1PlsT16UAW48LGuR1FT8EAjjioeRHHmpOc8dKAGOuR7jmlB3A5602cEdOvSoVl2AAn5qAFuCNmPzqCR1GyNeSe9OeTzSVIxwTVWPm4T60AaZJBUDk4qZeFDd1INRA4YmlcnYcdCOaAPQviNMbnSNFmOSWtl5rzm6QmPp25Feh66PtXgjRpH6xxlM+teeGQyGQdxxQBFbxkQAMM5PFblnAY0jMjYXP+RWPDKV2D0q296ZGVScAGgD0Lw34r+wj7FLF5tmflZTzxVHxp4VjaP8Atjw/+8tWOZIx1WuWjuvLBKn5gcn6V1fhjxR/Zp8t08y0lJDoaAPOpZzINmMMDnmqE7MJyXwCDmvRfil4Vi0w22uaX82m3eD8v8DHnBrzmUbpdx5yKALGo8yROD/CKqo5Zip6VKzbrdS3JHFQFgGyOM0AW7qUMqxAcIM1FjewFMSJ3UuOcU4k7FYdelAFnRp3kNzGy4WNgFb1rViyp5NUdPkVo8DAOeausDtbb17UAcX4hgRvEPlIOHK5/GuxiAXaFHyqAKzrjTBPqkF238AwR6mrpmSInc6jPqaAON8S2ctvqEkrDMcrFlb+lZFdv4p2yaM7Ag7XU/rXEGgBKXNJRQB0mhzNLpzxuSfJYAfQ1oIOQSeorH8MnMtyhPBiz+RFazLwAO1AGpYvmPDfeqwDgc8Vk28jfKAelW5blNhx17UAUpSVu93bdW1gbdw71hzcjg985rWtX3ImTQBMeAKTd+ppC3Wo5LhEGO9AE2MkEdqZ5b3V0sEClnbgAVHA8krhIVLu3AArt9Ps4fC2nNfXyh76RMxof4aAKVwq+GrAQKQ1/KPnI/hB7Vxlyx3EufmPU+tWbzUZL26eediS5zz2qvIpunynYdKAKzIwAYmrVqGkJGOT2qORCMg9q1PDkCyahFG3LMcAUAesfDVk8M/D/wAR68+BOU8iFv8AaPHFeQI5aRpZDueRizH1Nej+P7xLH4c2OmRNtknuzI6juAP8a8ytW3KwI6c0AWN27271QvPvtmruRncORjGKo34O84oAuWzBoV5qQtnGOtVLINggmroUfjQAwjCk4zTZT5iEjipWIBIPSmBQEPuKAILni2if8DWcQMsMc1oY3Wbp3U1nsRwaAI9RjNxodyvUxESAfzrj67yyxIJoWGVlUqPxFcNKpR2Q9VJFACLyea1tW0eLT9J0m9TU7C7e/ieRre3kLS2pVtu2UY4J6j2/XHooAfF/rU/3hRRF/rU/3hRQAS/61/8AeNa/hJd2tRH+6rH9KyJf9a/+8a2fCIP9qlgM7Y2NAGvKSZWGeAaGGMfXFEhDOcUZ+XI6ZoAktCGkY4+7V1181QF61WsUB3+pq7HGUAI9aAJDnYo9BTw/GOwocZwB6U0YVDkd6AGyE7sGs2YZl64NXpJDuGBmoTCznJxzQBBvYnGORxmprSLdPuOMCkuwsUaDvU9gp8vc3U0ATyYx0ph/1RH4U+Thce9UZrkCVVU/KKAPSIJRP8M2QtmS3nC5HYGuFnUK4ZRkscPXUaNIYfh7c/37i7GB7AVzGpAhSUGMn+VAFe4/dOxHNUkdzJuxgdasxy7wY364NIEwUU8ADJoAm04M6vJI2ATjmtdWCQIqDO7PI7ViSSbEUR9zmrqXJijDD+IbcHtQB6ZoTtr3w/13RpWEkscHnwg8kMnPFeLzcojhcdjXoHw81hbbxVaT7sW7t5MyHoQ3GaxPG2j/ANka7qNoo/drIWTHoelAHLo3yFfxppFN6Px3pWbBGeTQBoaWeZFYZBxUE423LKOmeKit52Rtw6d6uXKboxMnLCgCrHKY5OODnkVoC9VRk1moAzuz9epqWSB9gcjKmgB3iHUns7GLycb5CRn0rjJriWdt0sjMfc11OrW32+yjRDiSPlc965SaKSF9kqFW9xQA43Epi8oyOY/7ueKiNFJQAUUVLbwPPKEjGSf0oA1vDaENcy9gmz8Sf/rVsL9w8fN1pljbCC3S3jALHlj6mrTRGOYKec0AQQPsfJ7UrKRLgjqOKW7jEUpCnjGaSSUyKh6FRjNACDGNtadpxBFj8ay4ASFJ78Vcgl2WWQfmUkYoAlurgRgBepqhGkk8qqgZ3Y8AU2LdM+FBZieAK9L8O6Hb+HNJXWdYANw/+phPX6kUAWfDekWvhbSTqWpBZL2RCY4zztNchr2qT6ncyTTMcMchfQVPqurzX9xI0z5VuVGelYrMS5J6dKAII4wTyacEIPynBFMkBByDwe1LDJllz170AXMI/JPIHSut+G3h+XW9bVYjhtvHtXHKpeUEcDrxXpnwovm0jWzccERwSSv+CnigDA+LFwv/AAk39nQsDb2A8vcO7DrXJpw24dD1p2uX51Gd7oj95K7OxPfJzUdswljIH0oAsBArkjkGobpd0ZJ9KWJjHIA5z6VJP88RA9KAKds+2TaOlaC9M1lIfLbkZIrQhcmPJFAEoBIHrSt92oonJOakJOKAIIk5lT1Gaz2GCR/dODWn0uQD0YVnkf6RKhoAZC3l3CsvTNc14ig8jV5xjCud4/GuiQgOV71T8XwB4LS6Xngxt/MUActRRRQA+L/Wp/vCiiL/AFqf7wooAJf9a/8AvGt7wYP9PuCeggP8xWDL/rX/AN41v+Ehj7bJjpGBn8aAL/Rj9akAwjCo4/vZYcDg1LIccY5NAFzTQCmfWrTfd49ahtk2Rpj0qfBAyO1AC854FMlcInzetSLnaWz2qrOTK+D0BoAcOUYj8KlRcKDTQuFwtNuZfKU54oAqTgzTqqnOKuxptVcdhVeyT5i5HU1bL9dw4oAinLbCF6nis6KE/aAp9cVq9izd+lRabEst+hboZAP1oA67WFGn6PYWSH/VoXb6muYfMiknkCtrxlc7tWlVW+VAFGPpWFbblLoeSO3qO1AFK5iMaFxncv6inHMiJ6nitGS1klVcIShGDxSCzkRhlCAB6UAU7aMvLlvu9vai8fyycdATirZ/dQEspAbI6VVu4TPGGTkgfd9KAKdvcPbOrxMQQ+eK9D8bINX0DS9eh585fIn9mA715pKCvyYIrvfh3fx3Wm6h4fvGHlXKb4Cf4ZBQBwMiGORg3Y4pjqWXI/GtPWYGguWVlwwYq31FZxJxjGMjmgCdY4lsic5kIqxp8oKlGNUpDkgdMACiNir56UASXCYuGC8k8gVdS42whZBggdKpndnzOrDoaJ5WmmDsOdoHFACLuDE9qJ0iuIwlzGGA7kc/nToQxYA9DVpogyHAxQBztzosZw0EpXPZhmoE0OVjgzRj8DW6Ym3bR0q5BbhFywySKAOdi0IAgSSFvZRWjDZLbqUiTb/M1rAL2UZp2FJORQBRtD5cpZjjipBON7uRyRgZqWe3WTHl+lRpAWTaRjB60AQvGTG0khyW4FRspjABHDc1a1D5YowOoqpNMZo0yMY70AOcbI43H96kVQcgHhugqSf/AI8Y89c5ro/h54fOva3bxSri3Q75T/s0AdL4A8M2+maJL4i11AEU/wCjxuPvnHWuU17XbrWr+WW4YiLH7tOy89K6j4v+IhqOrRWOlELplkgjCJwCRxXBRssgZAcHtmgBQ5lgJB+ZDyKeGOwbuhOakW3ZJA5+VXGCPeleFmHHQYoAgnQBd2OM1UhyZMqOTWm9u8kZUKeuKa9sYlOFO5ulAD7NvLy5GccD6113hebyZ7mI8PNaSIT7kVylmn79PMHyJ8zVr6FdqNXPmHCzBkGe2RxQByHlsIyh/hplrMYZAOxraurQxySRsvzgkGsWeEpglcGgDWYB1U96WPlSPWmWzbolz1qQHZ17mgCjOgDsc/hV6EhkUjpVa7j3IWFNspCqkdc0AXguM4HFKB60xZNxIPGaUHAB/CgCOchZoj71TvQFvgx6EVbul6H3zUOrgB42AyMUAVHX7zelJcRfbdGuIergb1+oolzgYPbmpLRvLkUDo3WgDhKKv63afY9RmjAwhO5foaoUAPi/1qf7wooi/wBan+8KKACX/Wv/ALxrp/CiY068c/xMB+QrmJf9a/8AvGur0TKaBHgffkY/0oAeG5Zex5qUjcy4+lRhMsB6datWqgzDbzzzQBfA2kDtjFO3Z+lKwyT60zG0EdqAHt8sRY1EoBUkfWiZi2FqSPAiJxQAiuMktxis68l8+UAdBUt/MPug4JqtYpvlwaANOFdsSCnE5bbikHy4x2pIiWkJNADnG6I+vSruh2W+5jA6KdxNVUG5iQK3/DXklLoTOEZlwpIoAoahY3F1qjuQdpPXtV9La0tVEkpDygbSKn1jUg9skUIAKn5mHeufjkVpXEzk96AOkg1K2SIL5ORz0qUahZvtVrYlselY1jdR+VkICV65pbm/P2hPLUcUAatymmX6LGqGKQZPPTNc59lMU8hBHcVtw3sCyMs8QOEzkdqjuLBbu0+02UmWzgp3oA5u8tkPBX5j6VWshNZzJPASHjYMDV0+ZHKVk6jjB7U62bFwomwEY9fSgC74tgE08F3GP3d3GJP+Bd65y8iCxh17HBrs72B5/DzRAZezkJBHdTzXG3BKsyPnYelAFP8A5Z/WlDA9aYRsGO1OVcke9AFiJ92V7USxndkdM4pLc7WbIqzu6AigBtptLfNx6VZA5/CqajYd2O+KuRuOB/ERQBGiZckdjUrbj1NKhwMAc9KV89cUARkY5pRzml2M3OaFTk56igAB28jsKN+McdaTPBpM5Ax1oAZdoJYie4rP3jygn41pj7rZ6YrHkOJSex4oAtTndYxjr82K9O0Up4V8BXGo5xe3S7Yh35rzO0jMxghAyWcYrq/G9+biW202M4js4wCB/exQByq3MgbMmSScknvV+C0EiC6VfmU5CHvUdjZtMd0nEYG5ia27SSH58dBxn2oAo26XGoXRUKSpPynHQ11dtoFraQK2pXKK7AnYOTUVjbXEkK/Y0EFup5kPGc+9ag0uyhCyXMxnyQN2eOaAKU97plmhSzgEshOS7VHatHdKzG3UgdKt3As0crHAuF71SMsTh/JUKfbjFAFea0tHSUKpjlbqe2KxI9OuCWmgDOFPUVqzM6Kw3BsjHPaoLW+nsQyxNgONre9ADdXVswTOMSSplgPUcVkTwrKvPUVoX0skjBn6dB7VWJwM9qAKMXyHBqZhuHHUGkukO0sB70sOWUEUAKwBQg1nxApcBM8HkVosCCR6ipvD/h/U/E2t2umaJbme8kbGOiovdmPZR3P9aAIFQd+tPxtyO2K9G+IH/CN+G9EXwnoscOparHKs2oasR0kXjyoz2A5BHT1yc484ZuCaAI7sgQH1qK+UtbRn6U+T54n+nShsyWHPpxQBmz4OCvTGKCCoQjrSH7pA7GkdiyqfSgCp4uh822trtR0/dsf5Vy1d5NH9t0m4t8fNt3L9RXCHrzQA6L/Wp/vCiiL/AFqf7wooAJf9a/1NdhYAxaNZqeMgn864+T/XP/vGu7aJFjt4+yxj+VAFNMliSetaGnKA7OelUI+JGx0rSshtTkfeFAFh/vk0KwOe/tQxXy/pRERkgDjFADTjcW9aSSQRxHdU0oRYQc9OtY93MZH68ZxigCCR/MkLdqu6epUliOCarJFkA85q+iuqLgYxQBYb+I4+lEQG7nrTUP8Ae7mooZt9z8vQZFAF1RtORnFalpDi0V8Zy1Zu3AIz2zWkkpjsYkU/MoJNAGXezMd0afnWdtYsCSa0HYPGC33snJqGNFkbYvXrQBZtpFSJyfvcfjVjy975B7Ak+lNigG7ABqeFSWKqD0xQBIIwQ7NySuKhtJJIgDExDZFPmbZOVxwBimruAAA6igDR1SGHULJZ4ABcp/rAO49a5yTB4z0rc0rdHdKz/wCqJ2n3zVDXLMWepXEI+6GyD7GgDb8Fyi7a5sJiCzRNtz3rj9UgdPNidcPFIQa1NAvPsOtWdwPu79je4NbHj6xjttcZ4hmG5QOPc96APP4kMsTsD92k5CFe3Wnz/uJmVOholQgI6/dIoAamcAg855qyGy3JqqrbVI7sc1Ju5G3pjmgCxnMOfekBaOVSwpbcFgCBgZ6VZnQFenWgCNJASSO/NWFkXGCe1U47diQDxil8qSMcc0AXu3FMk4GaqRTEsQR2q0CGUUAMAyBRj5eO1HRsdhSnkcUAMc4ib6VlFfXqavXkoVdoOc9arW4864RT060Abvgy387WIlI+783PbHNS2aDUdR1C7lb92ZDk+g5/wp2gyiyttZvOjQ2xVT7txSWqm08OR/37tt5/3RQAy7uBISsQ2RjhVFaOkwQW9sbvUDiH+Fe7ms7TYxcXscTnCs3WrvxBie3mtEjUpCqcL74oA0L3XGv4fLgxHCo4RaqJczPYtAWO3IOK5ewuCjAE9a6GxkEjL6HigCxdXLgMN2BkL+nNZZmeKWRkYgdKvXsbtbsUBLBgKSDTHm4mIjXrluM0AZ80k3ln5jyc0yOd0O5zkdMGugbTreWMpHcIWxjrWJqMH2chGzuXg0AXjdxy6W8e0Fi4YN3GO1UeoHqapWr+TMQT8p4OauyRNHKAR8uNyn1FAAykqQPpUCny5MN0NT561f0LQ9Q8TavBpej27T3kx4A4VB3Zj2UdzQAeHNDv/EmtQaXpEDT3cx4HRVHdmPZR616D4n1zTvh5o914U8GTibWpxs1bWE4bd3iiPbHP0/3skO8R6/p3w70ibwp4OuBcazMNmraynByOsUR7Y5Ht9ckeRvhj8tAC2R+QK3UHFSyAY4qKPCsG9afk7yD3FACsvynb3GKr2wJs3B7EirKKdgB7VBY9JkPTJoAzU+/9eopWIDMF7ims3lzMcdDTmORuHU0ATWkvlXCcfL3rktatvs2p3EeMDduX6HmunUEurZ5BrN8Ywjzba4H8abT9RQBz0X+tT/eFFEX+tT/eFFADiM3BHq39a7e5yJ15/hArjbVd+pRrjOZRx+Ndfdkid8DgHAoAiHDE9q10K/KAOgrITnA961o8AZ7kUAOIyO1NgO5v0pq5GO+aS3O3OR6mgCteSuzeUvrRDYkjdLVu3gAYyEZJ6VazwQRQBRZAh+VelLvLg4BBAq3/AAjjikCKecCgDNeVz8oHJqzZW4jTJ+8astGobJUZp6rkjB7UAJL9wY9KltJSGDEFhjGDToLZ7hgig+59KlvWjt0MEXUDlvegCjM679idM5NS2CJks3rVJD8oYDmtBFVYPMPGKANSzeJsoxAI/WpWKLdskRUEL1rDhBa4Lc4HFTorJIu48setAF9oC0vzY3Hk+lVrrKTRoB1NSQM5kw7EnGfwpjSebNuxnBwpoAnv3EKRKobdkYA9ad4vAkezmxhpYQG+oqxbTJIwaRVLL0zVTxQ+VtFz0Ut+dAGFbkqU7lXB/Wur17OoaAbheZdPn2P3+Ruf51zFkpe7jjOPncD9a6fw+ftGpa1ZE7o7mJjj3Tn+lAHnqoWuJQeeTilRjzE/H1rRitGhuZg/IVyFpmoQDYJQPmQ/nQBnvEySYPY1Kke7cB3qzbSJfFIiAGcgZpYIjFJJG2MxsVoAWGMqig9jVkDK/hSMOABTwpwPzoAYV+fNObBBzQPvE0cHOKAIBGvOByailDIR6VcGO3pTGUNkHuaAIWZdoNQTXG35V6mpXTyoyG5A5qusA8vzXbrQBWkPUt1pbOTZKT3wajOZZCEGRUsMQRHJ4ZTzQBqTzlfDU6j7006g++BV/U9yQ2UJGNkC8fWsy4QnQISOhuzn2G0Vs66oXUmX+ERoB9NooAqWI2SI+cEMK1viPdi9ubeRDn5QrADoQKx5BhAFPJOa0pwshQXWPuc+ucUAcrapiQ7up6V02jW8r2+SpGOc1ShsVaUu2Ao6Vpf2m8cphAAQDAx9KAN6eaHRLHTpXhErXKtLz04OK5TUb64u7ppZTgE9B0FdN4wKv4T8KSpz+7mjJx33ZrkR8wOevpQA2OQhxtJ4rasXivUmguQPOdQI396xEHzZqzGxjZZFPzKcigBtxp7wsyyDlDg1Yt5jc6cY8ZmtwWHqVpsl7IzFn+Yk5Oant72KKfzPJUMw2Ej0oA7bxf4DYeMNE0PwpbSyzX2mQXTq7khWbO92b+FeMn9OwrT8S65YfDzRLjwt4OuRPrUw2arrCdQe8UR7Y5HHT/eyR2lz8TfBw0VIpYtbsry6sorSW9soUEuxB91XJOBy3bv614N4jGjrrU48OG9bS8L5Rvdvm5xznbx1zQBzshMc5U9PU1KpCkY5zS3cZdScYPWq1u/96gCwCSXj7nkU4PhFJ6jg01ARMG7CluVPmbkHytQBbVgcfSqtrzcTr+NSxMQgBHIqOAYvHOcAjmgDOuwPtDDHemonyN+lS6lhZ2IqBXO3JPXigBCe3pUOuxmXQt/XynB/PipB3qxt8/S7uD1jJ/LmgDiYv9an+8KKIx+9T6iigDQ0VN+uwj0kJ/Kuknb99Ix6Fq57QF3a4nsWP863Hc+YxPQkmgCWJfmQ46mtNTtkI9BmqdopedDjgCrbAhmoAfGdy5x0qPDO2xRyx4qSMdh0rR0a28yeSbGUgXcaAJlht7KIfaTukwOPSr0dvaarGotyIp8Yx2NctfXBuLhj706x1CSzmVk6UAaOpWsthcPBcLh1P51TQ/McHjvXVy3Nrr1tG0pxKo257moIvDKPvNtcKxAJ2mgDnw2VKjrmrVpp89y6GNfl7k9qu6Zaw20hmvwFjGQF9aqajrrl/LtgI4OQMUAXbi7hsbQ28DBpOdzVzdxIWlwDnvTt5+8Tw1NTDSADpjFADoB8wB78VoXC5gEY4x1qpCDuB9DmtCOPfb+Y3XNAElqojtTIw6HFUJpjJIWJPXitS4Vn8m1iHzOdx+gqxp+kI100twpMEX3Rj7xoAk0qwb7PPc3XCInFM1WySCzU2jBsfMT7U+TUJHt7suhWPO0CqumO90CmfkIySfSgDNjkdrpQCRk80/Vn86Uc8KNoq3aWnnzzypwsY3E+grLuZhl3HTPFAEVnKser2rM3yrKua6bwyJLTxxCCpO+YrjsVY4/lXCfO+91ODniuwsfFhtVinNupvkUKHI/WgDJux5d/eQ5P7q4dPwBNRgBgVbkYqC2Z3ubiSZsySuZD9SanH3v1oAyjAYr0qhI53LitCHOwu33s5NE6r56sR3pwAycng0AKQXIIqRiePTGKYuQvvThyOaAE7kUjcDjpSgcCg9PYUAIB8oHQ0Y4z75pRy+e1DcdKAIbiMyIVBxkday5pGk2RLn5Rj61qy524XqeKq2NsAxkbscUAT2tssCgkAnrmobuDdPlcBWHNXww28+lU58tOq5+XgmgC0U3eHJ4u8c4YfiK0NSkW7h0+6Q53wBHP+0vFVVGdHuNozmZc/QCptMQHRLtJP+WRDKfQmgB9lB5sNxKvMsYGxfX3rNjdpJDJKTgcc960dIuBb3O5z8rDBp15pjQ3ihv+PcneD2x2oApX05WIJGSGXnHqKWEiVFGPnAyahuhmZ3I+6Plp1nKVJkxzjBFAHW6dH/a3hKXTmP7+1l863z3B6iuQkV4pirggg4IPrXTaBKdhdG2yRtuOO4qzqGlJrcbXNmAt0CSy/wB6gDk05GRTnJ2e1Wn0u6tIjLNC6xA7ckcZqnIQcAdDQA0nIXPU0uQ3ynqKQ4BwT0pD83zUAdlpUSaj4X8lgC8RIVvQ+lczNG0cjK3BBwa6j4YkXV9cWb52uNw+tVvHFrHaaiwXALHtQBzbDcSD0qhcQFHyorQPPApsi5U+1AGfFPhtrHFW4zlORnHNZt6mHGOvWr9qzbCpPWgCSNh1x1pqgLc++KfEMJio2JM34UAU9UX94Mc5qqo4wat6jxMpPpVYMS/1NAEbdqt6epaSRD0ZSP0qpwHOOq1atJNs8R7k80AcQF2XAU9nx+tFWNQTy9WmT0mP86KALvhwE6yx9Fatp9rPtHrWN4bbGsuPVWFbkce6YkdQxoAu2IDZAPK1bKcZzVTTV2bj3q4+do5oAWFCzADvxWtp7Gxs7tZFPlzDaTiqOnLm5iHbcCa0fFN6sdssKqApOaAOVuUBlbyzwKrgsSfTpTJJjyQetNRyBjuaANfR5JEuYwp+XPNbmq3slnzExDE5yPSsOxykKyEYpt/cPcSck9MUAMe9mvJP3rnBOaikVo3XdznpTIRh9p7VcJDBQw4Hf0oARFBQqeSvNJCNiszfhUyJiJj69KjkAZgvbFAFqyO4kE+orodP06WeBURSeMnArH0ezkubiCCFSzl+gr2TUYLPwToEDXW03Uy5CnrmgDktM0iDSbiW+1p9qhcJH3Nc/rfiOS4kKWUawwAnaO9Z2taxc6nO0s7EjPA9qzNzE8jigDSstWfzQl0BJET8wrdvtU06HTFh0+DbI+QzHtXHlRuyRTmJOOaANOx1BrZbleCsylTmsLUCGAVDxU7Lu4BPFGxQc4oAyllMLYI4IqVrxWGNvNMvcySgKuMVAYWBJwaALyzKNsxIDdMVfJ7jpiufCuOG6eladlceZGEb7woAtSJlR6g5po+YcGpGGcCmEBG49elAAu7n0p3cU0N0HSnL1xQAAHlh0UZoUhloJOwjsetNUcUAO+lKB1qNQc+wpzPtZSOaAGOBnd3AoiZQn4ZNPOGYg9cU0Ku7A6dKAHtjI96peYHuZl6ADg1akyEZumOlUoykaSl/vN0oAt6XqQtptsgDROMOp71Z1PWomsWs7OHy0ZwzNnrWKkZR8sODVr7OsnagB9lP5ifOcGuniulvLOG2dhmPlSe/tXJToYol8tfmBJPuKtWNweMnDDmgC3qcflM+4fN/KslZ/n47VuXVwt1EI5QM44aqSWFsoJkkOfYUAS6LdGO/Bz+7bjFek+Foo7X7VeTYWBV3q5+nSuDsE022CNJvkxyRXcRT6ZrHhJrC2uTBdqxYK/GR6UAdBpmq6V4rspNHmCxyv/q245avNfEfhq50a7khddwQmqv2a/0W+iuEDB4mDhl6cV6R4guU8Q6Tb61bDJdRHMn91wO9AHj0i/Oc8UKDyq8knHFdbJp1lqM0cMUnkzk4Ynpmuk0TwVFZyRXFywlWNtxI6DFAEfw+0ptFifUr5SrSLtjTHJJ6VkeKNNmmY3N0w8487B/CK6D4hapNZtptxEuyP70a+vvWFp08mpq8szlyxyaAOVFs+cDrUMo8vdmugnRYLiYY6fpXOag+5ifU0AZt8CGVj1NWLRt9RSssp8vuBSWDbJCp7UAXiMHn1pox5oNKTmQ+namA/MD70AU9WbDj6VTBwU9e9XNVH7xT7VTIywxQAOR8xHU1JbgCeL1zUYIzg96dE+JgT24FAGBry7dfnHq4P8qKl8SDGvMfXaf0ooAZ4fP/ABOx77q6IEpMT2rmtEbbrkXu5H866GR/mYEfdY0AXLI4lYZ61pFC3NZMbjKHkVr7iu0Z4xQBZ0jH9oxA/dzg1J4ztf3g2ngDtVfTzi/i9zWx4mjLzIFGVIHT1oA4Bk28c1Zs4izMzDgCr91ZCNGZzj2qrI5FsfLoAf5h27DwF5pruyuTjINQlzgZ645qzCV2AHk0AMUbwWHDDigKd+TnpzVoIFUt2x+VVpmKSbkORigCVZSI1B6elSJG8mdgJOajgAkIUDvXV6TbRW8e+UD5sYzQB6L8HPDUMAl1bUlAjjXIz61wfxK8RP4i8S3EgYm3hJjjHbAr0vxRdnQfhtG6fJJccL9MV4MrZDMerc0AIzE5Ap+cAZqPPOacwIYUAP4wD3pODUbMRzTk5x9KAH5weKYwyM+9PIGc0HGMEc0ARbBuBxzUmxSnzDmo5G2HIpyPuHUUANMSHPyioJLTad8Zw1WgR1JHSlt282VY4wWdjgAUAVzK20k9R1FK2J0Yrwcg1py6cwJ+ZS3cA0RaXK4bagyBmgDPTBU5HIp561AzNDMUdcZ9alByOKAHBsg+lCsN3HYU0Zx+NOK/eIoAQZxn1oJCoCeuelKD8gzSYBOTxzQAyRtp4HJFQSKyt8ueasNFIoyRwKijLMfcUAEs262b1HBrOycAv61fIUOd3PtUdygc8DigCYxrJACO9TrxEPXFRxDEagDpTmDbRg9aAAqSfmFNaFQdydalViF+YZoU459aAIxuCknk0I+5iH4xTyDng1BcuoBA5Y0AXEC9D0pzOY2JQ4+lZ8Nwc81aSQSAnpmgDVsNbntwRL++jYYKvzXqXwtfTr/T9UsYXCyzDKwv2PtXjm0YA9ansb25026S5spWjlQ5BBoA6fxLod7o2sKxVtu7ctdj4cmuLiwaO4JEQUt9a6bw1rOl+OtBi/tBFTU4F2k/3veh7SCK+tdNtlw8mWfjoooAo+OPDP8AavhqyMaHesQKYrhPCVmsEF1AxzLD96verUj7DtkX92nyLn6V4zp2nT2mr63LIpEcpwp/GgDj9alC3E23ua5G9YgjHQGur8VpsmOBgjk1ymfMkAPPOaAG28QE5ZulRTfu7vcOFNW1IBc5wB2qreDdbK465oAupgqpzxigEbaoW90NgQ59BU7MQOPSgBupcbc9SKzUbBOR0q/qXzGLJ6rVHacg9iaAAc04KWCkdc051wwI6YxSxdl96AMXxN/yG1/3Uoo8THOvH2CD9KKAKWnts1eFvSX+tdbNtWaXjnJri0bZehv7smf1rsrmP/SGbseaACdxsTbxWnC5lttw64rIKkkZ6DpWjYuNpQd6AL1kQLiN8/dNdNqERNo1wjbkwCD71ycfyuOO9dT4RvIp5pdIvTiK6GInP8L9qAOT1B2mUFjwOoqgynYF7HmtPU7WWyvJ7aUYdGIIP1qoV2LjrgYzQBSOTIB1zVpT83A6jFV7dDu3ZOR0q2AFTLfeoAm4WMKT/wDXqFY97EAcdqRW81hV6FDGSxXgUAS2Vrt+YjBHNXo7h57y3gBwpdRVO5uQIwAe+TUFjMwvYJB0Dg0Aew/tBymDw/4ftI+F8pW+vFeKZ3cg4Ar2T9oENc+FfDWoIN0bxhM++K8NguDCCrqcE0AX5mCRF/Skin8zAxTYJkuFdccelVVZra7wnI6YoA0V+Y8n2IpcYAxVJ2dbne54fmrcbqyA5oAlGehprHkYHNBJJ460pwM0AQuPMOOlJ5YUkZNSsOhFVppGAJHrQAMQPUjFWNCuhaa1ay7Rt3YOfes8sSM0+1y9zAAOrigDVvGkh1aRQxOXIH51swXBhkRW6setZuoZe+kZR8ytVnTnN1Iiyj5s8UAN8SRo7QzooHmKcgeoNY6nBA9RxW/4hVYYbaEHO0uc/XFYDHA+lAD8HH1pzk4ximhwcHtSsOV5oAarArj9a0tGsxciWaQ4SMZ+tZUYyXX8q6Fx/ZXhzZIR50+PwFAFe8ureGSNAm4Oear/AGeO7tLie1O0x/MV9qouQy5HLDmrFtK1lpN1IOs58pfp3oAzLUs5LuO9WDt4BIqK3JK7QPlFTLCpcDoaAHpgnC9KfgH8KYBhuKkIA5oAjY9h9aapAGar3V0sR45NU2uJJW2KcA0AXppypAQbiarCJ3cZqxbRghQhyanLRW+qeQzZGBk+hNAEBj2QMeMiktpQ7Ko44zU1+fIjcNjI7VmWj5uYsd8cUAbJJXBboKcjBx7UswwpFQpxH+HFAG74b1mTQ9Q81GIViCwFfT/hm0tNX03T9YgC75V2s3tXyG/Kncc19O/BdZm+FtorORKJjIv+6DQB297pptlmAO5DhsV534qsTaRzOB8s0ny16tqE3nJD6MvNcprlot9JBanlFYGgD578fQeXACcCZxnFed25Ic+or0n4wkprhSEfKh24HtXnMzokgxx6igBFfKOx9cGlK7rA+p6UsaeYjKO5zU7oPK2joBQBix/fx3FXLYkscndxxVWZTHcEHjIqewO2cAnOeBQBNqPIhJHaqcjDy9v93vWhfKPs6s555xWXjcMH60ATuf3KGmwtmZOOppuSyEdhUluAZo1HUtQBgeITnxBNjsyj9BRUWsnOu3H/AF1xRQBQk/1r/U/zrt0ffFbuRw0a/wAq4iX/AFr/AO8a6/SpPO0e2OeUyv5UATFCT7A8VLbvtfK/Q0wMcsaRCFkAH8XNAGkSRID2NOuHMZimiba6HIIoX5lBNDoGiII70AdR4nT+2vDtnr1ug8xAILoD+8OhP1rjoyGJDcYFdt8Mp4Zb2fQL5sWepKY8nor/AMJrA1rRpNH1u8sLkYkicr9R2oAxQgVFOeM058Z4OeKddqsJwegqsriQ4HBoAswABVfvmtFGMhCn7pPNY6MxYKD3rTgJRFYjq3fvQBVvMCUoORmr+lqqypv+6vequobBMpU5J7VNbseQehoA9e1WQeKPgHdkDdc6HcCTA6+Wa8UuoI5bMSry2M16R8PtYFpBqumS822oW7ROvr6Vwj2v2ZZLcnIGVH0oA56ORlKsnHNWSsjHzh25qsBtRvVWxV+0YyJsIwuOtACTN5tsHJwwFVYWlC8ZxV02bMAu75RVtkUQrHxx3oApxXLDJPIqT7WpwCO1O+zoAcUq2qEcigBklyCmMciqczZOcnk1fFvHnkGhreM4yvSgDPSNnBxmtCyiVGhwfm3CpBGqjgDFQ78Sps6qc0AaN4rjULnORginwz/ZwrJ9/v7CpLtvtMqzIQA6/Nz0NJcSWnkpGrZbHzEDvQBHeSNMFZjnOSPaqDj7wPXFWJmBQlf4eBUD5POOooASP7gB7UOcISO1OXvnrQQDET3oAdbEDDEehrW8VOtzcxeUf9HMa7T74rHwQP5VbVjNbGBzyBuX60AZsKkT7XbAzwauawCunWcK8bdzMKy5jIJk65L9PxrX1sD+1LiLJ2LjH5UAZSP5ScEnNOSdjJ0NTrGiqABn1pQiqeBwKAASnAAHNNk81wAOBUuF60/cFAGOlAGabMnOTk+9VDuilIbjtW7jd0rPvIldxjrmgCGG9MaDaOR0pscLzSmZidxOc0kVr+9BPQ1qIoVAB2FAFK6jkBJclgR3qijFCCOCuDmt1sGPDcg1k3duY3/2TQBrNKrW+8ngjk+9JnfBle3NY8dw4iaHqM5rSspQ0Q9PumgCUHMPvX1H8Eyk/gjT1D/vAjAp7Zr5YjY+c69uor3z4IahJCdNgVuqOGHtmgD1S7vJIYZY5Rho8kH2qno12typkJ/eAnNT+LJljtZJCMOVKk1ymi3phgd2b5iORQBw3xo01YGa8C8Ekk49a8GuJMyHnPOa+s/G+mR654XuVUbmMefpXyhq1m+n6lJBKCCpxzQBdsuIt3c1KxwVHrVeElYQR0qdPmCsewoApalCW2nBwKrRtsKOPWtiXEihSO1ZRiISQD+E5FAFy9PmWcchrNyOMVflOdMX2NUCoB+tADsnAA6VY05c3Ueeec1BtOBjpmrNgwS6BxwATQBx985fVZmPeY/zoqFm3XZbOcvn9aKAGS/61/8AeNdJ4ak3adcR90bcPx//AFVzcv8ArX/3jWx4XkxdSwkf6xP1FAGwGyWBOM8U58xsnzcgU/ywynjpUGN5GfpQBsW04eBSRyKmDZPHSs+wl/e+X+VaYXI/GgB1tI9tcRTREiWJgykeor1bx/pS+JPC+neLLFfnMYS6I/vDua8pY5jGPvA817B8CdSj1HT9Z8KXrApcxmSHPY+1AHiOpxjfz9azmIBJBwa6bxtpcui65d2M4IMTYHuK5V8F8UAWLQFnIJ57Vsr8luA/VTnmsSwiY3XXgc1t3UoZVAHG3FAFD5pJt5q7C5A3EcDiqlswO4Y6CrPPloi896ANXQpGN6GQkEZp2ubY5kX+JUy31q14WjWO1vLyUfLEuAfVjWJqMpmJJOWbGaAMiODe+TwCxNaCKEBHGaSOPaCSKkZQCM96AAcjAOKZjkZ55p2QMnFNZgpHHNAEmR6UzJ3H0xSBuBmnqNwJoAYOST1pJCV6cn0pcnOAKUDd8xoAgHmP14FIQsSkmnXEyxLx1rOlnL9epoAmku2I2xk4606aYRRAZy7fpVe1Qebl+gFRTMplLHkDpQBrWj7oipOT3qWc4Cr0rIgm8q4xnCnFXHmDzmMnkDI96ALYwr569qU4C4Pemj5iv509lwMmgBueV+tOjDecGzgUildwA607G1wxOFHJoAuyC2UxTnBYAfL/ALVZFxKzzySyNyx5qNbnzJSoOQc4qpcudwBJ9KANFCTjbzmpV9GFY9tcNFLhm6c1rROsoyDQBJgbeBSMDsHHOaGUjkHjpSBskCgBPM2g1UiYPM/PTmrU2NhIFU7If6Q49qALyoNo46UpT8AaDwQBSNnpnigBpwPl7CkmUOmCM5p6gfxdaGII4FAGPJbmGcHqpNW9PGBImed1WXhEkeGGRWcjG3nYMaAL33ZkI5HQ16z8Hrwx+J0gJ4jiBAH1ya8qVVMakd+a9F+DwkbxXJcIpIWLk+nFAHuvjZhHoy3LHMbOSa8mXV3S7Zg37rBwK9e19Bd+AUM458wnPtXzvqlwbZ1RfujIoA9q8E6rBeWrW8rZ3p0NeP8Axn8JvFdyXtsmEJ7Cr3g/WGt5mO7HPX2r2LUdKi8ReFzNGgciPn8qAPjpHfyCmfn3YxWpbkBAPQYqTxDpw0nxI9vKuDknFRSfKeKAFUgtmoygMjD+9TkIHDdT0psziNgw+lAFY5FrKOynFU1O/bnqKvruazmbAwTmqEakKSPWgCUHcpAOMGpLYhPPY9o2OfwqBFbnB5p4JFlfMe0R/lQBxkX+tT6j+dFEf+tT6iigAl/1r/7xq3os3k6pbv0G7afx4qpL/rX/AN40iMVcMOoOaAO6n/dzuh6GqrjaFAHep5m85YZf76BqYF+cE/rQBJaxlZlYDk9a1wSjEN3NYnnMsgxgGthG8yNT64oAkzgg461qeEdZk0PxJZajCdvlyfP9KyzwQOtRkcMQRQB7N8c/DyanY2viDTQHWeIOdvORXgLxYLcEEHpX0f8ACPU08ReF20O9IaWAER59K848aeEDZahOIVx8+MUAef2KMq7gfatB4SYlPSr0Gi3CtsCE4OeBWwnh+8lGfJbZwAcd6AOVghCjbjO6tex02W7cCJcLjlz0FdZpng4IPPv5VihHLZ7CsHxR4ggQjTtGUJbx/K0g6vQBHql9Ba2K6dbHJBy7D+I1z7EuQM1CNzuS3JPNTINvzEc0ASA4ODQ3O0CkY+1KARQA44zg9AcUwpg/SnLz145oDAgg+tADBwTmn9FzTW6nijdhQO9AAvBJNJyyGkA545Jp7ZAA/KgChfYCe/Ws9cmQN2FWNRYmTb19aib92QvtQAsr4XA9eahKYx64pDl/Y5pWclyQOgxQAkgIwR0PFWId7OJAckDFRIC0OOmOan0tv3rq2ORQBowuAgz0FTMw2jHQ1QlcQHaxyG7VLISsakHgDdQA1pvK2ljzmobiaTySd3DnikuAXEJP8ZyabexhPungdqAIt3krGy+pFS3KiSMMvcVUZsrt9Dmnxy7sg8CgB7QmaEOo+ZfvUtrMYjkHj0qxYOC/P8XBqteQmC4YAfKeRQBqiTcgkU/LUmVAHqazbCYhthxsb9Kukb3K9x0oAfPzGRVG3JW4Jq7Kvy5zwKoBx54x60AasZPU9aaXy2KVOe/FGPmOaAH4H6Uwrg8UpfaDjqaQ52gigBfu8dRWZqcYIEgxnNX8kng1S1FQBjPB60AP02TzCUzwBXqHwEvBD45SwmwY7yNoxnsa8ks2EJdw3OMCu5+Fdx5XxE0CZTgmYD86APqL4kx/2Z4Q8pWAVW6+1fLviW5CXSqCMbck19I/HefGiRwBsb+tfKfiuX98FB+YjFAE+kaqVvYyG+UnBr6g+DOrx3unTWr4ZTxivjaGQxOMEgg1798ANXMepyQ7sq4GPY0Ac5+0doLaV4yW7RSIpAMY6V5wD5icd6+lf2odKN54StdRjTcycMRXzVa/6pD0OBQAsfzKPVaWZFkUgdcUICmR60Y2qT60AVYP+PCcZ6VRjY7yvrV2D/jznHY1TA2yg9KAFib5SemDSXD40bUWx1UDP1NNYnY3IGabqbeV4enHUyOoz+NAHKRf61PqKKIv9an+8KKACX/Wv/vGminS/wCtf/eNMoA7DTG87RLds/NGxSp5SCw29BWR4fvIorG5hmkRMsGXccflVtb232gefHwe7UAWpBhxjritWwb/AEcZ6g1hG/tt4/fx4z/eqzY6lbKZBJcxAHkZYUAbccZMjN2pSoVcdzVNdVsuf9Mgwf8AbFK2pWDDH223/wC+xQB1XgPXpPDviGG7RsRk7WHtXq/i2W11SRbuAgiRQwx618//ANpWHlYN7b/99iuo0bxpYxWkdvcahbgR/dJcUAev+GNEtZ7X7TclRgd6p+KvFGmaTZC3tvLLI3XvXn2s/ES0i02O3stStm3Z3bJBXn15rUF5OXnvYjk/3xQB0nibxZdashgt3ZIWJBwa56CMIFB5PeoY7zT0Bxdwdc/fFPGo2GP+PuD/AL7FAFtEAPFSDqMjtWe2qWY6XUH/AH2Keuq2J63UI/4GKALu7bgkUE5yRVI6nZn/AJfIMf74oGo2Kc/bIDkf3xQBb5P5UigjFVRqViOt5B0/vinf2rZf8/cGP98UAW2BwcVEVBOO+Kg/tSxzzdwH/gYpjalZA8XkHX++KALaqQfoKUyYRnboBxVRtSscAC8g56/OKr3upWhg8uO5iOfRxQBEz72DEfeOTUVy5aVsCo1vLUR8zx5/3hULXduDxNGe/wB6gC1G21GBHPamD7h9ajF5bty00ecf3qaLu3H/AC2j5P8AeoAsDOAKaZDFPleCKj+22+D++j/76pHurZhnzo8/7woAnlYuS5NXXnDWiDueDWZDdW3mYeaML/vCllvLYptWeLr/AHqALMspkKnsnSmksyMWqsbu3HAnjx/vU83lvtwLiLB6/NQAsXJOaV/lbkVA11bgHE8ee2DSm8gZRmaMn/eoAuWjbJk7A1p3cZmti/Up0rAW7t+D50Yx0+YVtQajY+SA15AM9QXFAGdHlW4NatrJvCt3FYsl1bK8gW5iIzwdwq7Z31nHGN91D0z96gDTuJBsAPeqMcQFxIOmaim1C0bBF1D/AN9Cnrf2Xmbjdw8j+8KANNBhRmlHOfQVRXU7JjhruDH++KV9RscYF5B/32KALDNjP6U9WBBHes86lZDBF1Cf+Bil/tWyDjFzF/31QBfA596r3qgwNnrTF1OxDZ+1w/8AfYqrealaMCFuYmz6MKAIAoVAO5rsvh+u3x3oRBxsnU/jXDLd27Spm4iC98sK7DwVq2lW3jLR5rnULWG3S4UySPIAqjPUmgD6T+PTBxAuTlVBIr5c8UgvqIA4IUV9B/F7xx4T1GRGsPEelXIKgERXKt/KvnbxJqNjLqG+C8gkU91cGgCg8eGzmu6+EWpPZeIoFJwGcZ57V5497bdriM/8CrQ0HWoLHWLSf7TEqq43HcOBQB9seMbEav8AC/UYmG9khZ1z7c18YWgxHgnlTivrfQviL4Kk8LS2954s0VXmhKFHu0BGVx0zXyHNfWMd7dIt7AYxM21g4wwzwRQBdwTgk96RvQ1T/tKy8sf6XBkHON4p/wDaVg0gJu4P++xQBWjXEVyB27VW3Fm3HsMU+O+tVkus3MOG4Hzdaq/a7b/nvF/31QBLICIBkYJPFQeIJCuiwxn+KX+QqX7Za+WMzxfL0G4VQ8R3UU9taLDIjkbi205xQBiRf61P94UURf61P94UUAXJbVPNfluppv2VPVqKKAD7Knq350fZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerfnR9lT1b86KKAD7Knq350fZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerfnR9lT1b86KKAD7Knq350fZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerfnR9lT1b86KKAD7Knq350fZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerfnR9lT1b86KKAD7Knq350fZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerfnR9lT1b86KKAD7Knq350fZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerUfZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerfnR9lT1b86KKAD7Knq350fZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerUfZU9W/OiigA+yp6t+dH2VPVvzoooAPsqerfnR9lT1b86KKAD7Knq350fZU9WoooAPsqerfnR9lT1b86KKAD7Knq350fZU9W/OiigA+yp6tR9lT1b86KKAD7Knq350fZU9W/OiigB0Vqnmpy3UUUUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal reconstruction of CT of the pelvis shows a well-defined benign tumor of the femoral neck with sclerotic border.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37857=[""].join("\n");
var outline_f36_62_37857=null;
var title_f36_62_37858="Intrauterine position";
var content_f36_62_37858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Intrauterine position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 569px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For most of gestation, the tibiae and feet are medially (internally) rotated, and the hips and femora are laterally (externally) rotated. The tibiae, feet, and femora become molded in these positions as the fetus grows.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37858=[""].join("\n");
var outline_f36_62_37858=null;
var title_f36_62_37859="Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure";
var content_f36_62_37859=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37859/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37859/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37859/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37859/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37859/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37859/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/62/37859/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ORAL CONTRACEPTIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have ever used oral contraceptives have a significantly lower mortality rate (adjusted relative risk 0.88, confidence interval 0.82 to 0.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/1\">",
"     1",
"    </a>",
"    ]. Nonetheless, chronic use of oral contraceptives will slightly increase the systemic blood pressure (BP) in most women and may have other adverse effects on cardiovascular risk. Early epidemiologic studies using high-dose estrogen found a mean elevation in BP of",
"    <span class=\"nowrap\">",
"     3-6/2-5",
"    </span>",
"    mmHg, with approximately 5 percent of women developing overt hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/2\">",
"     2",
"    </a>",
"    ]. This is more likely to occur in patients who developed hypertension during a prior pregnancy or who have a family history of hypertension. Although the rise in BP is usually mild, malignant hypertension can very rarely occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/3\">",
"     3",
"    </a>",
"    ]. Cessation of therapy typically leads to a return to baseline BP within two to 12 months, but proteinuria may persist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Dose-dependence and mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms responsible for the hypertensive effect of oral contraceptives are incompletely understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/2\">",
"     2",
"    </a>",
"    ]. Both estrogen and progesterone appear to contribute in a dose-dependent fashion. The 5 percent incidence of hypertension reported in 1988 was largely derived from studies of high-dose therapy in which the estrogen dose was at least 50 &micro;g and the progestin dose was 1 to 4 mg. However, current preparations contain as little as 20 percent of the estrogen and progestin in previous preparations. A report from the Nurses' Health Study prospectively evaluated almost 70,000 female nurses, aged 25 to 42 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/5\">",
"     5",
"    </a>",
"    ]. After adjustment for age, weight, smoking, family history and other risk factors, the relative risk of hypertension compared to women who never used oral contraceptives was 1.8 for current users and 1.2 for previous users. Overall, only 41.5 cases per 10,000 person-years could be attributed to oral contraceptive use; this risk rapidly declined with cessation of therapy.",
"   </p>",
"   <p>",
"    How hormone therapy might raise the blood pressure is unclear. The renin-angiotensin system may be involved, since estrogen stimulates the hepatic production of renin substrate (angiotensinogen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a similar response is seen in women who do or do not develop a rise in BP and the administration of an angiotensin converting enzyme inhibitor does not reverse the hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cardiovascular consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main concern with an oral contraceptive-induced rise in blood pressure is the development of persistent hypertension and subsequent premature cardiovascular disease. The incidence is greatest in women over the age of 35 and in those who have coronary risk factors, particularly smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/7\">",
"     7",
"    </a>",
"    ]. In a meta-analysis of 14 independent studies published from 1980 to 2003, the relative risk of stroke and heart attack was increased two-fold in current users of \"low-dose\" oral contraceptives (defined as less than 50 &micro;g of ethinyl estradiol) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/8\">",
"     8",
"    </a>",
"    ]. A statistically significant increase in risk for ischemic stroke was also seen with both second and third generation oral contraceptive formulations, while a trend toward an enhanced risk for myocardial infarction was noted among third generation low-dose oral contraceptive users.",
"   </p>",
"   <p>",
"    Since these risks are higher in women who are over age 35 and who smoke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/9\">",
"     9",
"    </a>",
"    ], current recommendations exclude such individuals from oral contraceptive use. However, some authorities have also questioned the use of oral contraceptives in younger, non-smoking women with either polycystic ovary syndrome or the metabolic syndrome since their increased baseline risk is likely to be aggravated by oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported increases in relative risk of hypertension with oral contraceptive use do not translate into increases in long term overall mortality. Thus, for most women, the dangers of oral contraceptive use are far outweighed by the multiple benefits of effective contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/9\">",
"     9",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ESTROGEN REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmenopausal estrogen replacement therapy (ERT, or HRT when combined with a progestin) consists of much lower estrogen doses than in oral contraceptives. It appears to have a neutral effect on blood pressure as illustrated by the following observations from two large randomized trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Women's Health Initiative is the largest (16,000 women) randomized, placebo-controlled trial that has evaluated the effect of estrogen-progestin replacement on outcomes in postmenopausal women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/10\">",
"       10",
"      </a>",
"      ]. At 5.2 years, hormone replacement produced only a small increase (1.5 mmHg) in systolic pressure compared to placebo. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"       \"Postmenopausal hormone therapy: Benefits and risks\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similar findings were noted in the PEPI trial in which ERT, with or without progestins, did not affect blood pressure at three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies involving fewer women have found a reduction of ambulatory BP and a greater dipping of nocturnal BP in ERT users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that HRT may slow the rise in systolic pressure over longer follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/14\">",
"     14",
"    </a>",
"    ]. However, because of the increases in coronary, stroke, and venous thromboembolic risk demonstrated in the WHI, HRT is not given for cardiovascular protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37859/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13075887\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic use of oral contraceptives will slightly increase the systemic blood pressure (BP) in most women but does not increase overall long-term mortality. Although the rise in BP is usually mild, malignant hypertension can very rarely occur. Cessation of therapy typically leads to a return to baseline BP within 2 to 12 months. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Oral contraceptives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms responsible for the hypertensive effect of oral contraceptives are incompletely understood. Both estrogen and progesterone appear to contribute in a dose-dependent fashion. The renin-angiotensin system may be involved, since estrogen stimulates the hepatic production of renin substrate (angiotensinogen). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Dose-dependence and mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of persistent hypertension is greatest in women over the age of 35 and in those who have coronary risk factors, particularly smoking. Recommendations exclude from oral contraceptive use women who are over age 35 and who smoke. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cardiovascular consequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postmenopausal estrogen replacement therapy (ERT, or HRT when combined with a progestin) consists of much lower estrogen doses than oral contraceptives, and appears to have a neutral effect on blood pressure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Estrogen replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/1\">",
"      Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010; 340:c927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/2\">",
"      Woods JW. Oral contraceptives and hypertension. Hypertension 1988; 11:II11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/3\">",
"      Lim KG, Isles CG, Hodsman GP, et al. Malignant hypertension in women of childbearing age and its relation to the contraceptive pill. Br Med J (Clin Res Ed) 1987; 294:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/4\">",
"      Ribstein J, Halimi JM, du Cailar G, Mimran A. Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 1999; 33:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/5\">",
"      Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/6\">",
"      Goldhaber SZ, Hennekens CH, Spark RF, et al. Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am Heart J 1984; 107:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/7\">",
"      Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989; 298:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/8\">",
"      Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005; 90:3863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/9\">",
"      Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003; 362:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/10\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/11\">",
"      Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/12\">",
"      Butkevich A, Abraham C, Phillips RA. Hormone replacement therapy and 24-hour blood pressure profile of postmenopausal women. Am J Hypertens 2000; 13:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/13\">",
"      Cagnacci A, Rovati L, Zanni A, et al. Physiological doses of estradiol decrease nocturnal blood pressure in normotensive postmenopausal women. Am J Physiol 1999; 276:H1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/14\">",
"      Scuteri A, Bos AJ, Brant LJ, et al. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 2001; 135:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37859/abstract/15\">",
"      Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330:342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3827 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37859=[""].join("\n");
var outline_f36_62_37859=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13075887\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ORAL CONTRACEPTIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Dose-dependence and mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cardiovascular consequences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conclusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ESTROGEN REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13075887\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_62_37860="Thompson squeeze test for Achilles tendon";
var content_f36_62_37860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Thompson squeeze test for Achilles tendon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This test is performed with the patient's feet hanging over the edge of the examining table. When the examiner squeezes the calf muscle, on the uninjured side there is normal plantar flexion of the foot; on the side with a complete Achilles tendon rupture, there is no plantar flexion. It is important to note that in patients with significant but incomplete rupture of the tendon, the patient may still demonstrate a normal Thompson test as well as substantial strength.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37860=[""].join("\n");
var outline_f36_62_37860=null;
var title_f36_62_37861="Evaluation and medical management of end-stage rheumatoid arthritis";
var content_f36_62_37861=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and medical management of end-stage rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37861/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37861/contributors\">",
"     Simon M Helfgott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37861/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37861/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37861/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37861/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/62/37861/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the availability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), other disease-modifying antirheumatic drugs (DMARDs), and biologic agents, some patients with rheumatoid arthritis (RA) fail to adequately respond to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37861/abstract/1\">",
"     1",
"    </a>",
"    ]. Via a variety of mechanisms, the joints of such patients may eventually be destroyed, requiring joint arthroplasty to restore function.",
"   </p>",
"   <p>",
"    This stage of the disease, termed &ldquo;end-stage RA,&rdquo; is characterized clinically by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain occurring with minimal activity and at rest",
"     </li>",
"     <li>",
"      Periarticular muscle atrophy and weakness",
"     </li>",
"     <li>",
"      A significant decline in functional status resulting in disability",
"     </li>",
"     <li>",
"      Radiographic evidence of articular damage (eg, severe loss of joint space",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erosions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the evaluation and medical management of patients with end-stage RA. The medical management of patients with active disease and the surgical management of those with end-stage RA are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=see_link\">",
"     \"Total joint replacement for severe rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95779434\">",
"    <span class=\"h1\">",
"     ETIOLOGIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progression of disease which culminates in end-stage RA usually occurs over years to decades. The causes of joint destruction include any combination of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Refractory disease, which has failed to respond to multiple therapies",
"     </li>",
"     <li>",
"      Intolerance or development of toxicity to one or more antirheumatic therapies, thereby requiring the discontinuation of agents which may have been beneficial",
"     </li>",
"     <li>",
"      Prolonged delay in the initiation of traditional nonbiologic disease-modifying antirheumatic drug (DMARD) therapy or of biologic DMARDs",
"     </li>",
"     <li>",
"      Poor compliance with the therapeutic regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When assessing the patient suspected of having end-stage disease, the principal clinical challenge is to identify whether an underlying inflammatory process is continuing or whether the joint damage and functional deterioration are due to secondary osteoarthritis. The following is a list of clinical findings which may help the clinician determine the presence or absence of ongoing inflammation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hallmarks of end-stage joint disease are pain and loss of function. Although pain at rest is highly suggestive of end-stage joint damage, an adjacent bursitis, tendonitis, or nerve entrapment syndrome may produce similar pain. These possibilities may be distinguished by findings on physical examination, by nerve conduction studies, and by radiographs of the affected joint, which should confirm the presence of joint destruction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42472?source=see_link\">",
"       \"Overview of soft tissue rheumatic disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To minimize the level of stress on a destroyed joint, most patients decrease their activities. Immobilization can reduce the degree of synovitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37861/abstract/2\">",
"       2",
"      </a>",
"      ]. However, over time, the lack of activity results in joint contractures, foreshortened tendons, muscle atrophy, and weakness. Movement against these contractures may result in pain.",
"     </li>",
"     <li>",
"      Morning stiffness is a symptom suggesting active joint inflammation; however, its presence may also reflect the presence of severe joint contractures and ankylosis, resulting from end-stage disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"       \"Clinical features of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Changes consistent with osteoarthritis may develop in joints previously damaged by an inflammatory synovitis. Bony hypertrophy and osteophyte formation can, therefore, be observed. These features should not be mistaken for the synovial thickening observed in active RA and can be detected using plain radiography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      magnetic resonance imaging (MRI). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=see_link\">",
"       \"Clinical manifestations of osteoarthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of more superficial joints, such as the elbows, wrists, knees, and metacarpophalangeal joints, may provide a better assessment for the presence of synovial thickening, which is considered a hallmark feature of active, inflammatory synovitis. By comparison, examination of deep-seated joints, such as the shoulders and hips, may be less helpful in determining the relative degree of inflammation.",
"     </li>",
"     <li>",
"      Neurologic examination should focus upon excluding conditions that could contribute to the functional decline of the patient. These include cervical myelopathy and peripheral neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37861/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"       \"Clinical features of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41080?source=see_link\">",
"       \"Cervical subluxation in rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20697?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The involvement of other major organ systems by longstanding RA may also contribute to the patient&rsquo;s functional decline. This may include pleural or parenchymal lung disease, as well as cardiac involvement. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link\">",
"       \"Overview of lung disease associated with rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=see_link&amp;anchor=H22#H22\">",
"       \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Cardiac disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite careful clinical observation, laboratory analysis is required to confirm the extent of active, ongoing inflammation in the patient with end-stage RA. The laboratory findings helpful in determining RA-associated disease activity include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of a normocytic, normochromic anemia",
"     </li>",
"     <li>",
"      An elevated erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      An elevated serum C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      A decreased serum albumin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is particularly helpful to compare the values obtained at the time of assessment with those obtained during a period of definite, ongoing inflammation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H344392649#H344392649\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Assessment of disease activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If surgery has been performed, the synovium in the patient with ongoing inflammation may show the characteristic histopathology of rheumatoid synovitis. By comparison, advanced fibrosis is observed in those with end-stage disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3754?source=see_link\">",
"     \"Synovial pathology in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of the patient with end-stage RA requires an accurate assessment of the current level of ongoing RA-associated inflammation. Specifically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is there sufficient evidence to suggest that the disease is still active?",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Are the clinical features, namely pain and loss of function, principally a result of noninflammatory damage?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the level and type of disease activity has been determined using the criteria discussed in the previous section, the optimal therapeutic choices may be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     DMARDs and anticytokine therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the RA is considered to be active still, therapeutic interventions using traditional DMARDs, biologic therapies, or an antirheumatic kinase inhibitor, alone or in combination, should be considered. The decision to initiate DMARD therapy that the patient has never previously received is largely empiric. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to offer other therapeutic agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    and biologic or other therapies, to patients with end-stage disease must be carefully weighed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .) If anticytokine therapy is chosen, the therapeutic trial does not need to be prolonged because, if effective, patients show a clinical response within several weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids, in low doses such as 2.5 to 7.5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day, may offer some relief of pain and stiffness. However, the risks and benefits of such therapy must be carefully weighed. Intraarticular glucocorticoid injections may provide temporary pain relief and can be repeated episodically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) including cyclooxygenase (COX)-2 inhibitors can alleviate some pain and stiffness. However, their use in patients with end-stage RA may be associated with a greater risk for gastrointestinal or cardiovascular toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37861/abstract/4\">",
"     4",
"    </a>",
"    ]. Whether a patient with end-stage rheumatoid arthritis would benefit from these agents should be weighed carefully against the option of using pure analgesics. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Analgesics'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analgesics, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , and tricyclic antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ), may provide pain relief. An increasingly used agent for neuropathic pain is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (neurontin). The application of ice, heat,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topical analgesics (such as Ben-Gay, Aspercreme,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , Tiger-Balm, or bag-balm) may also be useful.",
"   </p>",
"   <p>",
"    When necessary, the administration of opioid analgesics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , hydrocodone, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    , should be considered, particularly if the level of pain is severe and if surgical options, such as joint arthroplasty or joint fusion, are contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may play an important role in the management of patients with end-stage rheumatoid arthritis and in the avoidance of disability through interventions earlier in the disease course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37861/abstract/5\">",
"     5",
"    </a>",
"    ]. Significant cervical spine disease may be present in patients with longstanding RA, and surgery is sometimes required on an urgent basis in patients with severe involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=see_link\">",
"     \"Total joint replacement for severe rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41080?source=see_link&amp;anchor=H16#H16\">",
"     \"Cervical subluxation in rheumatoid arthritis\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rehabilitation therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful evaluation by an experienced physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occupational therapist is strongly recommended. The goals of such an assessment should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Development of a home exercise program to maintain joint range of motion and to prevent further functional decline",
"     </li>",
"     <li>",
"      The use of splints to prevent or correct joint contractures",
"     </li>",
"     <li>",
"      An assessment of activities of daily living to evaluate whether assistive devices would benefit the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95779423\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Events that may culminate in end-stage rheumatoid arthritis (RA) usually occur over years to decades and include any combination of the following: refractory disease, which has failed to respond to multiple therapies; intolerance or development of toxicity to one or more antirheumatic therapies, thereby requiring the discontinuation of agents which may have been beneficial; prolonged delay in the initiation of traditional disease-modifying antirheumatic drug (DMARD) therapy or of a biologic agent; and poor compliance with the therapeutic regimen. (See",
"      <a class=\"local\" href=\"#H95779434\">",
"       'Etiologic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      End-stage RA is characterized clinically by pain occurring with minimal activity and at rest, by periarticular muscle atrophy and weakness, by a significant decline in functional status resulting in disability, and by radiographic evidence of articular damage (eg, severe loss of joint space",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erosions). There is an absence of evidence for inflammation on the complete blood count and on measurement of acute phase reactants and serum albumin. Synovial histopathology in patients requiring surgery demonstrates advanced fibrosis, without evidence of active synovitis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients presumed to have end-stage RA should be carefully evaluated to exclude the possibility of untreated active synovitis. Low-dose oral glucocorticoids, intraarticular glucocorticoids, and various analgesic medications may be of benefit. Surgery, including intervention for severe cervical spine involvement, may play an important role in the management of patients with end-stage rheumatoid arthritis. Patients should be evaluated by a physical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occupational therapist with expertise in the care of patients with arthritis to optimize rehabilitative potential. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37861/abstract/1\">",
"      O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37861/abstract/2\">",
"      THOMPSON M, BYWATERS EG. Unilateral rheumatoid arthritis following hemiplegia. Ann Rheum Dis 1962; 21:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37861/abstract/3\">",
"      Nakano KK, Schoene WC, Baker RA, Dawson DM. The cervical myelopathy associated with rheumatoid arthritis: analysis of patients, with 2 postmortem cases. Ann Neurol 1978; 3:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37861/abstract/4\">",
"      Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37861/abstract/5\">",
"      Moran SL, Bishop AT. Clinical update: surgical management of rheumatoid hand. Lancet 2007; 370:372.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7522 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37861=[""].join("\n");
var outline_f36_62_37861=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95779423\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95779434\">",
"      ETIOLOGIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DMARDs and anticytokine therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rehabilitation therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95779423\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42472?source=related_link\">",
"      Overview of soft tissue rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3754?source=related_link\">",
"      Synovial pathology in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_62_37862="Repeat cesarean delivery";
var content_f36_62_37862=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Repeat cesarean delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37862/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37862/contributors\">",
"     Vincenzo Berghella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37862/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37862/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37862/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37862/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/62/37862/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 90 percent of women who undergo cesarean delivery have a repeat procedure in subsequent pregnancies and approximately one-third of cesarean deliveries in the United States are repeat operations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/1\">",
"     1",
"    </a>",
"    ]. Issues specific to repeat cesarean delivery will be discussed here. Primary cesarean delivery and topics common to both primary and repeat cesareans and trial of labor after a previous cesarean delivery are reviewed separately. (See individual topic reviews on cesarean delivery). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TIMING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20290923\">",
"    <span class=\"h2\">",
"     Previous lower uterine segment incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns delivered by planned or scheduled cesarean are at increased risk of respiratory and other morbidity compared with newborns delivered vaginally or by emergent cesarean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/2\">",
"     2",
"    </a>",
"    ]. The optimum time for repeat cesarean delivery appears to be at 39 to 40 weeks of gestation. Compared to earlier (37 to 38 weeks) or later (&ge;41 weeks) delivery, scheduled delivery during the 39th or 40th week results in the lowest rate of adverse neonatal outcome while minimizing the risk that spontaneous labor will ensue and avoiding the risk of postterm stillbirth. The American College of Obstetricians and Gynecologists (ACOG) recommends not performing non-medically indicated deliveries before 39 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=see_link&amp;anchor=H6#H6\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Assessment of fetal pulmonary maturity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This recommendation has been supported by several large studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As an example, a large prospective cohort study reported the incidence of the composite primary outcome (neonatal respiratory problems, hypoglycemia, sepsis, seizures, intensive care unit admission, hospitalization &ge;5 days, etc) by gestational age at elective repeat cesarean delivery was 15.3 percent at 37 weeks, 11.0 percent at 38 weeks, 8.0 percent at 39 weeks, 7.3 percent at 40 weeks, 11.3 percent at 41 weeks, and 19.5 percent at &ge;42 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/4\">",
"     4",
"    </a>",
"    ]. The higher incidence of adverse neonatal outcome before and after 39 to 40 weeks was statistically significant. Limitations of this study were absence of information about fetal lung maturity testing or stillbirth rates.",
"   </p>",
"   <p>",
"    Further analysis of data from this study also showed no maternal benefit from early delivery; elective delivery before 39 weeks did not significantly reduce the risk of adverse maternal outcomes compared to elective delivery after 39 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risks of iatrogenic early term birth appear to outweigh any theoretical benefits when the indication for delivery is &ldquo;soft,&rdquo; such as suspected macrosomia without maternal diabetes or history of fetal, maternal, or obstetric complication in a previous pregnancy.",
"   </p>",
"   <p>",
"    Some investigators have used ultrasound to assess the lower uterine segment of women with prior cesarean delivery to evaluate for risk of uterine scar rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/7\">",
"     7",
"    </a>",
"    ]. There is insufficient evidence to use this assessment for timing repeat cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Previous classical incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated the optimum timing of delivery in women with a prior classical hysterotomy incision. Intervention before 39 weeks of gestation may reduce the risk of uterine rupture associated with spontaneous labor at term. However, early delivery can also lead to complications from prematurity and may not prevent uterine rupture since it has been reported as early as the second trimester.",
"   </p>",
"   <p>",
"    In the stable patient with a previous classical uterine incision, repeat cesarean delivery is recommended at about",
"    <span class=\"nowrap\">",
"     36",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     37",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. We do not suggest assessing fetal pulmonary maturity by amniocentesis, given the risk of amniocentesis, as well as the continuing risk of uterine rupture as the uterus continues to grow and onset of spontaneous labor becomes more likely. Another option is to administer a complete course of glucocorticoids and then perform the cesarean delivery. This is an investigational approach, which we seldom use since the efficacy of glucocorticoids after 34 weeks of gestation for preventing neonatal respiratory problems has not been proven, although results from one trial showed a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link&amp;anchor=H13#H13\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Gestational age at administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study attempted to address the issue of timing delivery after a previous classical hysterotomy incision by performing a decision analysis of the following four options:",
"   </p>",
"   <p>",
"    &nbsp;(1) delivery at 36 weeks of gestation without amniocentesis,",
"   </p>",
"   <p>",
"    &nbsp;(2) amniocentesis at 36 weeks of gestation with delivery if the fetus is mature and 48 hours after antenatal corticosteroids if the fetus is immature,",
"   </p>",
"   <p>",
"    &nbsp;(3) weekly amniocentesis starting at 36 weeks of gestation with delivery upon fetal lung maturity,",
"   </p>",
"   <p>",
"    &nbsp;(4) delivery at 39 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors concluded that strategy (1) provided the lowest risk of a maternal-neonatal catastrophic outcome associated with uterine rupture. Their rationale was that although complications of prematurity at 36 weeks of gestation occur more frequently than uterine rupture, these complications are often minor and transient, and therefore, not as detrimental to maternal-neonatal quality of life. Thus, in this model, there was no benefit of offering fetal lung maturity testing because it would lead, in cases of negative results, to further expectant management in a risky situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative issues are generally similar to those for primary cesarean birth, with some exceptions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=see_link\">",
"     \"Cesarean delivery: Preoperative issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perioperative morbidity significantly increases with the number of cesarean deliveries performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This risk was illustrated in a series including over 30,000 women undergoing cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/14\">",
"     14",
"    </a>",
"    ]. The frequency of the following complications increased as the number of cesareans increased from one to six or more: placenta previa or accreta, hysterectomy, blood transfusion of four or more units, cystotomy, operative time, hospital days, postpartum endometritis, and need for postoperative mechanical ventilation (",
"    <a class=\"graphic graphic_table graphicRef80662 \" href=\"mobipreview.htm?21/43/22204\">",
"     table 1",
"    </a>",
"    ). Given these risks, preoperative patient counseling and consultation with an anesthesiologist are particularly important before repeat cesarean delivery.",
"   </p>",
"   <p>",
"    We suggest placing two large-bore intravenous lines for the surgical procedure in women with two or more prior cesarean deliveries, placental abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of dense adhesions. In the absence of red blood cell antibodies or additional risk factors for intraoperative or postpartum hemorrhage (eg, placenta accreta), a clot for type and antibody screen is probably sufficient.",
"   </p>",
"   <p>",
"    The surgeon should be prepared to manage a severe postpartum hemorrhage. For patients with four or more prior cesarean deliveries or with a history of intraoperative complications, it is prudent to have a general surgeon or an experienced gynecologic surgeon aware of the case and readily available to assist, if needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Informed consent should include the possibility of cesarean hysterectomy and injury to viscera. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29367?source=see_link\">",
"     \"Peripartum hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If placenta previa or accreta are suspected sonographically, more extensive preoperative preparation and patient counseling will be needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/60/42952?source=see_link\">",
"     \"Management of placenta previa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OPERATIVE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low transverse skin incision (eg, Pfannenstiel) is most commonly employed for repeat cesarean delivery. A midline vertical incision is rarely needed, but may be considered in some emergency cesarean deliveries or in cases of suspected placenta previa or accreta, where a vertical incision may be more likely than a low transverse incision to provide both rapid and good exposure of the uterus.",
"   </p>",
"   <p>",
"    Formation of adhesions is common after cesarean delivery, and the extent and density increase with increasing numbers of repeat cesarean deliveries: the reported prevalence of adhesions is 12 to 46 percent of women at their second cesarean and 26 to 75 percent of women at their third cesarean [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Because adhesions are often present in women with prior abdominal surgery, the fascia and peritoneum should be entered carefully to avoid injury to underlying, possibly adherent bowel or bladder. A surgeon experienced in complex abdominal surgery should be present if meticulous dissection of dense adhesions involving important structures is needed. Insertion of ureteral stents can be useful to facilitate intraoperative identification (and avoidance) of the ureters. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=see_link&amp;anchor=H20293380#H20293380\">",
"     \"Cesarean delivery: Technique\", section on 'Dense intraperitoneal adhesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If cystotomy occurs, we consult a urologist to evaluate the urinary tract and help with the repair. Similarly, if bowel injury occurs, we consult a general surgeon to evaluate the bowel and assist in the repair.",
"   </p>",
"   <p>",
"    General issues related operative technique are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IS THERE AN UNSAFE NUMBER OF REPEAT CESAREAN DELIVERIES?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who undergo multiple repeat cesarean deliveries are at increased risk of maternal morbidity, and the risk increases with the number of cesarean deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/14,20-23\">",
"     14,20-23",
"    </a>",
"    ]. However, there are insufficient data on which to base recommendations for the \"safe\" number of repeat cesarean deliveries.",
"   </p>",
"   <p>",
"    Several issues should be considered and discussed with the patient preoperatively:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complications relating to abnormal placentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of observational studies show that an increasing number of prior cesarean deliveries is strongly associated with an increased risk of abnormal placentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This was best illustrated in the largest prospective study of maternal morbidity associated with multiple cesarean deliveries, which included 6201 first, 15,808 second, 6324 third, 1452 fourth, 258 fifth, and 89 sixth cesarean deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/14\">",
"     14",
"    </a>",
"    ]. The odds of placenta previa and accreta progressively increased with the number of cesarean deliveries, and women with placenta previa were at very high risk of also having placenta accreta (",
"    <a class=\"graphic graphic_table graphicRef80662 \" href=\"mobipreview.htm?21/43/22204\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51302 \" href=\"mobipreview.htm?24/26/25003\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35032?source=see_link\">",
"     \"Clinical features, diagnosis, and course of placenta previa\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placental abnormalities may necessitate cesarean hysterectomy. In the series described above, the risk of peripartum hysterectomy at the fourth cesarean delivery was 1 in 40, increasing to 1 in 11 at the sixth cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of studies of maternal morbidity associated with multiple cesarean deliveries, the risk of placenta previa after one and after &ge;3 cesarean deliveries was",
"    <span class=\"nowrap\">",
"     10/1000",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     28/1000,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/25\">",
"     25",
"    </a>",
"    ]. The risk of placenta accreta in women with placenta previa and no cesarean deliveries and after &ge;4 cesarean deliveries was 3 to 4 percent and 50 to 67 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications relating to adhesion formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesions develop each time the abdomen is entered; however, the degree of adhesion formation from a cesarean delivery varies widely among individuals and is unpredictable.",
"   </p>",
"   <p>",
"    The presence of dense adhesions can make the surgical procedure (including extraction of the infant) more difficult and increase the risk of surgical complications, such as bowel or bladder injury and excessive blood loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/17,18,26\">",
"     17,18,26",
"    </a>",
"    ]. As an example, the large prospective series described above reported the incidence of cystotomy increased from 0.13 percent after a primary cesarean delivery to 1.94 percent after the fifth cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/14\">",
"     14",
"    </a>",
"    ]. Adhesions may cause the bladder to densely adhere to the lower uterine segment, eliminating the usual plane for blunt dissection, or they may distort the position of the bladder, requiring recognition that it may be adherent to the midportion of the uterus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=see_link&amp;anchor=H20293380#H20293380\">",
"     \"Cesarean delivery: Technique\", section on 'Dense intraperitoneal adhesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adhesions can also cause subfertility or small bowel obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Complications relating to trial of labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible desire for vaginal birth in a future pregnancy (vaginal birth after cesarean delivery [VBAC]) should also be considered by women planning a repeat cesarean delivery. The American College of Obstetricians and Gynecologists (ACOG) has recommended that women with two prior cesarean deliveries avoid a trial of labor in future pregnancies, unless they have also had a prior vaginal delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/27\">",
"     27",
"    </a>",
"    ]. These issues are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other long-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of incision-related complications, such as hernia or diastasis of rectus muscles, increases with increasing number of prior abdominal incisions. Attention to proper technique minimizes the risk of occurrence of these complications; however, if they do occur, we obtain surgical consultation for evaluation and repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11190914\">",
"    <span class=\"h1\">",
"     ANTEPARTUM UTERINE RUPTURE AND DEHISCENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine rupture is generally an obstetrical emergency requiring immediate intervention. (See",
"    <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=see_link\">",
"     \"Uterine rupture after previous cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history and appropriate management of asymptomatic uterine dehiscence remote from term is less clear. Most uterine dehiscences are diagnosed incidentally at repeat cesarean delivery before or during labor. Scar defects and uterine windows have also been detected in the nonpregnant uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] and during prenatal ultrasound examination, sometimes with extrusion of a sac containing fetal membranes and amniotic fluid. Management of these pregnancies is influenced by gestational age (eg, previable, preterm viable, term), but there is insufficient evidence to make firm recommendations. Near term, repeat cesarean delivery is probably the safest option to avoid progression to rupture. Remote from term, published and anecdotal case reports have described successful outcomes with expectant management, close monitoring, and early delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/30\">",
"     30",
"    </a>",
"    ] and with laparotomy to repair the defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/31\">",
"     31",
"    </a>",
"    ]. There is no standard or optimum approach; if the pregnancy is continued, the patient should be thoroughly counseled about potential risks to her and to the fetus.",
"   </p>",
"   <p>",
"    A defect in the scar can be seen as early as the first trimester, with the possibility of &ldquo;cesarean scar&rdquo; pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37862/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/21/16723?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/45/11988?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty percent of cesarean deliveries in the United States are repeat cesareans. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with a previous hysterotomy in the lower uterine segment, we suggest scheduling repeat cesarean delivery between 39 and 40 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This avoids the need for amniocentesis, but accepts a low risk that spontaneous labor will occur before the scheduled date of surgery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In stable patients with a previous classical uterine incision, we suggest repeat cesarean delivery at about 36 to 37 weeks, without confirmation of fetal lung maturity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This minimizes the risk of uterine rupture related to spontaneous labor, but also reduces the risk of complications related to preterm birth &lt;36 weeks. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Previous classical incision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no threshold below which the number of repeat cesarean deliveries can be guaranteed to be uncomplicated. Our approach is to discuss the increasing risk of complications with increasing numbers of cesarean deliveries (",
"      <a class=\"graphic graphic_table graphicRef80662 \" href=\"mobipreview.htm?21/43/22204\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef51302 \" href=\"mobipreview.htm?24/26/25003\">",
"       table 2",
"      </a>",
"      ). We inform each patient that the risk of placenta accreta rises in direct proportion to the number of previous cesareans, and this risk is dramatically increased if placenta previa is also present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Is there an unsafe number of repeat cesarean deliveries?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Martin, JA, Hamilton, BE, Ventura SJ, et al. Births: Final data for 2009. Natl Vital Stat Rep 2009. file://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_01.pdf (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/2\">",
"      Kamath BD, Todd JK, Glazner JE, et al. Neonatal outcomes after elective cesarean delivery. Obstet Gynecol 2009; 113:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/3\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 561: Nonmedically Indicated Early-Term Deliveries. Obstet Gynecol 2013; 121:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/4\">",
"      Tita AT, Landon MB, Spong CY, et al. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med 2009; 360:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/5\">",
"      Chiossi G, Lai Y, Landon MB, et al. Timing of Delivery and Adverse Outcomes in Term Singleton Repeat Cesarean Deliveries. Obstet Gynecol 2013; 121:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/6\">",
"      Tita AT, Lai Y, Landon MB, et al. Timing of elective repeat cesarean delivery at term and maternal perioperative outcomes. Obstet Gynecol 2011; 117:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/7\">",
"      Martins WP, Barra DA, Gallarreta FM, et al. Lower uterine segment thickness measurement in pregnant women with previous Cesarean section: reliability analysis using two- and three-dimensional transabdominal and transvaginal ultrasound. Ultrasound Obstet Gynecol 2009; 33:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/8\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/9\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/10\">",
"      Stutchfield P, Whitaker R, Russell I, Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005; 331:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/11\">",
"      Stotland NE, Lipschitz LS, Caughey AB. Delivery strategies for women with a previous classic cesarean delivery: a decision analysis. Am J Obstet Gynecol 2002; 187:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/12\">",
"      Clark EA, Silver RM. Long-term maternal morbidity associated with repeat cesarean delivery. Am J Obstet Gynecol 2011; 205:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/13\">",
"      Lyell DJ. Adhesions and perioperative complications of repeat cesarean delivery. Am J Obstet Gynecol 2011; 205:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/14\">",
"      Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/15\">",
"      Tulandi T, Agdi M, Zarei A, et al. Adhesion development and morbidity after repeat cesarean delivery. Am J Obstet Gynecol 2009; 201:56.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/16\">",
"      Soltan MH, Al Nuaim L, Khashoggi T, et al. Sequelae of repeat cesarean sections. Int J Gynaecol Obstet 1996; 52:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/17\">",
"      Makoha FW, Felimban HM, Fathuddien MA, et al. Multiple cesarean section morbidity. Int J Gynaecol Obstet 2004; 87:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/18\">",
"      Morales KJ, Gordon MC, Bates GW Jr. Postcesarean delivery adhesions associated with delayed delivery of infant. Am J Obstet Gynecol 2007; 196:461.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/19\">",
"      Uygur D, Gun O, Kelekci S, et al. Multiple repeat caesarean section: is it safe? Eur J Obstet Gynecol Reprod Biol 2005; 119:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/20\">",
"      Juntunen K, M&auml;k&auml;r&auml;inen L, Kirkinen P. Outcome after a high number (4-10) of repeated caesarean sections. BJOG 2004; 111:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/21\">",
"      Kirkinen P. Multiple caesarean sections: outcomes and complications. Br J Obstet Gynaecol 1988; 95:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/22\">",
"      Rashid M, Rashid RS. Higher order repeat caesarean sections: how safe are five or more? BJOG 2004; 111:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/23\">",
"      Cook JR, Jarvis S, Knight M, Dhanjal MK. Multiple repeat caesarean section in the UK: incidence and consequences to mother and child. A national, prospective, cohort study. BJOG 2013; 120:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/24\">",
"      Ananth CV, Smulian JC, Vintzileos AM. The association of placenta previa with history of cesarean delivery and abortion: a metaanalysis. Am J Obstet Gynecol 1997; 177:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/25\">",
"      Marshall NE, Fu R, Guise JM. Impact of multiple cesarean deliveries on maternal morbidity: a systematic review. Am J Obstet Gynecol 2011; 205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/26\">",
"      Nisenblat V, Barak S, Griness OB, et al. Maternal complications associated with multiple cesarean deliveries. Obstet Gynecol 2006; 108:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/27\">",
"      ACOG Practice Bulletin #54: vaginal birth after previous cesarean. Obstet Gynecol 2004; 104:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/28\">",
"      Osser OV, Jokubkiene L, Valentin L. Cesarean section scar defects: agreement between transvaginal sonographic findings with and without saline contrast enhancement. Ultrasound Obstet Gynecol 2010; 35:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/29\">",
"      Osser OV, Jokubkiene L, Valentin L. High prevalence of defects in Cesarean section scars at transvaginal ultrasound examination. Ultrasound Obstet Gynecol 2009; 34:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/30\">",
"      Hamar BD, Levine D, Katz NL, Lim KH. Expectant management of uterine dehiscence in the second trimester of pregnancy. Obstet Gynecol 2003; 102:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/31\">",
"      Matsunaga JS, Daly CB, Bochner CJ, Agnew CL. Repair of uterine dehiscence with continuation of pregnancy. Obstet Gynecol 2004; 104:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37862/abstract/32\">",
"      Sadeghi H, Rutherford T, Rackow BW, et al. Cesarean scar ectopic pregnancy: case series and review of the literature. Am J Perinatol 2010; 27:111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4457 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37862=[""].join("\n");
var outline_f36_62_37862=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TIMING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20290923\">",
"      Previous lower uterine segment incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Previous classical incision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREOPERATIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OPERATIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IS THERE AN UNSAFE NUMBER OF REPEAT CESAREAN DELIVERIES?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complications relating to abnormal placentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications relating to adhesion formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Complications relating to trial of labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other long-term complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11190914\">",
"      ANTEPARTUM UTERINE RUPTURE AND DEHISCENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4457\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4457|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/43/22204\" title=\"table 1\">",
"      Complications associated with multiple cesareans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/26/25003\" title=\"table 2\">",
"      Risk of placental abnormality by number of cesareans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=related_link\">",
"      Cesarean delivery: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35032?source=related_link\">",
"      Clinical features, diagnosis, and course of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/60/42952?source=related_link\">",
"      Management of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29367?source=related_link\">",
"      Peripartum hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=related_link\">",
"      Uterine rupture after previous cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_62_37863="Extracorporeal membrane oxygenation (ECMO) in adults";
var content_f36_62_37863=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extracorporeal membrane oxygenation (ECMO) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37863/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37863/contributors\">",
"     Jonathan Haft, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37863/contributors\">",
"     Robert Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37863/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37863/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37863/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37863/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/62/37863/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical cardiopulmonary support is most often applied intraoperatively to facilitate cardiac surgery (ie, cardiopulmonary bypass). However, cardiopulmonary support can also be delivered in a more prolonged fashion in an intensive care unit, although it is less common.",
"   </p>",
"   <p>",
"    Prolonged cardiopulmonary support is called extracorporeal membrane oxygenation (ECMO), extracorporeal life support, or extracorporeal lung assist. There are two types of ECMO &ndash; venoarterial (VA) and venovenous (VV). Both provide respiratory support, but only VA ECMO provides hemodynamic support.",
"   </p>",
"   <p>",
"    The impact of ECMO on clinical outcomes as well as patient selection, technical aspects, and complications will be reviewed here. Only adult applications are discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12225015\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival of patients undergoing ECMO can be categorized according to the indication for the ECMO: severe acute respiratory failure or cardiac failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Acute respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated the effect of ECMO on mortality in patients with severe acute respiratory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/1-11\">",
"     1-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial observational studies and uncontrolled clinical trials of patients with severe acute respiratory failure reported survival rates from 50 to 71 percent among patients who received ECMO [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/1-8\">",
"       1-8",
"      </a>",
"      ]. These survival rates were better than historical survival rates.",
"     </li>",
"     <li>",
"      A study of 75 matched pairs of patients with severe influenza H1N1-related acute respiratory distress syndrome found that referral and transfer to an ECMO center was associated with lower hospital mortality (23.7 versus 52.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/9\">",
"       9",
"      </a>",
"      ]. Eighty five percent of the patients referred to an ECMO center were managed with ECMO, while the others improved with conventional ventilation.",
"     </li>",
"     <li>",
"      The Conventional ventilatory support versus Extracorporeal membrane oxygenation for Severe Acute Respiratory failure (CESAR) trial randomly assigned 180 patients with severe acute respiratory failure to either be referred to a single ECMO center in the United Kingdom or undergo continued conventional management [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/10\">",
"       10",
"      </a>",
"      ]. The group referred to the ECMO center had significantly increased survival without disability at six months compared to conventional management (63 versus 47 percent). Twenty five percent of the patients referred for ECMO were not managed with ECMO because five died before transfer to the ECMO center and 16 recovered with the conventional ventilation protocol used by the ECMO center. Of note, the trial defined severe acute respiratory failure as hypercapnic respiratory acidosis with an arterial pH &lt;7.20 or a Murray score greater than 3.0. The Murray score quantitates the severity of lung disease on the basis of the ratio of arterial oxygen tension to the fraction of inspired oxygen",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       ),",
"      </span>",
"      positive end-expiratory pressure (PEEP), lung compliance, and chest radiograph. Important exclusion criteria included an age &lt;18 years or &gt;65 years, intubation greater than seven days, and contraindications to anticoagulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latter two studies described above demonstrate that referral to an ECMO center significantly improves recovery and survival from severe ARDS. Hence, we recommend that adult patients with severe ARDS be referred to an ECMO center, assuming that there are no contraindications. In experienced ECMO centers, approximately 25 percent of patients will improve and recover without ECMO, while 75 percent of patients will require ECMO. Among those who require ECMO, 60 to 70 percent will survive.",
"   </p>",
"   <p>",
"    The authors of this topic review feel that these studies provide evidence of a survival benefit from ECMO in severe ARDS. The editors and other expert reviewers for UpToDate are less confident that the survival benefit is due to ECMO itself because they believe that a potential benefit from co-interventions in the ECMO centers has not been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Cardiac failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venoarterial (VA) ECMO can provide acute support in cardiogenic shock or cardiac arrest in adults. Assuming that the brain function is normal or only minimally impaired, ECMO is provided until the patient recovers or receives a long-term ventricular assist device as a bridge to cardiac transplantation.",
"   </p>",
"   <p>",
"    Observational studies and case series have reported survival rates of 20 to 43 percent among patients who received VA ECMO for cardiac arrest, severe cardiogenic shock, or failure to wean from cardiopulmonary bypass following cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/12-18\">",
"     12-18",
"    </a>",
"    ]. In two observational studies, ECMO performed for cardiac arrest was associated with increased survival compared to conventional cardiopulmonary resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Long-term survivors of ECMO performed for cardiogenic shock have better general health, physical health, and social functioning than patients who require chronic hemodialysis, have advanced heart failure, or have recovered from ARDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12224985\">",
"    <span class=\"h2\">",
"     Neurological",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although neurologic injury is considered uncommon among adult ECMO survivors, one prospective cohort study of patients who received ECMO for more than 12 hours subsequently detected a neurological injury in 42 patients (approximately 50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/21\">",
"     21",
"    </a>",
"    ]. The types of neurological injury included coma of uncertain cause (11 patients), encephalopathy (11 patients), anoxic brain injury (9 patients), stroke (7 patients), brain death (3 patients), and myoclonus (1 patient). It is important to realize that these findings may be a consequence of the condition that prompted ECMO, rather than a complication of the ECMO process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines that describe the indications and practice of ECMO are published by the Extracorporeal Life Support Organization (ELSO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/22\">",
"     22",
"    </a>",
"    ]. Criteria for the initiation of ECMO include acute severe cardiac or pulmonary failure that is potentially reversible and unresponsive to conventional management. Examples of clinical situations that may prompt the initiation of ECMO include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoxemic respiratory failure with a ratio of arterial oxygen tension to fraction of inspired oxygen",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       )",
"      </span>",
"      of &lt;100 mmHg despite optimization of the ventilator settings, including the tidal volume, positive end-expiratory pressure (PEEP), and inspiratory to expiratory (I:E) ratio",
"     </li>",
"     <li>",
"      Hypercapnic respiratory failure with an arterial pH less than 7.20",
"     </li>",
"     <li>",
"      Refractory cardiogenic shock",
"     </li>",
"     <li>",
"      Cardiac arrest",
"     </li>",
"     <li>",
"      Failure to wean from cardiopulmonary bypass after cardiac surgery",
"     </li>",
"     <li>",
"      As a bridge to either cardiac transplantation or placement of a ventricular assist device",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECMO may not be initiated if anticoagulation is contraindicated (eg, bleeding, recent surgery, recent intracranial injury), if the cause of the respiratory or cardiac failure is irreversible, or if the patient is not a potential candidate for an implantable ventricular assist device.",
"   </p>",
"   <p>",
"    Additional considerations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with respiratory failure, ECMO might not be initiated if the patient has been mechanically ventilated for longer than seven days because outcomes may be poor in this population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      For patients with cardiac failure, ECMO might not be initiated if a ventricular assist device or transplantation is contraindicated (eg, the patient has preexisting renal failure, preexisting hepatic failure, significant aortic valve insufficiency, or inadequate social support)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other characteristics that may exclude some patients from receiving ECMO include advanced age, morbid obesity, neurologic dysfunction, or poor preexisting functional status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECMO should only by performed by clinicians with training and experience in its initiation, maintenance, and discontinuation.",
"   </p>",
"   <p>",
"    During ECMO, blood is drained from the native vascular system, circulated outside the body by a mechanical pump, and reinfused into the circulation. While outside the body, the blood passes through an oxygenator and heat exchanger. In the oxygenator, hemoglobin becomes fully saturated with oxygen, while carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ) is removed. Elimination of CO",
"    <sub>",
"     2",
"    </sub>",
"    is efficient and can be controlled by adjusting the rate of countercurrent gas flow through the oxygenator.",
"   </p>",
"   <p>",
"    ECMO can be venovenous (VV) or venoarterial (VA):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During VV ECMO, blood is extracted from the vena cava or right atrium and returned to the right atrium (",
"      <a class=\"graphic graphic_figure graphicRef56622 \" href=\"mobipreview.htm?31/62/32741\">",
"       figure 1",
"      </a>",
"      ). VV ECMO provides respiratory support, but the patient is dependent upon his or her own hemodynamics.",
"     </li>",
"     <li>",
"      During VA ECMO, blood is extracted from the right atrium and returned to the arterial system, bypassing the heart and lungs (",
"      <a class=\"graphic graphic_figure graphicRef80969 \" href=\"mobipreview.htm?7/27/7603\">",
"       figure 2",
"      </a>",
"      ). VA ECMO provides both respiratory and hemodynamic support. The additional benefit of hemodynamic support comes with additional risks, which are discussed below. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'VA ECMO-specific complications'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been decided that ECMO will be initiated, the patient is anticoagulated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and then the cannulae are inserted. ECMO support is initiated once the cannulae are connected to the appropriate limbs of the ECMO circuit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cannulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cannulas are usually placed percutaneously by Seldinger technique. The largest cannulas that can be placed in the vessels are used.",
"   </p>",
"   <p>",
"    For VV ECMO, venous cannulae are usually placed in the right common femoral vein (for drainage) and right internal jugular vein (for infusion). The tip of the femoral cannula should be maintained near the junction of the inferior vena cava and right atrium, while the tip of the internal jugular cannula should be maintained near the junction of the superior vena cava and right atrium. Alternatively, a double lumen cannula is available that is large enough to accommodate 4 to 5",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    of blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/23\">",
"     23",
"    </a>",
"    ]. It is available in a variety of sizes, with 31 French being the largest and most appropriate for adult males. The drainage and infusion ports have been engineered to minimize recirculation.",
"   </p>",
"   <p>",
"    For VA ECMO, a venous cannula is placed in the inferior vena cava or right atrium (for drainage) and an arterial cannula is placed into the right femoral artery (for infusion).",
"   </p>",
"   <p>",
"    Femoral access is preferred for VA ECMO because insertion is relatively easy. The main drawback of femoral access is ischemia of the ipsilateral lower extremity. The likelihood of this complication can be decreased by inserting an additional arterial cannula distal to the femoral artery cannula and redirecting a portion of the infused blood to the additional cannula for \"reperfusion\" of the extremity. Alternatively, a cannula can be inserted into the posterior tibial artery for retrograde flow to the extremity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, the femoral vessels are unsuitable for cannulation for VA ECMO (eg, patients with severe occlusive peripheral artery disease or prior femoral arterial reconstruction). In such circumstances, the right common carotid artery or subclavian artery can be used. In our experience, there is a 5 to 10 percent risk of a large watershed cerebral infarction when the right common carotid artery is used. Use of the subclavian artery offers the advantage of allowing patients on ECMO to ambulate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For postcardiotomy ECMO, the cannulas employed for cardiopulmonary bypass can be transferred from the heart lung machine to the ECMO circuit, with blood drained from the right atrium and reinfused into the ascending aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Titration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following cannulation, the patient is connected to the ECMO circuit and the blood flow is increased until respiratory and hemodynamic parameters are satisfactory. Reasonable targets include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An arterial oxyhemoglobin saturation of &gt;90 percent for VA ECMO, or &gt;75 percent for VV ECMO",
"     </li>",
"     <li>",
"      A venous oxyhemoglobin saturation of 70 to 80 percent for VA ECMO, measured on the venous line",
"     </li>",
"     <li>",
"      Adequate tissue perfusion, as determined by the arterial blood pressure, venous oxygen saturation, and blood lactate level",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the initial respiratory and hemodynamic goals have been achieved, the blood flow is maintained at that rate. Frequent assessment and adjustments are facilitated by continuous venous oximetry, which directly measures the oxyhemoglobin saturation of the blood in the venous limb of the ECMO circuit. When the venous oxyhemoglobin saturation is below target, interventions that may be helpful include increasing one or more of the following: blood flow, intravascular volume, or hemoglobin concentration. Decreasing the systemic oxygen uptake by reducing the temperature may also be helpful.",
"   </p>",
"   <p>",
"    Anticoagulation is sustained during ECMO with a continuous infusion of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , titrated to an activated clotting time (ACT) of 180 to 210 seconds. The ACT target is decreased if bleeding develops. ACT is easily determined at the point of care, but plasma PTT (1.5 times normal) can also be used.",
"   </p>",
"   <p>",
"    Platelets are continuously consumed during ECMO because they are activated by exposure to the foreign surface area. Platelet counts should be maintained greater than",
"    <span class=\"nowrap\">",
"     100,000/microliter,",
"    </span>",
"    which may require platelet transfusion.",
"   </p>",
"   <p>",
"    Ventilator settings are reduced during ECMO in order to avoid barotrauma, volutrauma (ie, ventilator-induced lung injury), and oxygen toxicity. Plateau airway pressures should be maintained less than 20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and FiO",
"    <sub>",
"     2",
"    </sub>",
"    less than 0.5. Reduction of ventilator support is usually accompanied by increased venous return and cardiac output, which improves cardiac output.",
"   </p>",
"   <p>",
"    We perform early tracheostomy to reduce dead space and improve patient comfort. Patients typically require light sedation during ECMO, although we prefer to maintain patients awake, extubated, and breathing spontaneously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11945?source=see_link\">",
"     \"Overview of tracheostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Special considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;VV ECMO is typically used for respiratory failure, while VA ECMO is used for cardiac failure. There are unique considerations for each type of ECMO, which influence management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood flow &ndash; Near maximum flow rates are usually desired during VV ECMO to optimize oxygen delivery. In contrast, the flow rate used during VA ECMO must be high enough to provide adequate perfusion pressure and venous oxyhemoglobin saturation (measured on drainage blood), but low enough to provide sufficient preload to maintain left ventricular output.",
"     </li>",
"     <li>",
"      Diuresis &ndash; Since most patients are fluid overloaded when ECMO is initiated, aggressive diuresis is warranted once the patient is stable on ECMO. Ultrafiltration can be easily added to the ECMO circuit if patients are unable to produce sufficient urine for diuresis.",
"     </li>",
"     <li>",
"      Left ventricular monitoring &ndash; Left ventricular output must be rigorously monitored during VA ECMO because left ventricular output may worsen. The cause is usually multifactorial, including the underlying left ventricular dysfunction and insufficient unloading of the distended left ventricle due to ongoing blood flow to the left ventricle from the bronchial circulation and right ventricle. Left ventricular output can be closely monitored by identifying pulsatility in the arterial line's waveform and by frequent echocardiography. Interventions that can improve left ventricular output include inotropes (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      ) to increase contractility and intra-aortic balloon counterpulsation to reduce afterload and facilitate left ventricular output. Immediate left ventricular decompression is essential to avoid pulmonary hemorrhage if left ventricular ejection cannot be maintained despite intra-aortic balloon counterpulsation and inotropic agents. This can be accomplished surgically or percutaneously. Methods of percutaneous left ventricular decompression include transatrial balloon septostomy or insertion of a left ventricular drainage catheter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Weaning from ECMO",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with respiratory failure, improvements in radiographic appearance, pulmonary compliance, and arterial oxyhemoglobin saturation indicate that the patient may be ready to be liberated from ECMO. For patients with cardiac failure, enhanced aortic pulsatility correlates with improved left ventricular output and indicates that the patient may be ready to be liberated from ECMO.",
"   </p>",
"   <p>",
"    One or more trials of taking the patient off ECMO should be performed prior to discontinuing ECMO permanently:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VV ECMO trials are performed by eliminating all countercurrent sweep gas through the oxygenator. Extracorporeal blood flow remains constant, but gas transfer does not occur. Patients are observed for several hours, during which the ventilator settings that are necessary to maintain adequate oxygenation and ventilation off ECMO are determined.",
"     </li>",
"     <li>",
"      VA ECMO trials require temporary clamping of both the drainage and infusion lines, while allowing the ECMO circuit to circulate through a bridge between the arterial and venous limbs. This prevents thrombosis of stagnant blood within the ECMO circuit. In addition, the arterial and venous lines should be flushed continuously with heparinized saline or intermittently with heparinized blood from the circuit. VA ECMO trials are generally shorter in duration than VV ECMO trials because of the higher risk of thrombus formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the decision has been made to discontinue ECMO, the cannulae are removed. Hemostasis is achieved by compressing the insertion site. For patients who received VA ECMO, at least thirty minutes of compression is required for the arterial site. Low doses of protamine can be administered to reverse the remaining systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and facilitate hemostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding occurs in 30 to 40 percent of patients who receive ECMO and can be life threatening. It is due to both the necessary continuous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    infusion and platelet dysfunction. Meticulous surgical technique, maintaining platelet counts greater than",
"    <span class=\"nowrap\">",
"     100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    and maintaining the target ACT reduce the likelihood of bleeding.",
"   </p>",
"   <p>",
"    Intervention is necessary when major bleeding occurs. Bleeding from surgical wounds often requires prompt exploration with liberal use of electrocautery. Hemorrhage into body cavities (eg, abdomen, pleural space) may require surgical exploration to achieve hemostasis, after which vacuum-assisted closure is recommended because it allows removal and measurement of the blood. Plasminogen inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    ) can be infused or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    can be discontinued for several hours, but these actions may increase the risk of circuit thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Infusion of activated factor VII has been reported with mixed results and should only be considered for life threatening hemorrhage after all other options have failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The target ACT is usually reduced once bleeding occurs. As an example, the target ACT may become 170 to 190 seconds, instead of 210 to 230 seconds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic thromboembolism due to thrombus formation within the extracorporeal circuit is an infrequent complication that can be devastating. Its impact is greater with VA ECMO than VV ECMO because infusion is into the systemic circulation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    infusion that achieves its target ACT and vigilant observation of the circuit for signs of clot formation successfully prevents thromboembolism in most patients.",
"   </p>",
"   <p>",
"    Observation of the circuit for signs of clot formation includes routine inspection of all connectors and monitoring the pressure gradient across the oxygenator. A sudden change in the pressure gradient suggests that a thrombus had developed. Large or mobile clots require immediate circuit or component exchange. Primed circuits are usually kept at the bedside if the target ACT has been reduced due to bleeding because the risk of thrombus formation is greatest in this situation. Having a primed circuit available facilitates urgent exchange, if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cannulation-related",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of complications can occur during cannulation, including vessel perforation with hemorrhage, arterial dissection, distal ischemia, and incorrect location (eg, venous cannula within the artery). These complications are rare (&lt;5 percent). A skilled and experienced surgeon is important to avoid or address such complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Heparin-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) can occur in patients receiving ECMO. When HIT is proven, the heparin infusion should be replaced by a non-heparin anticoagulant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/31\">",
"     31",
"    </a>",
"    ]. We favor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    because its half life is short and a similar ACT target range is effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     VA ECMO-specific complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary hemorrhage &ndash; Pulmonary hemorrhage can occur in patients who receive VA ECMO.",
"     </li>",
"     <li>",
"      Cardiac thrombosis &ndash; There is retrograde blood flow in the ascending aorta whenever the femoral artery and vein are used for VA ECMO. Stasis of the blood can occur if left ventricular output is not maintained, which may result in thrombosis.",
"     </li>",
"     <li>",
"      Coronary or cerebral hypoxia &ndash; During VA ECMO, fully saturated blood infused into the femoral artery from the ECMO circuit will preferentially perfuse the lower extremities and the abdominal viscera. Blood ejected from the heart will selectively perfuse the heart, brain, and upper extremities. As a result, the oxyhemoglobin saturation of the blood perfusing the lower extremities and abdominal viscera may be substantially higher than that perfusing the heart, brain, and upper extremities. Cardiac and cerebral hypoxia could exist and be unrecognized if oxygenation is monitored using only blood from the lower extremity. To avoid this complication, arterial oxyhemoglobin saturation should be monitored in both the upper extremity (eg, blood gases from the radial artery or pulse oximetry on a finger) and the lower extremity (eg, blood gases from the femoral artery). Poor arterial oxyhemoglobin saturations measured from the upper extremity is corrected by infusing some oxygenated blood into the right atrium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FUTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Applications for ECMO may expand in the future to include percutaneous temporary left ventricular assistance and low flow ECMO for CO",
"    <sub>",
"     2",
"    </sub>",
"    removal (ECOOR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, new technologies will improve the simplicity and safety of ECMO, including new oxygenators, pumps, and surface coatings.",
"   </p>",
"   <p>",
"    New oxygenators that use hollow fibers constructed of polymethyl-pentene are available for short term use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Advantages include lower priming volume, rapid priming time, diminished plasma leakage, and low blood flow resistance, which may reduce platelet activation and consumption.",
"   </p>",
"   <p>",
"    In the past, ECMO centers depended upon servoregulated (ie, automatic) roller pumps for blood flow generation, which required continuous observation by trained personnel. Centrifugal pumps without servoregulation have replaced roller pumps in some centers. However, these pumps can cause microcavitation and hemolysis. Newer centrifugal pumps have special rotors, which reduce heat generation and microcavitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. These pumps are now widely used for ECMO.",
"   </p>",
"   <p>",
"    Surface coatings that mimic the endothelial lining of blood vessels and reduce blood cell activation are being developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37863/abstract/38\">",
"     38",
"    </a>",
"    ]. In an ECMO circuit, such coatings could reduce thrombogenicity, obviate the need for continuous anticoagulation, and reduce the incidence of related complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extracorporeal membrane oxygenation (ECMO) is a type of prolonged mechanical cardiopulmonary support that is usually delivered in the intensive care unit. ECMO should only be performed in centers with the appropriate equipment and expertise. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with severe, but potentially reversible, acute respiratory or cardiac failure that is unresponsive to conventional management be evaluated for ECMO if it is available within the medical center (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients who are in a medical center that does not provide ECMO, transfer to another medical center to be evaluated for ECMO should be considered as soon as it is clear that the patient is not responding to management. The final decision should carefully weigh the survival rates for patients referred to an ECMO center versus the risk of transferring the patient. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two types of ECMO, venovenous (VV) and venoarterial (VA) (",
"      <a class=\"graphic graphic_figure graphicRef56622 \" href=\"mobipreview.htm?31/62/32741\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef80969 \" href=\"mobipreview.htm?7/27/7603\">",
"       figure 2",
"      </a>",
"      ). VV ECMO is used in patients with respiratory failure, while VA ECMO is used in patients with cardiac failure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it has been determined that ECMO will be initiated, the patient is anticoagulated with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . Cannulae are then inserted and the patient is connected to the ECMO circuit. The blood flow is increased until respiratory and hemodynamic parameters are satisfactory. Once the initial respiratory and hemodynamic goals have been achieved, blood flow is maintained, ventilator support is minimized, and vasoactive drugs are decreased to minimal levels. Frequent reassessment and adjustments are usually necessary. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initiation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Maintenance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient's readiness for weaning from ECMO should be evaluated frequently. Prior to discontinuing ECMO permanently, one or more trials should be performed during which the patient is off ECMO. Such trials give the clinician the opportunity to determine whether conventional supportive care is sufficient for the patient. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Weaning from ECMO'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bleeding is the most common complication (30 to 40 percent) of ECMO. Thromboembolism and cannula complications are rare (&lt;5 percent). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/1\">",
"      Hemmila MR, Rowe SA, Boules TN, et al. Extracorporeal life support for severe acute respiratory distress syndrome in adults. Ann Surg 2004; 240:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/2\">",
"      Peek GJ, Moore HM, Moore N, et al. Extracorporeal membrane oxygenation for adult respiratory failure. Chest 1997; 112:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/3\">",
"      Lewandowski K, Rossaint R, Pappert D, et al. High survival rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation. Intensive Care Med 1997; 23:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/4\">",
"      Ullrich R, Lorber C, R&ouml;der G, et al. Controlled airway pressure therapy, nitric oxide inhalation, prone position, and extracorporeal membrane oxygenation (ECMO) as components of an integrated approach to ARDS. Anesthesiology 1999; 91:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/5\">",
"      Rich PB, Awad SS, Kolla S, et al. An approach to the treatment of severe adult respiratory failure. J Crit Care 1998; 13:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/6\">",
"      Kolla S, Awad SS, Rich PB, et al. Extracorporeal life support for 100 adult patients with severe respiratory failure. Ann Surg 1997; 226:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/7\">",
"      Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators, Davies A, Jones D, et al. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA 2009; 302:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/8\">",
"      Brogan TV, Thiagarajan RR, Rycus PT, et al. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database. Intensive Care Med 2009; 35:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/9\">",
"      Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011; 306:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/10\">",
"      Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/11\">",
"      Pham T, Combes A, Roz&eacute; H, et al. Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med 2013; 187:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/12\">",
"      Younger JG, Schreiner RJ, Swaniker F, et al. Extracorporeal resuscitation of cardiac arrest. Acad Emerg Med 1999; 6:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/13\">",
"      Massetti M, Tasle M, Le Page O, et al. Back from irreversibility: extracorporeal life support for prolonged cardiac arrest. Ann Thorac Surg 2005; 79:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/14\">",
"      Smedira NG, Blackstone EH. Postcardiotomy mechanical support: risk factors and outcomes. Ann Thorac Surg 2001; 71:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/15\">",
"      Kelly RB, Porter PA, Meier AH, et al. Duration of cardiopulmonary resuscitation before extracorporeal rescue: how long is not long enough? ASAIO J 2005; 51:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/16\">",
"      Combes A, Leprince P, Luyt CE, et al. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med 2008; 36:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/17\">",
"      Pagani FD, Aaronson KD, Swaniker F, Bartlett RH. The use of extracorporeal life support in adult patients with primary cardiac failure as a bridge to implantable left ventricular assist device. Ann Thorac Surg 2001; 71:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/18\">",
"      Kagawa E, Dote K, Kato M, et al. Should we emergently revascularize occluded coronaries for cardiac arrest?: Rapid-response extracorporeal membrane oxygenation and intra-arrest percutaneous coronary intervention. Circulation . Published online ahead of print, August 16, 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/19\">",
"      Shin TG, Choi JH, Jo IJ, et al. Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: A comparison with conventional cardiopulmonary resuscitation. Crit Care Med 2011; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/20\">",
"      Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet 2008; 372:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/21\">",
"      Mateen FJ, Muralidharan R, Shinohara RT, et al. Neurological injury in adults treated with extracorporeal membrane oxygenation. Arch Neurol 2011; 68:1543.",
"     </a>",
"    </li>",
"    <li>",
"     ELSO guidelines for ECMO centers (updated February 2005) file://www.elso.med.umich.edu/guide.htm (Accessed on June 19, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/23\">",
"      Wang D, Zhou X, Liu X, et al. Wang-Zwische double lumen cannula-toward a percutaneous and ambulatory paracorporeal artificial lung. ASAIO J 2008; 54:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/24\">",
"      Madershahian N, Nagib R, Wippermann J, et al. A simple technique of distal limb perfusion during prolonged femoro-femoral cannulation. J Card Surg 2006; 21:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/25\">",
"      Navia JL, Atik FA, Beyer EA, Ruda Vega P. Extracorporeal membrane oxygenation with right axillary artery perfusion. Ann Thorac Surg 2005; 79:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/26\">",
"      Wilson JM, Bower LK, Fackler JC, et al. Aminocaproic acid decreases the incidence of intracranial hemorrhage and other hemorrhagic complications of ECMO. J Pediatr Surg 1993; 28:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/27\">",
"      Biswas AK, Lewis L, Sommerauer JF. Aprotinin in the management of life-threatening bleeding during extracorporeal life support. Perfusion 2000; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     Peek, G, Wittenstein, et al. Management of bleeding during ECLS. In: ECMO in Critical Care, Van Meurs, K, Lally, KP, Peek, G, Zwischenberger, JB (Eds), Extracorporeal life support organization, Ann Arbor 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/29\">",
"      Bui JD, Despotis GD, Trulock EP, et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/30\">",
"      Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005; 6:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/31\">",
"      Cornell T, Wyrick P, Fleming G, et al. A case series describing the use of argatroban in patients on extracorporeal circulation. ASAIO J 2007; 53:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/32\">",
"      Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/33\">",
"      Peek GJ, Killer HM, Reeves R, et al. Early experience with a polymethyl pentene oxygenator for adult extracorporeal life support. ASAIO J 2002; 48:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/34\">",
"      Toomasian JM, Schreiner RJ, Meyer DE, et al. A polymethylpentene fiber gas exchanger for long-term extracorporeal life support. ASAIO J 2005; 51:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/35\">",
"      Khoshbin E, Roberts N, Harvey C, et al. Poly-methyl pentene oxygenators have improved gas exchange capability and reduced transfusion requirements in adult extracorporeal membrane oxygenation. ASAIO J 2005; 51:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/36\">",
"      Hoshi H, Shinshi T, Takatani S. Third-generation blood pumps with mechanical noncontact magnetic bearings. Artif Organs 2006; 30:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/37\">",
"      Lawson DS, Ing R, Cheifetz IM, et al. Hemolytic characteristics of three commercially available centrifugal blood pumps. Pediatr Crit Care Med 2005; 6:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37863/abstract/38\">",
"      Zhang H, Annich GM, Miskulin J, et al. Nitric oxide releasing silicone rubbers with improved blood compatibility: preparation, characterization, and in vivo evaluation. Biomaterials 2002; 23:1485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1625 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-5203FA14AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37863=[""].join("\n");
var outline_f36_62_37863=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12225015\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Acute respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Cardiac failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12224985\">",
"      Neurological",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cannulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Titration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maintenance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Special considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Weaning from ECMO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cannulation-related",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VA ECMO-specific complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FUTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1625\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1625|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/62/32741\" title=\"figure 1\">",
"      Venovenous ECMO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/27/7603\" title=\"figure 2\">",
"      Venoarterial ECMO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11945?source=related_link\">",
"      Overview of tracheostomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_62_37864="Duloxetine: Drug information";
var content_f36_62_37864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Duloxetine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/42/9894?source=see_link\">",
"    see \"Duloxetine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cymbalta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5687669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cymbalta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Major depressive disorder:",
"     </b>",
"     Oral: Initial: 40-60 mg/day; dose may be divided (ie, 20 or 30 mg twice daily) or given as a single daily dose of 60 mg; maintenance: 60 mg once daily; for doses &gt;60 mg/day, titrate dose in increments of 30 mg/day over 1 week as tolerated to a maximum dose: 120 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;60 mg/day have not been demonstrated to be more effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diabetic neuropathy:",
"     </b>",
"     Oral: 60 mg once daily; lower initial doses may be considered in patients where tolerability is a concern and/or renal impairment is present.",
"     <b>",
"      Note:",
"     </b>",
"     Doses up to 120 mg/day administered in clinical trials offered no additional benefit and were less well tolerated than dose of 60 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Fibromyalgia:",
"     </b>",
"     Oral: 30 mg once daily for 1 week, then increase to 60 mg once daily as tolerated.",
"     <b>",
"      Note:",
"     </b>",
"     Doses up to 120 mg/day administered in clinical trials offered no additional benefit and were less well tolerated than dose of 60 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Generalized anxiety disorder:",
"     </b>",
"     Oral: Initial: 30-60 mg/day as a single daily dose; patients initiated at 30 mg/day should be titrated to 60 mg/day after 1 week; maximum dose: 120 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;60 mg/day have not been demonstrated to be more effective than 60 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic musculoskeletal pain:",
"     </b>",
"     Oral: 30 mg once daily for 1 week, then increase to 60 mg once daily as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stress incontinence (unlabeled use):",
"     </b>",
"     Oral: 40 mg twice daily (Dmochowski, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Upon discontinuation of duloxetine therapy, gradually taper dose. If intolerable symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate. Stopping or initiating MAO inhibitor therapy for psychiatric disorders must be appropriately timed with stopping or initiating duloxetine.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Major depressive disorder:",
"     </b>",
"     Oral: Manufacturer does not recommend specific dosage adjustment. Conservatively, may initiate at a dose of 20 mg 1-2 times/day; increase to 40-60 mg/day as a single daily dose or in divided doses",
"     <b>",
"      or",
"     </b>",
"     initiate therapy at 30 mg/day for 1 week then increase to 60 mg/day as tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Other indications:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F163742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or ESRD (contraindicated in Canadian labeling). In mild-moderate impairment, lower initial doses may be considered with titration guided by response and tolerability.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F163743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in hepatic impairment (contraindicated in Canadian labeling).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, enteric coated pellets, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cymbalta&reg;: 20 mg, 30 mg, 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088579.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088579.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F163715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule should be swallowed whole; do not crush or chew. Although the manufacturer does not recommend opening the capsule to facilitate administration; the contents of capsule may be sprinkled on applesauce or in apple juice and swallowed (without chewing) immediately. Do not sprinkle contents on chocolate pudding (Wells, 2008). Administer without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute and maintenance treatment of major depressive disorder (MDD); treatment of generalized anxiety disorder (GAD); management of diabetic peripheral neuropathic pain (DPNP); management of fibromyalgia (FM); chronic musculoskeletal pain (eg, chronic low back pain, osteoarthritis)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F163751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of stress incontinence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cymbalta&reg; may be confused with Symbyax&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DULoxetine may be confused with FLUoxetine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (13% to 14%), somnolence (10% to 12%; dose related), fatigue (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (23% to 25%), xerostomia (11% to 15%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (10%), insomnia (10%; dose related), agitation (3% to 5%), anxiety (3%), dreams abnormal (1% to 2%), yawning (1% to 2%), hypoesthesia (&ge;1%), lethargy (&ge;1%), vertigo (&ge;1%), chills (1%), sleep disorder (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperhydrosis (6% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (2% to 4%), hot flushes (1% to 3%), orgasm abnormality (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal:  Constipation (10%; dose related), diarrhea (9% to 10%), appetite decreased (7% to 9%; dose related), abdominal pain (4% to 6%), vomiting (3% to 5%), dyspepsia (2%), weight loss (2%), flatulence (&ge;1%), taste abnormal (&ge;1%), weight gain (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Erectile dysfunction (4% to 5%), ejaculation delayed (3%; dose related),  ejaculatory dysfunction (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT &gt;3x ULN (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms (3%), tremor (2% to 3%; dose related), musculoskeletal pain (&ge;1%), paresthesia (&ge;1%), rigors (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (5%), cough (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, anaphylactic reaction, angioneurotic edema, apathy, bruxism, contact dermatitis, dehydration, dermatitis, diastolic blood pressure increased, diplopia, disorientation, dysarthria, dyskinesia, dysuria, eructation, erythema, erythema multiforme, EPS, gastritis, gastroenteritis, glaucoma, gynecological bleeding, hallucinations, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     increased, hepatic failure, hepatitis, hepatomegaly, hyperbilirubinemia, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypersensitivity, hypertensive crisis, hyponatremia, hypothyroidism, jaundice, malaise, mania, MI, micturition urgency, mood swings, muscle spasm, muscle tightness, muscle twitching, night sweats, nocturia, orthostatic hypotension, peripheral coldness, photosensitivity, polyuria, rash, restless leg syndrome, seizure, serotonin syndrome, SIADH, Stevens-Johnson syndrome, stomatitis, supraventricular arrhythmia, syncope, systolic blood pressure increased, tachycardia, thirst, throat tightness, transaminases increased, trismus, urinary retention, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use or within 14 days of discontinuing MAO inhibitor (intended to treat psychiatric disorders); concomitant use with linezolid or intravenous methylene blue; uncontrolled narrow-angle glaucoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment with MAO inhibitors for psychiatric disorders should not be initiated until 5 days after the discontinuation of duloxetine. Although acceptable alternatives should be considered, there may be circumstances when it is necessary to initiate an MAO inhibitor (eg, linezolid or intravenous methylene blue) in a patient taking duloxetine; in this case, discontinue duloxetine prior to administering the MAO inhibitor.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to duloxetine or any component of the formulation; hepatic impairment; severe renal impairment (eg, Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or end-stage renal disease (ESRD); concomitant use with thioridazine or with CYP1A2 inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior; the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants in children and teenagers should be dispensed with each prescription.",
"     <b>",
"      Duloxetine is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial (generally first 1-2 months) few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin or NSAIDs due to ulcerogenic potential. Data are inconclusive regarding extent of bleeding risk of SNRIs in combination with warfarin or other anticoagulants. Bleeding related to SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic: Severe skin reactions (including Stevens-Johnson syndrome and erythema multiforme) have been reported; discontinue immediately if hypersensitivity reaction suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Avoid use in patients with substantial ethanol intake, evidence of chronic liver disease or hepatic impairment (contraindicated in Canadian labeling). Rare cases of hepatic failure (including fatalities) have been reported with use. Hepatitis with abdominal pain, hepatomegaly, elevated transaminase levels &gt;20 times the upper limit of normal (ULN) with and without jaundice have all been observed. Discontinue therapy with the presentation of jaundice or other signs of hepatic dysfunction and do not reinitiate therapy unless another source or cause is identified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Modest increases in serum glucose and hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) levels have been observed in some diabetic patients receiving duloxetine therapy for diabetic peripheral neuropathic pain (DPNP).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension/syncope: May cause orthostatic hypotension/syncope, especially within the first week of therapy and after dose increases. Carefully monitor blood pressure with initiation of therapy, dose increases (especially in patients receiving &gt;60 mg/day), or when using concomitant vasodilators or CYP1A2 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome (SS) reactions: SS reactions have occurred with duloxetine when used alone and particularly when used in combination with other serotonergic agents (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St John's wort) and drugs that inhibit serotonin metabolism (eg, MAO inhibitors, specifically linezolid, methylene blue, and others used for psychiatric disorders). The diagnosis of SS can be made using the Hunter Serotonin Toxicity Criteria (Dunkley, 2003). Monitor patients closely for signs/symptoms of SS which may include mental status changes (eg, agitation, hallucinations, delirium), seizures, autonomic instability (eg, tachycardia, dizziness, diaphoresis), neuromuscular symptoms (eg, tremor, rigidity, myoclonus), or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea). Discontinue treatment (and any concomitant serotonergic agents) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary hesitancy: May cause increased urinary resistance; advise patient to report symptoms of urinary hesitation/difficulty.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastroparesis: Use caution in patients with impaired gastric motility (eg, some diabetics); may affect stability of the capsule's enteric coating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use caution in patients with hypertension. Although no statistically significant differences in the frequency of sustained elevations of blood pressure were observed in clinical trials when compared with placebo, modest increases in blood pressure have been reported with use. Additionally, rare cases of hypertensive crisis have been reported in patients with pre-existing hypertension; blood pressure should be evaluated prior to initiating therapy and periodically thereafter; consider dose reduction or gradual discontinuation of therapy in individuals with sustained hypertension during therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Duloxetine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Narrow-angle glaucoma: Associated with an increased risk of mydriasis in patients with controlled narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution; clearance is decreased and plasma concentrations are increased; not recommended for use when Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or ESRD (contraindicated in Canadian labeling).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use caution with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents which lower seizure threshold: Concurrent therapy with other drugs which lower the seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants/antiplatelets: Use caution with concomitant use of NSAIDs, ASA, or other drugs that affect coagulation; the risk of bleeding may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Use caution with concomitant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP1A2 inhibitors (eg, fluvoxamine, ciprofloxacin): Concomitant use with duloxetine may increase levels/adverse effects of duloxetine and is not recommended (contraindicated in Canadian labeling).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 inhibitors/substrates: Concomitant use of CYP2D6 inhibitors with duloxetine may increase levels/adverse effects of duloxetine; concomitant use of duloxetine with CYP2D6 substrates (tricyclic antidepressants, type 1C antiarrhythmics) may lead to substrate-induced toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Potential for severe reaction when used with MAO inhibitors; autonomic instability, coma, death, delirium, diaphoresis, hyperthermia, mental status changes/agitation, muscular rigidity, myoclonus, neuroleptic malignant syndrome features, and seizures may occur. Concurrent use with or within 14 days of MAO inhibitors is contraindicated. Allow 5 days to elapse after discontinuation of duloxetine before initiating an MAO inhibitor for psychiatric disorders. If already receiving duloxetine and urgent treatment with MAO inhibitors (eg, linezolid or I.V. methylene blue) is required, stop duloxetine and initiate linezolid or I.V. methylene blue if the potential benefits outweigh the risk of SS. Monitor for SS for 5 days or for 24 hours after the last dose of linezolid or methylene blue, whichever occurs first; may resume duloxetine 24 hours after the last dose of linezolid or methylene blue. The risks associated with methylene blue doses &lt;1 mg/kg or when administered nonparenterally are unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proserotonergic agents: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans), agents which reduce duloxetine's metabolism, or antidopaminergic agents (including antipsychotics). Concurrent use of serotonergic agents is not recommended; however, if clinically indicated, use with caution and advise patients of increased SS risk especially during initiation and dose increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thioridazine: Concomitant use is contraindicated in Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sucrose intolerance: Formulation contains sucrose; patients with fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency should avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal syndrome: May cause dysphoric mood, irritability, agitation, dizziness, sensory disturbances (eg, electric shock-like sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. To discontinue therapy with duloxetine, gradually taper dose. If intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, then resuming the previous dose with a more gradual taper should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F163748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran. Management: Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol.  Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: May enhance the adverse/toxic effect of DULoxetine. ARIPiprazole may enhance the serotonergic effect of DULoxetine. This could result in serotonin syndrome. DULoxetine may increase the serum concentration of ARIPiprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: DULoxetine may enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of DULoxetine.  Management: Coadminister these agents with great caution.  If duloxetine and fluvoxamine are used in combination, monitor for signs and symptoms of serotonin toxicity/serotonin syndrome, as well as other toxic effects of duloxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: DULoxetine may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of DULoxetine.  Management: Coadminister with caution.  If duloxetine and paroxetine are used in combination, monitor for signs and symptoms of serotonin toxicity/serotonin syndrome, as well as other toxic effects of duloxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: DULoxetine may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F163733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase hepatotoxic potential of duloxetine and increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may increase CNS depression. Management: Avoid valerian, St John's wort, SAMe, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hyper- or hypotonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SNRIs/SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SNRI/SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll women exposed to duloxetine during pregnancy in the Cymbalta&reg; Pregnancy Registry (866-814-6975 or file://cymbaltapregnancyregistry.com).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F163746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F163722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duloxetine is excreted in human milk and has been detected in the serum of a nursing infant. Breast-feeding is not recommended by the manufacturer. The long-term effects on neurobehavior have not been studied, thus one should prescribe duloxetine to a mother who is breast-feeding only when the benefits outweigh the potential risks.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F163723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F163720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, enteric pellets",
"     </b>",
"     (Cymbalta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $424.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $238.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (30): $238.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F163708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure should be checked prior to initiating therapy and then regularly monitored, especially in patients with a high baseline blood pressure; mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks; glucose levels and Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     levels in diabetic patients, creatinine, BUN, transaminases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     For musculoskeletal pain: Pain relief",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ariclaim (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Cymbalta (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GT, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, RU, SE, SG, SK, TH, TR, TW);",
"     </li>",
"     <li>",
"      Delok (IN);",
"     </li>",
"     <li>",
"      Doxet (PE);",
"     </li>",
"     <li>",
"      Duloxeteg (SV);",
"     </li>",
"     <li>",
"      Duxetin (UY);",
"     </li>",
"     <li>",
"      Xeristar (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, HN, IE, IT, MT, NL, NO, PL, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Yentreve (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, HN, IE, IL, IT, MT, MX, NL, NO, NZ, PL, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a weak inhibitor of dopamine reuptake. Duloxetine has no significant activity for muscarinic cholinergic, H",
"     <sub>",
"      1",
"     </sub>",
"     -histaminergic, or alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors. Duloxetine does not possess MAO-inhibitory activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed, 2-hour delay in absorption after ingestion; food decreases extent of absorption ~10% (no effect on C",
"     <sub>",
"      max",
"     </sub>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 1640 L (range: 701-3800 L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90%; primarily to albumin and &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP1A2 and CYP2D6; forms multiple metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 12 hours (range: 8-17 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 6 hours; 10 hours when ingested with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70%; &lt;1% of total dose as unchanged drug); feces (~20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(4):1001-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/18378767/pubmed\" id=\"18378767\" target=\"_blank\">",
"        18378767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arnold LM, Lu Y, Crofford LJ, et al, &ldquo;A Double-Blind, Multicenter Trial Comparing Duloxetine With Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2004, 50(9):2974-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/15457467/pubmed\" id=\"15457467\" target=\"_blank\">",
"        15457467",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/16467545/pubmed\" id=\"16467545\" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chappell AS, Ossanna MJ, Liu-Siefert H, et al, &ldquo;Duloxetine, A Centrally Acting Analgesic, in the Treatment of Patients With Osteoarthritis Knee Pain: A 13-Week, Randomized, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Pain",
"      </i>",
"      , 2009, 146(3):253-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/19625125/pubmed\" id=\"19625125\" target=\"_blank\">",
"        19625125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dmochowski RR, Miklos JR, Norton PA, et al, &ldquo;Duloxetine Versus Placebo for the Treatment of North American Women With Stress Urinary Incontinence,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2003, 170(4 Pt 1):1259-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/14501737/pubmed\" id=\"14501737\" target=\"_blank\">",
"        14501737",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkley EJ, Isbister GK, Sibbritt D, et al, &ldquo;The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,&rdquo;",
"      <i>",
"       QJM",
"      </i>",
"      , 2003, 96(9):635-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/12925718/pubmed\" id=\"12925718\" target=\"_blank\">",
"        12925718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fava M, Mallinckrodt CH, Detke MJ, et al, &ldquo;The Effect of Duloxetine on Painful Physical Symptoms in Depressed Patients: Do Improvements in These Symptoms Result in Higher Remission Rates?&rdquo;,",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2004, 65(4):521-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/15119915/pubmed\" id=\"15119915\" target=\"_blank\">",
"        15119915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldstein DJ, Lu Y, Detke MJ, et al, &ldquo;Duloxetine in the Treatment of Depression: A Double-Blind Placebo-Controlled Comparison With Paroxetine,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2004, 24(4):389-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/15232330/pubmed\" id=\"15232330\" target=\"_blank\">",
"        15232330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hardy T, Sachson R, Shen S, et al, &ldquo;Does Treatment With Duloxetine for Neuropathic Pain Impact Glycemic Control?,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2007, 30(1):21-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/17192327/pubmed\" id=\"17192327\" target=\"_blank\">",
"        17192327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Millard RJ, Moore K, Rencken R, et al, &ldquo;Duloxetine vs Placebo in the Treatment of Stress Urinary Incontinence: A Four-Continent Randomized Clinical Trial,&rdquo;",
"      <i>",
"       BJU Int",
"      </i>",
"      , 2004, 93(3):311-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/14764128/pubmed\" id=\"14764128\" target=\"_blank\">",
"        14764128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raskin J, Wiltse CG, Siegal A, et al, &ldquo;Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(6):900-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/17541049/pubmed\" id=\"17541049\" target=\"_blank\">",
"        17541049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skljarevski V, Desaiah D, Liu-Siefert H, et al, &ldquo;Efficacy and Safety of Duloxetine in Patients With Chronic Low Back Pain,&rdquo;",
"      <i>",
"       Spine",
"      </i>",
"      ,  2010, 35(13):E578-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/20461028/pubmed\" id=\"20461028\" target=\"_blank\">",
"        20461028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skljarevski V, Zhang S, Chappell AS, et al, &ldquo;Maintenance of Effect of Duloxetine in Patients With Chronic Low Back Pain: A 41-Week Uncontrolled, Dose-Blinded Study,&rdquo;",
"      <i>",
"       Pain Med",
"      </i>",
"      , 2010, 11(5):648-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/20546509/pubmed\" id=\"20546509\" target=\"_blank\">",
"        20546509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skljarevski V, Zhang S, Desaiah D, et al, &ldquo;Duloxetine Versus Placebo in Patients With Chronic Low Back Pain: A 12-Week, Fixed-Dose, Randomized, Double-Blind Trial,&rdquo;",
"      <i>",
"       J Pain",
"      </i>",
"      , 2010, 11(12):1282-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/20472510/pubmed\" id=\"20472510\" target=\"_blank\">",
"        20472510",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, &ldquo;Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1290-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Kerrebroeck P, Abrams P, Lange R, et al, &ldquo;Duloxetine Versus Placebo in the Treatment of European and Canadian Women With Stress Urinary Incontinence,&rdquo;",
"      <i>",
"       BJOG",
"      </i>",
"      , 2004, 111(3):249-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/14961887/pubmed\" id=\"14961887\" target=\"_blank\">",
"        14961887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells KA and Losin WG, &ldquo;",
"      <i>",
"       In vitro",
"      </i>",
"      Stability, Potency, and Dissolution of Duloxetine Enteric-Coated Pellets After Exposure to Applesauce, Apple Juice, and Chocolate Pudding,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2008, 30(7):1300-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/18691989/pubmed\" id=\"18691989\" target=\"_blank\">",
"        18691989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(3):703-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/62/37864/abstract-text/19701065/pubmed\" id=\"19701065\" target=\"_blank\">",
"        19701065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8484 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37864=[""].join("\n");
var outline_f36_62_37864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708710\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163737\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5687669\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163755\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163740\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163741\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163742\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163743\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163711\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163696\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874615\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163715\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163714\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163751\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163762\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163753\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163718\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163700\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163748\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163704\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163733\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163706\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163721\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163746\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163722\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163723\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163720\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163708\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539848\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163699\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163717\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8484\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8484|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/42/9894?source=related_link\">",
"      Duloxetine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_62_37865="Chronic placenta underperfusion";
var content_f36_62_37865=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Preterm placenta from a pregnancy complicated by severe preterm preeclampsia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrows show areas of accelerated maturity of the villi (short arrow) and a central infarct (long arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37865=[""].join("\n");
var outline_f36_62_37865=null;
var title_f36_62_37866="Medical management and follow-up of gestational diabetes mellitus";
var content_f36_62_37866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management and follow-up of gestational diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37866/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37866/contributors\">",
"     Donald R Coustan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37866/contributors\">",
"     Lois Jovanovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37866/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37866/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37866/contributors\">",
"     Michael F Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/62/37866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/62/37866/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/62/37866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general approach to treatment of gestational diabetes mellitus (GDM) will be reviewed here. Screening, diagnosis, and obstetrical management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying women with GDM is important because meta-analysis of randomized trials has shown that appropriate therapy can decrease maternal and fetal morbidity, particularly macrosomia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. An effective treatment regimen consists of dietary therapy, self blood glucose monitoring, and the administration of insulin if target blood glucose concentrations are not met with diet alone, but more research to determine the optimum approach is needed.",
"   </p>",
"   <p>",
"    The value of treatment of GDM was best illustrated in two large trials that randomly assigned women with mild GDM to a regimen of either",
"    <span class=\"nowrap\">",
"     diet/blood",
"    </span>",
"    glucose",
"    <span class=\"nowrap\">",
"     monitoring/insulin",
"    </span>",
"    as needed or routine obstetrical care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. One trial was performed in Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"     2",
"    </a>",
"    ] and the other in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/3\">",
"     3",
"    </a>",
"    ]. A strength of both trials was that clinicians and patients in the control group did not know the results of the glucose tolerance testing, thus increasing the probability that the control group actually received routine care. The trials differed in two ways: (1) the method of diagnosis of mild GDM (abnormal three-hour 100 g glucose tolerance test [GTT] with normal fasting but two elevated post-challenge values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/3\">",
"     3",
"    </a>",
"    ]) versus abnormal 75 g two-hour GTT with fasting below 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (average fasting plasma glucose 86",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.8",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    and an elevated two-hour value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"     2",
"    </a>",
"    ]) and (2) no upper limit to GTT results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/3\">",
"     3",
"    </a>",
"    ] versus two-hour plasma glucose between 140 and 198",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 to 11",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both trials observed that treatment resulted in a significant decrease in the prevalence of macrosomia (US trial: 6 versus 14 percent with usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/3\">",
"     3",
"    </a>",
"    ]; Australian trial: 10 versus 21 percent with usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"     2",
"    </a>",
"    ]), and the reduction in macrosomia was associated with a significant decrease in shoulder dystocia in one trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/3\">",
"     3",
"    </a>",
"    ] and the composite outcome of shoulder dystocia, nerve palsy, bone fracture, and death in the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of cesarean delivery was significantly reduced in the treatment group of one trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/3\">",
"     3",
"    </a>",
"    ], and not increased in the other trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"     2",
"    </a>",
"    ], although an increase is often observed in women with gestational diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/5\">",
"     5",
"    </a>",
"    ]. Treatment did not lead to a significant reduction in the prevalence of neonatal metabolic abnormalities (eg, hypoglycemia, hyperbilirubinemia) in either trial.",
"    <span class=\"nowrap\">",
"     Fetal/neonatal",
"    </span>",
"    death was rare in all groups in both trials.",
"   </p>",
"   <p>",
"    Both trials reported lower pregnancy weight gain in the treated group than in the control group. It is unclear how much of the study benefit can be explained by limitation of weight gain, although a secondary analysis of the data from the US trial showed an effect of treatment independent of weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/6\">",
"     6",
"    </a>",
"    ]. The US trial also reported a significant decrease in the rates of preeclampsia and gestational hypertension in the treatment group (8.6 versus 13.6 percent with usual care) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/3\">",
"     3",
"    </a>",
"    ] and the Australian trial noted a significantly reduced rate of gestational hypertension (12 versus 18 percent with usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"     2",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    A long-term follow-up study of a subset of the Australian trial reported that although treatment of GDM substantially reduced macrosomia at birth, it did not result in a change in BMI in offspring at age 4 to 5 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/7\">",
"     7",
"    </a>",
"    ]. However, a number of previous longitudinal studies of offspring of diabetic mothers reported that adiposity usually manifested at age 6 to 7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], so longer follow-up is needed.",
"   </p>",
"   <p>",
"    In randomized trials, the potential harms resulting from treatment of GDM include an increased number of prenatal visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/1,3\">",
"     1,3",
"    </a>",
"    ] and possibly an increased rate of induction of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NUTRITIONAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with GDM should receive nutritional counseling by a registered dietitian (when possible) upon diagnosis and be placed on an appropriate diet. The goals of medical nutritional therapy are to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Achieve normoglycemia",
"     </li>",
"     <li>",
"      Prevent ketosis",
"     </li>",
"     <li>",
"      Provide adequate weight gain",
"     </li>",
"     <li>",
"      Contribute to fetal well-being",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed review of medical nutritional treatment of individuals with diabetes can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    .) Non-caloric sweeteners, such as aspartame, sucralose, and others, may be used in moderation.",
"   </p>",
"   <p>",
"    There is scanty level I evidence to support most aspects of the nutritional prescription for GDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/10\">",
"     10",
"    </a>",
"    ]. The American Diabetes Association (ADA) recommends that nutrition therapy for GDM provide adequate nutrition to promote fetal and maternal well-being while achieving normoglycemia with absence of ketones, and providing adequate energy levels for appropriate weight gain in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/11\">",
"     11",
"    </a>",
"    ]. In clinical practice, women often require 1800 to 2500 kcal per day. For women who are at ideal body weight during pregnancy, the caloric requirement is 30",
"    <span class=\"nowrap\">",
"     kcal/kg/day;",
"    </span>",
"    for women who are overweight, the caloric requirement is 22 to 25",
"    <span class=\"nowrap\">",
"     kcal/kg/day;",
"    </span>",
"    and for morbidly obese women, the caloric requirement is 12 to 14",
"    <span class=\"nowrap\">",
"     kcal/kg/day",
"    </span>",
"    (present pregnant weight). For those women who are underweight, the caloric requirement may be up to 40",
"    <span class=\"nowrap\">",
"     kcal/kg/day",
"    </span>",
"    to achieve recommended weight gains, blood glucose goals, and nutrient intake.",
"   </p>",
"   <p>",
"    Once the caloric needs are calculated, carbohydrate intake needs to be distributed across meals and snacks to blunt postprandial hyperglycemia. Carbohydrate intake is limited to less than 40 percent of total calories, while assuring that ketonemia does not ensue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical meal plan for women with GDM includes three small-to-moderate sized meals and two to four snacks. Many women will need individual adjustment (ie, 15 to 30 g of carbohydrate at breakfast or other meals), depending on postprandial glucose levels. Postprandial blood glucose concentrations are directly dependent upon the carbohydrate content of the meal or snack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/13\">",
"     13",
"    </a>",
"    ]. The postprandial glucose rise, therefore, can be blunted if the diet is carbohydrate restricted. A practical approach is to advise patients to minimize bread, rice, cereal, pasta, tortillas, potatoes, and sweet fruits and juices. Complex carbohydrates (low glycemic index), such as those in starches and vegetables, are more nutrient dense and raise postprandial blood glucose concentrations less than simple sugars, but a clear effect on pregnancy outcome, particularly incidence of macrosomia, has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=see_link&amp;anchor=H17#H17\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\", section on 'Nutritional content'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remaining calories come from protein (less than 20 percent of total calories) and fats (40 percent of total calories; saturated fat intake should be &lt;7 percent of total calories). Protein intake should be distributed throughout the day, and included in all meals and snacks to promote satiety and provide adequate calories. A bedtime snack may be needed to prevent accelerated (starvation) ketosis overnight. Adjustment of the meal plan should be ongoing, and based upon results of self glucose monitoring, appetite, and weight gain patterns.",
"   </p>",
"   <p>",
"    Close follow-up is important to ensure nutritional adequacy. Individual assessment and self blood glucose monitoring are used to determine and modify specific",
"    <span class=\"nowrap\">",
"     nutrition/food",
"    </span>",
"    recommendations. If insulin therapy is added to nutrition therapy, a primary goal is to maintain carbohydrate consistency at meals and snacks to facilitate insulin adjustments.",
"   </p>",
"   <p>",
"    After prescribing the diet, it is important to pay attention to subsequent changes in weight. A retrospective cohort study including 31,074 women with GDM showed that those with appropriate weight gain (per Institute of Medicine 2000 recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/18\">",
"     18",
"    </a>",
"    ]) had optimal outcomes, while excessive weight gain was associated with a significantly increased risk of having a large for gestational age infant, preterm birth, and cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/19\">",
"     19",
"    </a>",
"    ]. Suboptimal weight gain increased the likelihood of avoiding medical therapy of GDM and decreased the likelihood of having a large for gestational age neonate; however, there were more small for gestational age neonates in this group (7.3 versus 5.6 percent). The data in this study were not corrected for potential confounders, such as smoking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19304?source=see_link&amp;anchor=H4#H4\">",
"     \"Weight gain and loss in pregnancy\", section on 'Recommendations for weight gain during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss in pregnancy is not generally recommended, although controversy exists regarding this recommendation for markedly obese women. Maternal obesity often worsens impaired glucose tolerance. Furthermore, maternal GDM and obesity are independently associated with adverse pregnancy outcomes, such as excessive fetal growth and preeclampsia, and their combination has a greater impact than either disorder alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caloric restriction may be useful in treating overweight and obese women with GDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. For obese women (BMI&gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    a modest energy restriction to slow weight gain can be achieved by restricting caloric intake by about 30 percent below the Dietary Reference Intakes (DRI) for pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/25\">",
"     25",
"    </a>",
"    ]. Restriction of carbohydrates to less than 40 percent of total calories has been demonstrated to improve maternal glucose levels and improve pregnancy outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/26\">",
"     26",
"    </a>",
"    ]. The remaining calories are divided between protein and fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/13,25,27,28\">",
"     13,25,27,28",
"    </a>",
"    ]. This can be achieved while meeting Institute of Medicine (IOM) weight gain recommendations and without causing ketosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19304?source=see_link&amp;anchor=H4#H4\">",
"     \"Weight gain and loss in pregnancy\", section on 'Recommendations for weight gain during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nutritional therapy to decrease the risk of macrosomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major fetal effect of GDM is on birth weight and body composition: infants of diabetic mothers are at high risk of being large for gestational age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, macrosomia may not be prevented by dietary therapy alone. A Cochrane review of four studies involving 612 women with GDM treated with primary dietary therapy or no specific treatment found no differences in birthweight greater than 4000 g (OR 0.78, 95% CI 0.45-1.35) or cesarean deliveries (OR 0.97, 95% CI 0.65-1.44) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the variable quality of these studies and wide confidence intervals precluded a definitive conclusion about the value of dietary intervention. As an example, the investigators did not consistently assess dietary compliance or postprandial glucose concentration in women in whom a diet was prescribed. In the two randomized trials in which diagnosis and treatment of mild GDM improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], only 20 and 8 percent of women, respectively, required insulin, while 80 and 92 percent of women, respectively, were treated satisfactorily with diet.",
"   </p>",
"   <p>",
"    Some experts have suggested medical nutritional therapy for women who do not meet oral GTT criteria for GDM, but have fasting blood glucose concentrations &gt;90",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/30\">",
"     30",
"    </a>",
"    ], an abnormal glucose challenge test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], or one abnormal value on the oral GTT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .) The rationale for this approach is that there appears to be a continuous relationship between glucose concentration and fetal",
"    <span class=\"nowrap\">",
"     growth/adverse",
"    </span>",
"    fetal outcome, even in women who did not meet the ADA criteria for diagnosis of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/5,30-35\">",
"     5,30-35",
"    </a>",
"    ]. This was best illustrated in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, which included more than 23,000 pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/35\">",
"     35",
"    </a>",
"    ]. After a 75-g oral two-hour glucose tolerance test, the risk of macrosomia increased as much as five-fold as fasting blood glucose concentration increased above 75",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    or one-hour glucose concentration increased above 105",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    or two-hour glucose concentration increased above 90",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and the risk increased continuously across the spectrum of glucose results. There was also a positive, but weaker, correlation between increasing glucose concentration and maternal complications (eg, preeclampsia) and neonatal metabolic morbidity (eg, hypoglycemia, hyperbilirubinemia), but not long-term childhood morbidity, such as obesity at age two years in a small subset of offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/36\">",
"     36",
"    </a>",
"    ], although, as noted above, previous longitudinal studies have suggested that obesity does not manifest itself until the age of 6 to 7 years. Of note, women with significant hyperglycemia were excluded from the HAPO analysis (exclusion criteria: fasting glucose concentration greater than 105",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.8",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    two-hour glucose concentration greater than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.1",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    or a random glucose concentration later in gestation greater than 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [8.9",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    In a 2012 systematic review of four randomized trials (n = 543 women) of women with one or more elevated glucose levels on GTT who did not meet standard criteria for GDM, glucose monitoring and medical nutritional therapy (with or without insulin) resulted in a reduction in delivery of large for gestational age infants compared with usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/37\">",
"     37",
"    </a>",
"    ]. Similarly, in the ACHOIS trial, medical nutritional therapy (with or without insulin) initiated at two-hour 75 g GTT levels of 140 to 198",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 to 11.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (ie, a range between a normal and a diabetic response on oral GTT) resulted in a lower rate of serious perinatal complications compared with routine care (1 versus 4 percent; adjusted RR 0.33; 95% CI 0.14-0.75) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GLUCOSE MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with GDM should measure their blood glucose concentration at least four times daily (fasting and one or two hours after the first bite of each meal) to determine whether hyperglycemia severe enough to increase fetal risk is occurring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/25\">",
"     25",
"    </a>",
"    ]. Results should be recorded in a glucose log, along with dietary information. This facilitates recognition of glycemic patterns and helps immeasurably in interpreting results stored in the memory of modern meters.",
"   </p>",
"   <p>",
"    Multiple daily self measurements of blood glucose are important for women managed with medical nutritional therapy alone, as well as those on anti-hyperglycemic agents. Multiple daily measurements allow recognition of women who should begin an anti-hyperglycemic agent and appear to decrease the risk of macrosomia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/38\">",
"     38",
"    </a>",
"    ]. Although there are no data on the duration of good control sufficient to reduce the frequency of self-monitoring or the appropriate frequency of testing in GDM that is well controlled with nutritional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/39\">",
"     39",
"    </a>",
"    ], many providers decrease the frequency of glucose monitoring when good glycemic control is accomplished with medical nutritional therapy.",
"   </p>",
"   <p>",
"    Once the new IADPSG recommendations for the diagnosis of GDM are in widespread use, resulting in as many as 18 percent of pregnant women diagnosed with this condition, there will be even greater need for more efficient and effective monitoring and treatment strategies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .) Therefore, studies to test alternative approaches such as less frequent monitoring are necessary. Fortunately, intervention trials of mild GDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] demonstrated that only a small proportion of such individuals required intervention beyond dietary management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from most available glucose meters and commercial laboratories reflect plasma (not whole blood) glucose levels. However, meters cannot correct for the fact that postprandial glucose concentrations tend to be higher in capillary samples because of",
"    <span class=\"nowrap\">",
"     arterial/venous",
"    </span>",
"    mixing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Timing and frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most nonpregnant individuals with diabetes on insulin therapy self-monitor preprandial glucose levels or both preprandial and postprandial glucose levels. For all women with GDM, we suggest blood glucose be measured upon awakening and one or two hours after the beginning of each meal throughout pregnancy because the degree of fasting glycemia alone does not predict the need for insulin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/40\">",
"     40",
"    </a>",
"    ]. Given limited data, assessment of blood glucose can be performed either one or two hours postprandially; the optimum time has not been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. The advent of continuous glucose monitoring has the potential to allow determination of peak postprandial glucose levels; future research should determine whether using such peak values in management of GDM will improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of fasting plus postprandial versus preprandial measurement was suggested by a trial that randomly assigned 66 insulin-treated patients with GDM to have their diabetes managed according to results of preprandial or fasting plus postprandial monitoring (one hour after meals) of blood glucose concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/46\">",
"     46",
"    </a>",
"    ]. One hour postprandial monitoring was associated with the following benefits as compared to preprandial monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Better glycemic control (HbA1c value 6.5 versus 8.1 percent)",
"     </li>",
"     <li>",
"      A lower incidence of large for gestational age infants (12 versus 42 percent)",
"     </li>",
"     <li>",
"      A lower rate of cesarean delivery for cephalopelvic disproportion (12 versus 36 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucose target",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glucose level at which the disadvantages of initiating insulin therapy are clearly outweighed by the benefits has not been definitively determined; there is little consensus in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/47\">",
"     47",
"    </a>",
"    ]. The ADA recommends the following upper limits for glucose levels, with insulin therapy initiated if they are exceeded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little guidance is available as to what proportion of measurements exceeding these thresholds should trigger intervention, and some suggest insulin for two or more elevated values in a two-week interval while others await more consistent elevations, particularly if it is judged that further nutritional counseling may be effective.",
"   </p>",
"   <p>",
"    ADA glucose targets:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fasting blood glucose concentration &le;95",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      One-hour postprandial blood glucose concentration &le;140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Two-hour postprandial glucose concentration &le;120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, ACOG suggests administration of insulin to reduce the risk of macrosomia when the following target glucose levels are exceeded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACOG glucose target:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fasting glucose concentration &le;95",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or",
"     </li>",
"     <li>",
"      One hour-postprandial glucose &lt;130 to 140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.2 to 7.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or",
"     </li>",
"     <li>",
"      Two hour-postprandial blood concentration &le;120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These targets, which represent the upper limit of desirable glucose concentration, are well above the mean glucose values in nondiabetic pregnant women described in a 2011 literature review of studies of the normal 24-hour glycemic profile of pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/49\">",
"     49",
"    </a>",
"    ]. In this review of 12 studies with a total of 255 nondiabetic women who were mostly nonobese and in the late third trimester, the pooled weighted mean glucose values (&plusmn; 1 SD) were fasting 71 &plusmn; 8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.9 &plusmn; 0.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    one-hour postprandial 109 &plusmn; 13",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.0 &plusmn; 0.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    two-hour postprandial 99 &plusmn; 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.5 &plusmn; 0.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and 24-hour glucose 88 &plusmn; 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.9 &plusmn; 0.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    These levels were derived from measurements on whole blood, plasma, self-monitored capillary glucose measurements, and tissue glucose measurements using continuous glucose monitoring systems. Despite the variations in methodology, there was some consistency in the results.",
"   </p>",
"   <p>",
"    If two standard deviations are added to the means outlined above, the upper limit of normal fasting glucose would be 87",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the corresponding one-hour postprandial value would be 135",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and the upper limit of normal two-hour value would be 119",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.6",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    while the fasting value is somewhat lower than the target 95",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    , the postprandial values are not dissimilar to the targets described above.",
"   </p>",
"   <p>",
"    Mean blood glucose values throughout the day appear to be 5 to 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.3 to 0.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    higher in nondiabetic obese pregnant women than in normal weight pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described above, the Hyperglycemia and Adverse Pregnancy Outcome trial (HAPO) showed a continuous relationship between maternal glucose and adverse outcomes, with a fasting plasma glucose level greater than 105",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    associated with a risk of macrosomia five-fold greater than that with a fasting glucose level less than 75",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (25 versus 5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/35\">",
"     35",
"    </a>",
"    ]. Subsequent studies have consistently reported an association between increasing fasting maternal glucose levels and increasing neonatal",
"    <span class=\"nowrap\">",
"     adiposity/size",
"    </span>",
"    that is large for gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether there would be benefit to lowering the targets for initiating therapy in GDM in an effort to further lower the increased prevalence of large for gestational age infants is a hypothesis which could be tested. However, there is evidence that overly tight metabolic control in GDM (ie, average blood glucose levels &le;86",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    can result in an increase in small for gestational age offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glycated hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycated hemoglobin (A1C) may be a helpful ancillary test in assessing glycemic control during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In a series of patients diagnosed with GDM early in pregnancy (12.2 &plusmn; 7.4 weeks), and whose initial A1C was above 7 percent (average 8.8 percent), the decline in A1C when treatment was initiated averaged 0.47 percent per week over the initial four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/56\">",
"     56",
"    </a>",
"    ]. Using the IADPSG and ADA classification, these women would be classified as having overt diabetes (initial A1C above 6.5 percent); it is not clear how useful frequent A1C measurements would be in GDMs with lower initial A1C levels.",
"   </p>",
"   <p>",
"    It should be noted that A1C values tend to be lower in pregnant compared to nonpregnant women because the average blood glucose concentration is about 20 percent lower in pregnant women and, in the first half of pregnancy, there is a rise in red cell mass and a slight decrease in red blood cell life span [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Other factors that affect A1C levels include race (A1C concentration is higher in African American, Hispanic and Asian women than in white women) and iron status (chronic iron deficiency anemia, treatment of iron deficiency anemia with iron). Sources of variation in A1C levels are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link&amp;anchor=H3#H3\">",
"     \"Estimation of blood glucose control in diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MONITORING FOR KETONURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not routinely monitor urinary ketones in women with GDM. There is conflicting evidence as to whether ketonuria is associated with an adverse effect on cognitive development of the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetic ketoacidosis is rare in women with gestational diabetes. It is characteristically associated with type 1 diabetes and also occurs in type 2 diabetes under conditions of extreme stress such as serious infection, trauma, or cardiovascular or other emergencies. In general, women with diabetes should test their urine for ketones if the blood glucose concentration is above 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    during periods of illness or stress, or if there are symptoms compatible with ketoacidosis such as nausea, vomiting, and abdominal pain.",
"   </p>",
"   <p>",
"    The presence of ketones in the urine does not necessarily mean that the person has impending ketoacidosis. Ketonuria indicates that the person is in a catabolic state and is breaking down fat, and can occur in anyone who has a negative caloric balance. Pregnant women develop elevated &beta;-hydroxybutyrate levels more rapidly than nonpregnant individuals during a 12- to 18-hour fast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/62\">",
"     62",
"    </a>",
"    ], and it is not known whether such elevated levels have an adverse impact on fetal development. Several studies have suggested that early maternal malnutrition can affect neurobehavioral development in children of women with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/9,59-61,63\">",
"     9,59-61,63",
"    </a>",
"    ]. In one such study, plasma beta-hydroxybutyrate levels independent of glucose levels had an adverse association with cognitive development in pregnancies in women with prepregnancy diabetes, GDM, and in normal pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/63\">",
"     63",
"    </a>",
"    ]. However, in these studies it is difficult to prove that ketosis is the causal factor as opposed to one or more other maternal metabolic disturbances. Nevertheless, it is prudent to advise pregnant women, with or without GDM, to avoid prolonged fasting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular conditioning appears to improve glycemic control primarily from increased tissue sensitivity to insulin. As a result, both fasting and postprandial blood glucose concentrations can be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/64-66\">",
"     64-66",
"    </a>",
"    ] and, in some women with GDM, the need for insulin may be obviated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Circuit resistance training has a similar effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one small randomized trial, six weeks of a cardiovascular fitness program using arm ergometry three times a week for 20 to 30 minutes per session resulted in normalization of glucose tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/67\">",
"     67",
"    </a>",
"    ]. The mean fasting blood glucose concentration fell to 55 to 65",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.1 to 3.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and the mean blood glucose concentration was 106",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    one hour after a 50-gram oral glucose challenge. In another small randomized trial, use of a recumbent bicycle was associated with reduction in glucose levels such that exercise-trained subjects and insulin-treated control subjects had comparable mean glucose values during pregnancy, comparable infant birth weights, and comparable macrosomia rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/70\">",
"     70",
"    </a>",
"    ]. A third randomized trial confirmed the safety and cardiovascular benefits of exercise programs in women with GDM, but was unable to demonstrate reduction in glucose levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of exercise in women with GDM requires further exploration to determine the potential range of benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Nevertheless, based on the data cited above and that in nonpregnant individuals, the ADA encourages a program of moderate exercise as part of the treatment plan for women with GDM and no medical or obstetrical contraindications to this level of physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/29/4568?source=see_link\">",
"     \"Anatomical and physiological changes of pregnancy and exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/30/7657?source=see_link\">",
"     \"Recommendations for exercise during pregnancy and the postpartum period\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If normoglycemia cannot be maintained by medical nutritional therapy, then anti-hyperglycemic agents should be initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/74\">",
"     74",
"    </a>",
"    ]. There are two options in pregnant patients who require medical therapy aimed at controlling blood glucose: insulin (and some insulin analogs), which is the only recommended approach in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/25\">",
"     25",
"    </a>",
"    ]; and selected oral anti-hyperglycemic agents, which are used in some other countries.",
"   </p>",
"   <p>",
"    Hospitalization is not necessary to initiate insulin. However, if teaching of insulin technique and dosage of multiple insulin injections, self-monitoring blood glucose, and charting of the blood glucose and insulin is not possible in the outpatient setting, then the use of an inpatient setting to utilize the expertise of the hospital's nursing staff may justify the cost of hospitalization. We do not use insulin pumps in women with GDM because there are no data to suggest that they are necessary or more effective than conventional therapy and the cost of an insulin pump is not justified over the relatively short duration of a pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with GDM are placed on insulin therapy when target glucose levels are exceeded despite dietary therapy (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Glucose target'",
"    </a>",
"    above). In addition, randomized trials have suggested that prescribing insulin to the subgroup of women with indirect evidence of fetal hyperinsulinemia (eg, ultrasound showing abdominal circumference &gt;75",
"    <sup>",
"     th",
"    </sup>",
"    percentile early in the third trimester) allows targeted treatment of those at highest risk of delivering a macrosomic infant and avoids treatment of those at low risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/25,75-78\">",
"     25,75-78",
"    </a>",
"    ]. It is reasonable for women with fetuses with large abdominal circumferences to receive insulin to decrease the risk of macrosomia, even if they have no or mild hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/39\">",
"     39",
"    </a>",
"    ]. Conversely, it is reasonable to relax self-glucose monitoring and initiation of insulin for mild hyperglycemia in women whose fetuses have a small abdominal circumference (&lt;75",
"    <sup>",
"     th",
"    </sup>",
"    percentile). Withholding insulin when there is no evidence of increased somatic growth may limit the risk of iatrogenic growth restriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of insulin varies in different populations because of varied rates of obesity, ethnic characteristics, degree of hyperglycemia, and other demographic criteria, but the majority of studies have reported a total insulin dose ranging from 0.7 to 2 units per kilogram (present pregnant weight) to achieve glucose control. The dose and type of insulin used is calculated based upon the specific abnormality of blood glucose noted during monitoring. One principle we have found useful is to start with the simplest regimen and increase the complexity as needed to address the particular situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/79\">",
"     79",
"    </a>",
"    ]. Typically, regardless of body weight, a patient whose glucose elevations are mostly postprandial is prescribed a starting dose of 30 units (20 units of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/7/10359?source=see_link\">",
"     intermediate acting insulin",
"    </a>",
"    and 10 units of rapid acting insulin) in the morning prior to breakfast. If the GDM is diagnosed and therapy instituted prior to the third trimester, we generally start with half this dose, since insulin resistance has not reached its maximum level in the second trimester. The 2:1 proportion of intermediate to rapid acting insulin is based on the pattern of insulin release in normal pregnant women in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/80\">",
"     80",
"    </a>",
"    ]. If the post-dinner glucose level remains elevated, then an additional injection of rapid acting insulin is given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin, or can be administered separately at bedtime. Sometimes an additional dose of rapid acting insulin is necessary to maintain euglycemia after lunch, so that a total of four injections per day are needed. A four times per day regimen improved glycemic control and perinatal outcome compared to a twice-daily regimen in one randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/81\">",
"     81",
"    </a>",
"    ], although macrosomia rates were not impacted. Subsequent adjustments in the various components of the insulin regimen are made based upon the corresponding glucose levels. Because any insulin regimen requires serial readjustment of dosage in response to specific fasting or postprandial glucose levels, the starting dose should be considered just that, a starting point. Adjustments in insulin dosage in response to high glucose values are typically in the range of 10 to 20 percent, particularly in obese patients with GDM who are unlikely to develop hypoglycemia unless a meal is omitted after insulin is given.",
"   </p>",
"   <p>",
"    The titration of insulin dose to blood glucose levels is based upon frequent self-monitoring. Four to six glucose measurements each day are needed to optimize therapy (fasting and one or two hours postprandial with the possible addition of pre-lunch and pre-dinner) and ensure a smooth increase of insulin as insulin requirements increase with pregnancy progression. Twin gestations complicated by GDM may require an approximate doubling of the insulin requirement throughout pregnancy.",
"   </p>",
"   <p>",
"    Hypoglycemia remote from meal or snack time is rare in women with GDM, and is treated by administering 10 to 20 g of a mixed protein and carbohydrate snack immediately. The administration of a pure simple sugar in a pregnant woman with diabetes may lead to rapid elevation of glucose followed by rapid decline. The mixed protein and carbohydrate snack tends to dampen the fluctuation. Once the woman &ldquo;feels&rdquo; better, she is better and may need to give herself extra insulin to compensate for overtreatment of the symptoms. If low glucose values are encountered more than once at the same time of day, insulin doses are adjusted downward accordingly.",
"   </p>",
"   <p>",
"    An alternative approach to insulin therapy, somewhat more complex and likely most appropriate for individuals whose glucose levels are not well controlled with simpler paradigms, is described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If insulin is required because the fasting blood glucose concentration is high, an intermediate-acting insulin, such as NPH insulin, is given before bedtime; an initial dose of 0.2",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      body weight is utilized.",
"     </li>",
"     <li>",
"      If postprandial blood glucose concentrations are high,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/42/10920?source=see_link\">",
"       insulin aspart",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17160?source=see_link\">",
"       insulin lispro",
"      </a>",
"      is given before meals at a dose calculated to be 1.5 units per 10 grams carbohydrate in the breakfast meal and 1 unit per 10 grams carbohydrate in the lunch and dinner meals. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15225?source=see_link\">",
"       \"General principles of insulin therapy in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If both preprandial and postprandial blood glucose concentrations are high or if the woman's postprandial glucose levels can only be blunted if starvation ketosis occurs, then a six injection per day regimen is utilized. The total starting dose is 0.7",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      up to week 12, 0.8",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      for weeks 13 to 26, 0.9",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      for weeks 26 to 36, and 1.0",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      for weeks 36 to term. In a severely obese woman, the initial doses of insulin may need to be increased to 1.5 to 2.0",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      to overcome the combined insulin resistance of pregnancy and obesity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The insulin is divided according to the following schedule: 50 percent as NPH insulin (given in three equal doses before breakfast, before dinner and before bedtime) and 50 percent as three preprandial rapid-acting insulin injections. Of the insulin analogs, only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    have safety and efficacy data in pregnancy (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Type of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of insulin preparations of low antigenicity may minimize the transplacental transport of insulin antibodies: human insulin is the least immunogenic of the commercially available preparations. The three rapid acting insulin analogs (lispro, aspart, glulisine) are comparable in immunogenicity to human",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , but only lispro and aspart have been investigated in pregnancy and shown to have acceptable safety profiles, minimal transfer across the placenta, and no evidence of teratogenesis. Neonatal outcomes are similar to those of women treated with regular insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/47\">",
"     47",
"    </a>",
"    ]. These two insulin analogs both improve postprandial excursions compared to human regular insulin and are associated with lower risk of delayed postprandial hypoglycemia.",
"   </p>",
"   <p>",
"    Long-acting insulin analogs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    ) have not been studied extensively in pregnancy. In 2012, a multinational trial on the safety and efficacy of insulin detemir for the treatment of women with type 1 diabetes reported reassuring safety and efficacy results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], which led the FDA to reclassify insulin detemir from &lsquo;C&rsquo; to &lsquo;B&rsquo; . In vitro perfusion studies have demonstrated that insulin glargine does not cross the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/84\">",
"     84",
"    </a>",
"    ]; however, concern about transplacental transfer of glargine in vivo remains. Based on available data, we prefer use of human NPH insulin as part of a multiple injection regimen in pregnant women with GDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/85\">",
"     85",
"    </a>",
"    ]. There are good data supporting the safety and effectiveness of NPH in pregnancy and doses can be adjusted frequently and quickly in response to changing requirements in pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15225?source=see_link&amp;anchor=H6#H6\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Oral anti-hyperglycemic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review by the Johns Hopkins University Evidence-based Practice Center for the Agency for Healthcare Research and Quality presented evidence from randomized trials and observational studies that (1) maternal glucose levels did not differ substantially between gravidae treated with insulin versus those treated with oral glucose-lowering agents, and (2) there was no consistent evidence of an increase in any adverse maternal or neonatal outcome with use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    compared with use of insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/47,86\">",
"     47,86",
"    </a>",
"    ]. Another systematic review confirmed these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/87\">",
"     87",
"    </a>",
"    ]. However, inconsistencies in clinical outcome measures across studies and lack of data regarding long-term outcomes made it difficult to draw firm conclusions.",
"   </p>",
"   <p>",
"    The ADA and ACOG do not endorse the use of oral anti-hyperglycemic agents during pregnancy and such therapy has not been approved by the Unites States Food and Drug Administration (FDA) for treatment of GDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. We concur, but",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    may be a reasonable alternative for women who fail diet therapy and refuse to take, or are unable to comply with, insulin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Glyburide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of GDM with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    is becoming more prevalent, even though the Fifth International Workshop advised caution regarding its use during pregnancy until safety concerns have been investigated more thoroughly. There are conflicting data regarding the transplacental passage of glyburide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/88-91\">",
"     88-91",
"    </a>",
"    ]. Studies have generally found that maternal use of glyburide was not associated with an excess risk of neonatal hypoglycemia or congenital anomalies and that it was an effective treatment of GDM, particularly in women with mild to moderate degrees of hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/89,92-100\">",
"     89,92-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The only large, randomized study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      therapy in pregnancy included 404 women with mild GDM who were randomly assigned to receive glyburide or insulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/89,94\">",
"       89,94",
"      </a>",
"      ]. Clinical providers were not blinded to the treatment allocation. The mean blood glucose concentration during treatment was 105",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in both groups, and there were no differences in the frequency of macrosomia, neonatal hypoglycemia, or other neonatal morbidities or in cord serum insulin concentrations. Four percent of women in the glyburide group required insulin therapy. A subsequent report from the same center [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/99\">",
"       99",
"      </a>",
"      ] noted that 20 percent of women initially treated with glyburide needed to be switched to insulin.",
"     </li>",
"     <li>",
"      A smaller trial that randomly assigned 99 women with GDM to treatment with insulin or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      found no statistically significant differences between groups in neonatal fat mass, body mass index, ponderal index, skinfold sum, or arm fat area, although there were significantly more infants &gt;4000 g in the glyburide group:",
"      <span class=\"nowrap\">",
"       9/41",
"      </span>",
"      (22 percent) versus",
"      <span class=\"nowrap\">",
"       1/41",
"      </span>",
"      (2.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/101\">",
"       101",
"      </a>",
"      ]. The study did not have adequate power to detect small differences in outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, an in vitro model of placental perfusion suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    could be actively transported against a concentration gradient from the fetal to the maternal circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/102\">",
"     102",
"    </a>",
"    ]. In another study, cord levels averaged 70 percent of maternal levels, although levels in both mother and fetus were quite low at the time of measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with insulin therapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    must be carefully balanced with meals and snacks to prevent maternal hypoglycemia. There is some evidence that glyburide may be less successful in obese patients or those with marked hyperglycemia earlier in pregnancy. More research is needed to determine: (a) if maternal and neonatal outcomes with glyburide are equivalent to those obtained with insulin therapy; (b) if glyburide affects the potential postpartum progression of the woman with GDM towards impaired glucose",
"    <span class=\"nowrap\">",
"     tolerance/diabetes,",
"    </span>",
"    or on the possibility of GDM recurrence; (c) whether glyburide affects the long-term well-being of offspring. Patients who are contemplating glyburide therapy should be counseled regarding the absence of information about these important questions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18999792\">",
"    <span class=\"h3\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second and third trimester",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    treatment of GDM appears to be safe, and is effective in many women, but between one third and one half of women will need insulin to achieve glycemic targets. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest trial assessing its use, 751 Australian women with GDM at 20 to 33 weeks of gestation were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      (with insulin supplementation if needed) or insulin therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/103\">",
"       103",
"      </a>",
"      ]. Perinatal morbidity was reported as the composite rate of neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, prematurity, and low Apgar score. One-third of women in each group experienced composite morbidity. There were no serious adverse effects related to metformin use; however, almost one-half of the women taking it needed supplemental insulin to achieve glycemia control.",
"     </li>",
"     <li>",
"      A randomized trial that directly compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      in treatment of GDM found use of glyburide was more likely to result in adequate glycemic control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/104\">",
"       104",
"      </a>",
"      ]. Insulin was eventually required in only 16 percent of those randomized to glyburide compared with about 35 percent of patients randomized to metformin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the above trials and other independent trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    to insulin, patients using metformin consistently were more likely to need supplemental insulin than patients using glyburide (32 to 46 percent versus 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/89,103-105\">",
"     89,103-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    has also been used to \"prevent\" GDM since it is an oral anti-hyperglycemic agent and would be expected to maintain euglycemia in some women who would otherwise be diagnosed with GDM. Although observational studies of metformin use in women with PCOS supported this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/106,107\">",
"     106,107",
"    </a>",
"    ], a randomized trial did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/108\">",
"     108",
"    </a>",
"    ]. In this trial, 273 pregnancies among 257 women with PCOS were randomly assigned to receive metformin (2000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo from the first trimester until delivery. There was no significant difference in prevalence of GDM between groups (metformin 17.6 percent versus placebo 16.9 percent). In this trial, and most other metformin trials, women in the metformin group gained less weight during pregnancy than those in the placebo group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=see_link&amp;anchor=H19#H19\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Diabetes mellitus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=see_link&amp;anchor=H20#H20\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    crosses the placenta and, in one study, cord arterial levels were twice as high as maternal venous levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/109\">",
"     109",
"    </a>",
"    ]. It is not known whether fetal exposure to an insulin sensitizing agent such as metformin is beneficial or harmful, and thus caution is warranted in its use in pregnancy. A two-year follow-up study of the offspring of the Metformin in Gestational diabetes [MiG] trial reported no difference in total fat or central adiposity between metformin-exposed and non-exposed offspring, but there was an increase in subcutaneous fat deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/110\">",
"     110",
"    </a>",
"    ]. Whether this is beneficial or harmful remains to be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. Because offspring of diabetic mothers may not manifest obesity until the age of 5 to 7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/113\">",
"     113",
"    </a>",
"    ], longer term studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19000274\">",
"    <span class=\"h3\">",
"     Tolbutamide and chlorpropamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/49/42774?source=see_link\">",
"     Tolbutamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    (older sulfonylureas) therapy is not recommended in women with GDM because these drugs cross the placenta and can cause fetal hyperinsulinemia, which can lead to macrosomia and prolonged neonatal hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/114-116\">",
"     114-116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44197?source=see_link\">",
"     Acarbose",
"    </a>",
"    , an alpha glucosidase inhibitor, is poorly absorbed from the gastrointestinal tract. Two preliminary studies have suggested efficacy in reducing postprandial glucose excursions in GDM, but with the expected high frequency of abdominal cramping. Since a small proportion of this drug may be absorbed systemically, and isolated cases of hepatic impairment have been reported, further study should evaluate potential transplacental passage.",
"   </p>",
"   <p>",
"    Use of thiazolidinediones, glitinides (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/25/4503?source=see_link\">",
"     repaglinide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/21/11606?source=see_link\">",
"     nateglinide",
"    </a>",
"    ), and GLP-1 during pregnancy is considered experimental. There are no controlled data available in pregnancy. One study reported that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    (note: use has been limited by the FDA because of potential cardiovascular side effects) crossed the human placenta at 10 to 12 weeks of gestation, fetal tissue levels were about half of maternal serum levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/117\">",
"     117",
"    </a>",
"    ]. Ex vivo human placental perfusion studies of GLP-1 agonists detected minimal levels on the fetal side (fetal:maternal ratio 0.017).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PERIPARTUM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6998924\">",
"    <span class=\"h2\">",
"     Pregnancy issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetrical management of the pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4313?source=see_link\">",
"     \"Obstetrical management of pregnancies complicated by gestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Glucose control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal hyperglycemia should be avoided during labor to reduce the risk of fetal acidosis and neonatal hypoglycemia. The risk of adverse neonatal metabolic outcomes (hypoglycemia, hyperbilirubinemia, hypocalcemia, erythremia) is related to both antepartum and intrapartum maternal hyperglycemia and appears to increase with the degree of maternal hyperglycemia. Intrapartum management of diet, glucose, and insulin and management of insulin before cesarean delivery are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/29/2519?source=see_link\">",
"     \"Intrapartum and postpartum management of insulin and blood glucose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any type of contraception is acceptable in women with prior diabetes (",
"    <a class=\"graphic graphic_table graphicRef69329 \" href=\"mobipreview.htm?19/34/20013\">",
"     table 1",
"    </a>",
"    ). Options for breastfeeding women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link&amp;anchor=H20#H20\">",
"     \"Principles of medication use during lactation\", section on 'Contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low dose estrogen-progestin oral contraceptives may be used in women with a history of GDM as long as the usual medical contraindications to their use are absent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progestin-only (but not combined estrogen-progestin) oral contraceptives (OCs) have been associated with an increased risk of developing type 2 diabetes in women with recent GDM. In a study of Hispanic women with recent GDM who were breastfeeding, the use of progestin-only OCs was associated with an increased risk of type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/118\">",
"     118",
"    </a>",
"    ]; however, the applicability of these findings to other women is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     FUTURE RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with GDM are normoglycemic after delivery. However, they are at high risk for recurrent GDM, prediabetes (impaired glucose tolerance or impaired fasting glucose), and overt diabetes over the subsequent five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;One-third to two-thirds of women with GDM will have GDM in a subsequent pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/119-122\">",
"     119-122",
"    </a>",
"    ]. In a study including over 65,000 pregnancies, the risk of GDM in the second pregnancy among women with and without previous GDM was 41 and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/122\">",
"     122",
"    </a>",
"    ]. Women who have a recurrence tend to be older, more parous, and have a greater increase in weight between their pregnancies than women without a recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/120\">",
"     120",
"    </a>",
"    ]. Higher infant birth weight in the index pregnancy and higher maternal prepregnancy weight have also been associated with recurrent GDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Long-term risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of GDM is predictive of an increased risk of developing type 2 diabetes, type 1 diabetes, and cardiovascular disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As many as 20 percent of women with GDM have impaired glucose tolerance during the early postpartum period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/123,124\">",
"       123,124",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review and meta-analysis found that women with GDM were at significantly higher risk of developing subsequent type 2 diabetes than women with normoglycemic pregnancies (RR 7.43, 95% CI 4.79-11.51; 20 cohort studies including 675,455 women of whom 10,859 had type 2 diabetes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/125\">",
"       125",
"      </a>",
"      ]. The relative risk was 4.69 within the first five years after delivery and 9.34 more than five years after delivery. As an example, a population-based study reported the incidence of type 2 diabetes in women with previous GDM was 3.7 percent 9 months postpartum, 4.9 percent 15 months postpartum, 13.1 percent 5 years postpartum, and 18.9 percent 9 years postpartum (versus 2 percent in controls without GDM) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/126\">",
"       126",
"      </a>",
"      ]. In fact, 10 to 31 percent of parous nonpregnant women with diabetes have experienced a pregnancy complicated by GDM prior to their diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/127\">",
"       127",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Waist circumference and BMI are the strongest anthropometric measures associated with development of type 2 diabetes in women with GDM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/47,128\">",
"       47,128",
"      </a>",
"      ]. Type 2 diabetes develops in 50 to 75 percent of obese (BMI &ge;30",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      women with a history of GDM versus fewer than 25 percent of women with GDM who achieve normal body weight after delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/129-131\">",
"       129-131",
"      </a>",
"      ]. Other major risk factors are gestational requirement for insulin and early gestational age at the time of diagnosis (ie, less than 24 weeks of gestation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/128\">",
"       128",
"      </a>",
"      ]. Additional risk factors for impaired glucose tolerance and overt diabetes later in life include autoantibodies (eg, glutamic acid decarboxylase, insulinoma antigen-2), high fasting blood glucose concentrations during pregnancy and early postpartum, higher fasting blood glucose at diagnosis of GDM and high glucose levels in oral glucose tolerance testing, neonatal hypoglycemia, and GDM in more than one pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/47,123,124,129,132-135\">",
"       47,123,124,129,132-135",
"      </a>",
"      ]. Parity, large birth weight, and diabetes in a first-degree relative are less correlated with later diabetes.",
"     </li>",
"     <li>",
"      GDM is also a risk factor for the development of type 1 diabetes, particularly in populations with a high prevalence of this disorder. Specific HLA alleles (DR3 or DR4) may predispose to the development of type 1 diabetes postpartum, as does the presence of islet-cell autoantibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/136-138\">",
"       136-138",
"      </a>",
"      ]. GDM in lean pregnant women, need for insulin treatment of GDM, diabetic ketoacidosis during pregnancy, and postpartum hyperglycemia also suggest preexisting unrecognized type 1 diabetes or high risk of developing type 1 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women with GDM are at higher risk of developing cardiovascular disease and developing it at a younger age than women with no history of GDM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/139,140\">",
"       139,140",
"      </a>",
"      ]. Even mild glucose impairment defined as an abnormal glucose challenge test with a normal glucose tolerance test appears to identify women at increased risk of future development of cardiovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/141\">",
"       141",
"      </a>",
"      ]. Whether this increase in risk is independent of the future development of type 2 diabetes remains unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Follow-up and prevention of type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACOG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/142\">",
"     142",
"    </a>",
"    ], the ADA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/25\">",
"     25",
"    </a>",
"    ] and the Fifth International Workshop Conference on Gestational Diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/39\">",
"     39",
"    </a>",
"    ] recommend long-term follow-up of women with GDM.",
"   </p>",
"   <p>",
"    All women with previous GDM should undergo an oral glucose tolerance test 6 to 12 weeks after delivery, using a two-hour 75 gram oral glucose tolerance test. Breastfeeding during the test appears to have a modest effect on glucose levels. In a prospective cohort study of nursing women with previous GDM who underwent a glucose tolerance test 6 to 9 weeks postpartum, mean two-hour glucose levels were 5 percent lower in women who breastfed during the test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/143\">",
"     143",
"    </a>",
"    ], which could affect interpretation of a borderline test. The patient should be informed in advance that she might need to repeat the test if this happens so she can make an informed decision about breastfeeding during the test versus planning the test at a",
"    <span class=\"nowrap\">",
"     time/later",
"    </span>",
"    date when breastfeeding can be avoided.",
"   </p>",
"   <p>",
"    An abnormal fasting blood glucose level is diagnostic (diabetes if &ge;126",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    impaired fasting glucose (IFG) if 100 to 125",
"    <span class=\"nowrap\">",
"     mg/dL);",
"    </span>",
"    however, sensitivity for diagnosis of diabetes is low. Impaired glucose tolerance (IGT) is diagnosed if the two-hour value is 140 to 199",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Collectively, IFG and IGT are known as &ldquo;prediabetes.&rdquo;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with an abnormal oral glucose tolerance test are then classified as having prediabetes or overt diabetes mellitus (",
"      <a class=\"graphic graphic_table graphicRef61853 \" href=\"mobipreview.htm?28/3/28731\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef82479 \" href=\"mobipreview.htm?1/61/2011\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"       \"Diagnosis of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Those with prediabetes should be counseled about their subsequent risk for developing overt diabetes and referred for discussion of management options (eg, lifetime modification such as medical nutritional therapy, indications for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      ). They should try to achieve their ideal body weight through diet and exercise and, if possible, they should avoid drugs that may adversely affect glucose tolerance (eg, glucocorticoids). They should have yearly assessment of glycemic status. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A woman who has overt diabetes mellitus should receive appropriate education and treatment. She should also be given advice regarding contraception and the planning of future pregnancies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"       \"Overview of medical care in adults with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with prediabetes or overt diabetes should be counseled regarding the importance of good metabolic control prior to any future pregnancies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=see_link\">",
"       \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with normal glucose tolerance should be counseled regarding their risk of developing GDM in subsequent pregnancies and type 2 diabetes in the future. Lifestyle interventions (weight loss, exercise) are clearly beneficial for reducing the incidence of these disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/144,145\">",
"       144,145",
"      </a>",
"      ]. Drug therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      ) also may have a role in preventing future type 2 diabetes. In a multicenter randomized trial, both intensive lifestyle and metformin therapy reduced the incidence of future diabetes by approximately 50 percent compared to placebo in women with a history of GDM; metformin was much less effective than lifestyle intervention in parous women without previous GDM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/62/37866/abstract/145\">",
"       145",
"      </a>",
"      ]. This topic is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term follow-up is essential. Reassessment of glycemic status should be undertaken at a minimum of every three years, but the best means of follow-up has not been defined. More frequent assessment may be important in women who may become pregnant again, since early detection of diabetes is important to preconception and early prenatal care. The 75-g oral two-hour glucose tolerance test is the more sensitive test for diagnosis of diabetes and impaired glucose tolerance in most populations, but the fasting blood glucose is more convenient, specific, and reproducible, and less expensive. Glycated hemoglobin (A1C) is convenient and the preferred test for patients who have not fasted overnight. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link&amp;anchor=H6#H6\">",
"     \"Screening for diabetes mellitus\", section on 'Screening tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women who did not undergo screening for GDM, but diabetes is suspected postpartum because of infant outcome, postpartum glucose tolerance testing may be considered. However, a negative postpartum GTT only excludes the presence of type 1 or type 2 diabetes or prediabetes at the time of the test; it does not exclude the possibility that glucose impairment was present in association with the metabolic changes occurring during the pregnancy itself. Indications for screening and screening tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/46/12002?source=see_link\">",
"       \"Patient information: Gestational diabetes (diabetes that starts during pregnancy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/13/32979?source=see_link\">",
"       \"Patient information: Gestational diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that women with gestational diabetes mellitus receive treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Randomized trials have shown that a program of medical nutritional therapy, self-monitoring of blood glucose levels, and insulin therapy, when needed, improves perinatal outcome (reduction in preeclampsia, macrosomia, shoulder dystocia). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical nutritional therapy is the initial approach. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nutritional therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Calories are generally divided over three meals and two to four snacks and are composed of about 40 percent carbohydrate, 20 percent protein, and 40 percent fat.",
"     </li>",
"     <li>",
"      Self blood glucose monitoring should be performed to evaluate the effectiveness of medical nutritional therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Glucose monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend a program of moderate exercise as part of the treatment plan for women with no medical or obstetrical contraindications to this level of physical activity (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend initiating insulin therapy in women who do not achieve adequate glycemic control with nutritional therapy and exercise alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Insulin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest administering insulin when fasting blood glucose concentration is &ge;95",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or one-hour postprandial blood glucose concentration is &ge;130 to 140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.2 to 7.8",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      or two-hour glucose is &gt;120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on two or more occasions within a one-week interval despite dietary therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucose target'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who require insulin therapy, we suggest monitoring glucose upon awakening and one or two hours after each meal to guide medical management (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Our goal for fasting blood glucose concentration is &lt;95",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and for one-hour postprandial blood glucose concentration the goal is &lt;130 to 140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.2 to 7.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and for two hours postprandial &lt;120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Timing and frequency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest insulin rather than oral anti-hyperglycemic agents during pregnancy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Oral anti-hyperglycemic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During labor and delivery, we suggest maintaining maternal blood glucose concentration between 70 and 90",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.9 and 5",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This can often be achieved without administration of insulin. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Peripartum management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with gestational diabetes are at increased risk of developing diabetes after pregnancy. We suggest they be tested postpartum and that they receive screening at least every three years thereafter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Future risks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/1\">",
"      Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol 2005; 192:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/2\">",
"      Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/3\">",
"      Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/4\">",
"      Alwan N, Tuffnell DJ, West J. Treatments for gestational diabetes. Cochrane Database Syst Rev 2009; :CD003395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/5\">",
"      Sermer M, Naylor CD, Gare DJ, et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecol 1995; 173:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/6\">",
"      Walters BN. Treatment for mild gestational diabetes. N Engl J Med 2010; 362:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/7\">",
"      Gillman MW, Oakey H, Baghurst PA, et al. Effect of treatment of gestational diabetes mellitus on obesity in the next generation. Diabetes Care 2010; 33:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/8\">",
"      Vohr BR, McGarvey ST, Tucker R. Effects of maternal gestational diabetes on offspring adiposity at 4-7 years of age. Diabetes Care 1999; 22:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/9\">",
"      Silverman BL, Rizzo TA, Cho NH, Metzger BE. Long-term effects of the intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Diabetes Care 1998; 21 Suppl 2:B142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/10\">",
"      Han S, Crowther, CA, et al. Different types of dietary advice for women with gestational diabetes mellitus. Cochrane Database Syst Rev 2013; :CD009275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/11\">",
"      Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2003; 26 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     The Art and Science of Diabetes Self-Management Education, Mensing, C (Eds), American Association of Diabetes Educators, 2006. p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/13\">",
"      Peterson CM, Jovanovic-Peterson L. Percentage of carbohydrate and glycemic response to breakfast, lunch, and dinner in women with gestational diabetes. Diabetes 1991; 40 Suppl 2:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/14\">",
"      Moses RG, Barker M, Winter M, et al. Can a low-glycemic index diet reduce the need for insulin in gestational diabetes mellitus? A randomized trial. Diabetes Care 2009; 32:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/15\">",
"      Louie JC, Markovic TP, Perera N, et al. A randomized controlled trial investigating the effects of a low-glycemic index diet on pregnancy outcomes in gestational diabetes mellitus. Diabetes Care 2011; 34:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/16\">",
"      Grant SM, Wolever TM, O'Connor DL, et al. Effect of a low glycaemic index diet on blood glucose in women with gestational hyperglycaemia. Diabetes Res Clin Pract 2011; 91:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/17\">",
"      Walsh JM, McGowan CA, Mahony R, et al. Low glycaemic index diet in pregnancy to prevent macrosomia (ROLO study): randomised control trial. BMJ 2012; 345:e5605.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board, Committee on Nutritional Status During Pregnancy, part I: Nutritional Status and Weight Gain. National Academy Press, Washington DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/19\">",
"      Cheng YW, Chung JH, Kurbisch-Block I, et al. Gestational weight gain and gestational diabetes mellitus: perinatal outcomes. Obstet Gynecol 2008; 112:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/20\">",
"      Jovanovic-Peterson L, Peterson, CM. Nutritional management of the obese pregnant woman. Nutrition and the MD 1991; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/21\">",
"      HAPO Study Cooperative Research Group. Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: associations with maternal body mass index. BJOG 2010; 117:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/22\">",
"      Catalano PM, McIntyre HD, Cruickshank JK, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care 2012; 35:780.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Gestational Diabetes. ACOG practice bulletin #30, American College of Obstetricians and Gynecologists, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/24\">",
"      Knopp RH, Magee MS, Raisys V, Benedetti T. Metabolic effects of hypocaloric diets in management of gestational diabetes. Diabetes 1991; 40 Suppl 2:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/25\">",
"      American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2004; 27 Suppl 1:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/26\">",
"      Major CA, Henry MJ, De Veciana M, Morgan MA. The effects of carbohydrate restriction in patients with diet-controlled gestational diabetes. Obstet Gynecol 1998; 91:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/27\">",
"      Jovanovic-Peterson L, Peterson CM. Nutritional management of the obese gestational diabetic pregnant woman. J Am Coll Nutr 1992; 11:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/28\">",
"      Jovanovic-Peterson L, Peterson CM. Dietary manipulation as a primary treatment strategy for pregnancies complicated by diabetes. J Am Coll Nutr 1990; 9:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/29\">",
"      Walkinshaw SA. Dietary regulation for 'gestational diabetes'. Cochrane Database Syst Rev 2000; :CD000070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/30\">",
"      Schrader HM, Jovanovic-Peterson L, Bevier WC, Peterson CM. Fasting plasma glucose and glycosylated plasma protein at 24 to 28 weeks of gestation predict macrosomia in the general obstetric population. Am J Perinatol 1995; 12:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/31\">",
"      Bevier WC, Fischer R, Jovanovic L. Treatment of women with an abnormal glucose challenge test (but a normal oral glucose tolerance test) decreases the prevalence of macrosomia. Am J Perinatol 1999; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/32\">",
"      Scholl TO, Sowers M, Chen X, Lenders C. Maternal glucose concentration influences fetal growth, gestation, and pregnancy complications. Am J Epidemiol 2001; 154:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/33\">",
"      Parretti E, Mecacci F, Papini M, et al. Third-trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies: correlation with sonographic parameters of fetal growth. Diabetes Care 2001; 24:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/34\">",
"      Jensen DM, Korsholm L, Ovesen P, et al. Adverse pregnancy outcome in women with mild glucose intolerance: is there a clinically meaningful threshold value for glucose? Acta Obstet Gynecol Scand 2008; 87:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/35\">",
"      HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/36\">",
"      Pettitt DJ, McKenna S, McLaughlin C, et al. Maternal glucose at 28 weeks of gestation is not associated with obesity in 2-year-old offspring: the Belfast Hyperglycemia and Adverse Pregnancy Outcome (HAPO) family study. Diabetes Care 2010; 33:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/37\">",
"      Han S, Crowther CA, Middleton P. Interventions for pregnant women with hyperglycaemia not meeting gestational diabetes and type 2 diabetes diagnostic criteria. Cochrane Database Syst Rev 2012; 1:CD009037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/38\">",
"      Hawkins JS, Casey BM, Lo JY, et al. Weekly compared with daily blood glucose monitoring in women with diet-treated gestational diabetes. Obstet Gynecol 2009; 113:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/39\">",
"      Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007; 30 Suppl 2:S251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/40\">",
"      Laird J, McFarland KF. Fasting blood glucose levels and initiation of insulin therapy in gestational diabetes. Endocr Pract 1996; 2:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/41\">",
"      Weisz B, Shrim A, Homko CJ, et al. One hour versus two hours postprandial glucose measurement in gestational diabetes: a prospective study. J Perinatol 2005; 25:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/42\">",
"      Moses RG, Lucas EM, Knights S. Gestational diabetes mellitus. At what time should the postprandial glucose level be monitored? Aust N Z J Obstet Gynaecol 1999; 39:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/43\">",
"      Sivan E, Weisz B, Homko CJ, et al. One or two hours postprandial glucose measurements: are they the same? Am J Obstet Gynecol 2001; 185:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/44\">",
"      Chen R, Yogev Y, Ben-Haroush A, et al. Continuous glucose monitoring for the evaluation and improved control of gestational diabetes mellitus. J Matern Fetal Neonatal Med 2003; 14:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/45\">",
"      Chitayat L, Zisser H, Jovanovic L. Continuous glucose monitoring during pregnancy. Diabetes Technol Ther 2009; 11 Suppl 1:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/46\">",
"      de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/47\">",
"      Nicholson WK, Wilson LM, Witkop CT, et al. Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. Evid Rep Technol Assess (Full Rep) 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/48\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/49\">",
"      Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged? Diabetes Care 2011; 34:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/50\">",
"      Harmon KA, Gerard L, Jensen DR, et al. Continuous glucose profiles in obese and normal-weight pregnant women on a controlled diet: metabolic determinants of fetal growth. Diabetes Care 2011; 34:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/51\">",
"      Durnwald CP, Mele L, Spong CY, et al. Glycemic characteristics and neonatal outcomes of women treated for mild gestational diabetes. Obstet Gynecol 2011; 117:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/52\">",
"      Uvena-Celebrezze J, Fung C, Thomas AJ, et al. Relationship of neonatal body composition to maternal glucose control in women with gestational diabetes mellitus. J Matern Fetal Neonatal Med 2002; 12:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/53\">",
"      Catalano PM, Thomas A, Huston-Presley L, Amini SB. Increased fetal adiposity: a very sensitive marker of abnormal in utero development. Am J Obstet Gynecol 2003; 189:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/54\">",
"      Langer O, Levy J, Brustman L, et al. Glycemic control in gestational diabetes mellitus--how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol 1989; 161:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/55\">",
"      Griffiths RJ, Vinall PS, Stickland MH, Wales JK. Haemoglobin A1c levels in normal and diabetic pregnancies. Eur J Obstet Gynecol Reprod Biol 1987; 24:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/56\">",
"      Jovanovic L, Savas H, Mehta M, et al. Frequent monitoring of A1C during pregnancy as a treatment tool to guide therapy. Diabetes Care 2011; 34:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/57\">",
"      Lurie S, Mamet Y. Red blood cell survival and kinetics during pregnancy. Eur J Obstet Gynecol Reprod Biol 2000; 93:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/58\">",
"      Bunn HF, Haney DN, Kamin S, et al. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976; 57:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/59\">",
"      Stehbens JA, Baker GL, Kitchell M. Outcome at ages 1, 3, and 5 years of children born to diabetic women. Am J Obstet Gynecol 1977; 127:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/60\">",
"      Naeye RL, Chez RA. Effects of maternal acetonuria and low pregnancy weight gain on children's psychomotor development. Am J Obstet Gynecol 1981; 139:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/61\">",
"      Churchill JA, Berendes HW, Nemore J. Neuropsychological deficits in children of diabetic mothers. A report from the Collaborative Sdy of Cerebral Palsy. Am J Obstet Gynecol 1969; 105:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/62\">",
"      Metzger BE, Ravnikar V, Vileisis RA, Freinkel N. \"Accelerated starvation\" and the skipped breakfast in late normal pregnancy. Lancet 1982; 1:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/63\">",
"      Rizzo T, Metzger BE, Burns WJ, Burns K. Correlations between antepartum maternal metabolism and child intelligence. N Engl J Med 1991; 325:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/64\">",
"      Horton ES. Exercise in the treatment of NIDDM. Applications for GDM? Diabetes 1991; 40 Suppl 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/65\">",
"      Pedersen O, Beck-Nielsen H, Heding L. Increased insulin receptors after exercise in patients with insulin-dependent diabetes mellitus. N Engl J Med 1980; 302:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/66\">",
"      Schneider, SH, Ruderman, NB. Exercise and NIDDM. Diabetes Care 1993; 16:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/67\">",
"      Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol 1989; 161:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/68\">",
"      Artal R, Wiswell R, Romem Y. Hormonal responses to exercise in diabetic and nondiabetic pregnant patients. Diabetes 1985; 34 Suppl 2:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/69\">",
"      de Barros MC, Lopes MA, Francisco RP, et al. Resistance exercise and glycemic control in women with gestational diabetes mellitus. Am J Obstet Gynecol 2010; 203:556.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/70\">",
"      Bung P, Artal R, Khodiguian N, Kjos S. Exercise in gestational diabetes. An optional therapeutic approach? Diabetes 1991; 40 Suppl 2:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/71\">",
"      Avery MD, Leon AS, Kopher RA. Effects of a partially home-based exercise program for women with gestational diabetes. Obstet Gynecol 1997; 89:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/72\">",
"      Ceysens G, Rouiller D, Boulvain M. Exercise for diabetic pregnant women. Cochrane Database Syst Rev 2006; :CD004225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/73\">",
"      Carpenter MW. The role of exercise in pregnant women with diabetes mellitus. Clin Obstet Gynecol 2000; 43:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/74\">",
"      Thompson DJ, Porter KB, Gunnells DJ, et al. Prophylactic insulin in the management of gestational diabetes. Obstet Gynecol 1990; 75:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/75\">",
"      Bonomo M, Cetin I, Pisoni MP, et al. Flexible treatment of gestational diabetes modulated on ultrasound evaluation of intrauterine growth: a controlled randomized clinical trial. Diabetes Metab 2004; 30:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/76\">",
"      Kjos SL, Schaefer-Graf U, Sardesi S, et al. A randomized controlled trial using glycemic plus fetal ultrasound parameters versus glycemic parameters to determine insulin therapy in gestational diabetes with fasting hyperglycemia. Diabetes Care 2001; 24:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/77\">",
"      Rossi G, Somigliana E, Moschetta M, et al. Adequate timing of fetal ultrasound to guide metabolic therapy in mild gestational diabetes mellitus. Results from a randomized study. Acta Obstet Gynecol Scand 2000; 79:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/78\">",
"      Buchanan TA, Kjos SL, Montoro MN, et al. Use of fetal ultrasound to select metabolic therapy for pregnancies complicated by mild gestational diabetes. Diabetes Care 1994; 17:275.",
"     </a>",
"    </li>",
"    <li>",
"     Coustan, DR. Management of gestational diabetes. In: Diabetes in Women, Reece, EA, Coustan, DR, Gabbe, SG (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.227.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/80\">",
"      Lewis SB, Wallin JD, Kuzuya H, et al. Circadian variation of serum glucose, C-peptide immunoreactivity and free insulin normal and insulin-treated diabetic pregnant subjects. Diabetologia 1976; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/81\">",
"      Nachum Z, Ben-Shlomo I, Weiner E, Shalev E. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ 1999; 319:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/82\">",
"      Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized controlled trial comparing insulin determir with NPH insulin in 310 pregnant women with type 1 diabetes mellitus. Diabetes Care 2012; :in press.",
"     </a>",
"    </li>",
"    <li>",
"     Hod M, McCance DR, Ivanisevic M, et al. Perinatal Outcomes in a Randomized Trial Comparing Insulin Detemir with NPH Insulin in 310 Pregnant Women with Type 1.  Abstract 62-LB. American Diabetes Association. 71st Scientific Sessions. June 24 - 28, 2011 San Diego Convention Center - San Diego, California",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/84\">",
"      Pollex EK, Feig DS, Lubetsky A, et al. Insulin glargine safety in pregnancy: a transplacental transfer study. Diabetes Care 2010; 33:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/85\">",
"      Jovanovic L, Pettitt DJ. Treatment with insulin and its analogs in pregnancies complicated by diabetes. Diabetes Care 2007; 30 Suppl 2:S220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/86\">",
"      Nicholson W, Bolen S, Witkop CT, et al. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol 2009; 113:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/87\">",
"      Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203:457.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/88\">",
"      Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991; 165:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/89\">",
"      Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/90\">",
"      Elliott BD, Schenker S, Langer O, et al. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol 1994; 171:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/91\">",
"      Hebert MF, Ma X, Naraharisetti SB, et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009; 85:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/92\">",
"      Lim JM, Tayob Y, O'Brien PM, Shaw RW. A comparison between the pregnancy outcome of women with gestation diabetes treated with glibenclamide and those treated with insulin. Med J Malaysia 1997; 52:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/93\">",
"      Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol 2004; 190:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/94\">",
"      Langer O, Yogev Y, Xenakis EM, Rosenn B. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol 2005; 192:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/95\">",
"      Yogev Y, Ben-Haroush A, Chen R, et al. Undiagnosed asymptomatic hypoglycemia: diet, insulin, and glyburide for gestational diabetic pregnancy. Obstet Gynecol 2004; 104:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/96\">",
"      Jacobson GF, Ramos GA, Ching JY, et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005; 193:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/97\">",
"      Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet Gynecol 2003; 102:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/98\">",
"      Saade G. Gestational diabetes mellitus: a pill or a shot? Obstet Gynecol 2005; 105:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/99\">",
"      Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med 2004; 15:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/100\">",
"      Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol 2006; 195:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/101\">",
"      Lain KY, Garabedian MJ, Daftary A, Jeyabalan A. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol 2009; 200:501.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/102\">",
"      Kraemer J, Klein J, Lubetsky A, Koren G. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol 2006; 195:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/103\">",
"      Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/104\">",
"      Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol 2010; 115:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/105\">",
"      Ij&auml;s H, V&auml;&auml;r&auml;sm&auml;ki M, Morin-Papunen L, et al. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. BJOG 2011; 118:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/106\">",
"      Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/107\">",
"      Glueck CJ, Pranikoff J, Aregawi D, Wang P. Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril 2008; 89:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/108\">",
"      Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010; 95:E448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/109\">",
"      Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005; 83:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/110\">",
"      Rowan JA, Rush EC, Obolonkin V, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care 2011; 34:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/111\">",
"      Barbour LA, Van Pelt RE, Brumbaugh DE, et al. Comment on: Rowan et al. Metformin in Gestational diabetes: The Offspring Follow-Up (MiG TOFU): body composition at 2 years of age. Diabetes Care 2011;34:2279-2284. Diabetes Care 2012; 35:e28; author reply e30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/112\">",
"      Feig DS, Moses RG. Metformin therapy during pregnancy: good for the goose and good for the gosling too? Diabetes Care 2011; 34:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/113\">",
"      Silverman BL, Rizzo T, Green OC, et al. Long-term prospective evaluation of offspring of diabetic mothers. Diabetes 1991; 40 Suppl 2:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/114\">",
"      Garcia-Bournissen F, Feig DS, Koren G. Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet 2003; 42:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/115\">",
"      Kemball ML, McIver C, Milner RD, et al. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child 1970; 45:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/116\">",
"      Zucker P, Simon G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics 1968; 42:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/117\">",
"      Chan LY, Yeung JH, Lau TK. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril 2005; 83:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/118\">",
"      Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/119\">",
"      Philipson EH, Super DM. Gestational diabetes mellitus: does it recur in subsequent pregnancy? Am J Obstet Gynecol 1989; 160:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/120\">",
"      Moses RG. The recurrence rate of gestational diabetes in subsequent pregnancies. Diabetes Care 1996; 19:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/121\">",
"      MacNeill S, Dodds L, Hamilton DC, et al. Rates and risk factors for recurrence of gestational diabetes. Diabetes Care 2001; 24:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/122\">",
"      Getahun D, Fassett MJ, Jacobsen SJ. Gestational diabetes: risk of recurrence in subsequent pregnancies. Am J Obstet Gynecol 2010; 203:467.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/123\">",
"      Catalano PM, Vargo KM, Bernstein IM, Amini SB. Incidence and risk factors associated with abnormal postpartum glucose tolerance in women with gestational diabetes. Am J Obstet Gynecol 1991; 165:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/124\">",
"      Kjos SL, Buchanan TA, Greenspoon JS, et al. Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitus in the first two months post partum. Am J Obstet Gynecol 1990; 163:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/125\">",
"      Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/126\">",
"      Feig DS, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. CMAJ 2008; 179:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/127\">",
"      Cheung NW, Byth K. Population health significance of gestational diabetes. Diabetes Care 2003; 26:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/128\">",
"      Baptiste-Roberts K, Barone BB, Gary TL, et al. Risk factors for type 2 diabetes among women with gestational diabetes: a systematic review. Am J Med 2009; 122:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/129\">",
"      Dornhorst A, Bailey PC, Anyaoku V, et al. Abnormalities of glucose tolerance following gestational diabetes. Q J Med 1990; 77:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/130\">",
"      O'Sullivan JB. Diabetes mellitus after GDM. Diabetes 1991; 40 Suppl 2:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/131\">",
"      O'Sullivan JB. Body weight and subsequent diabetes mellitus. JAMA 1982; 248:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/132\">",
"      Stangenberg M, Agarwal N, Rahman F, et al. Frequency of HLA genes and islet cell antibodies (ICA) and result of postpartum oral glucose tolerance tests (OGTT) in Saudi Arabian women with abnormal OGTT during pregnancy. Diabetes Res 1990; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/133\">",
"      Damm P, K&uuml;hl C, Bertelsen A, M&oslash;lsted-Pedersen L. Predictive factors for the development of diabetes in women with previous gestational diabetes mellitus. Am J Obstet Gynecol 1992; 167:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/134\">",
"      L&ouml;bner K, Knopff A, Baumgarten A, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 2006; 55:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/135\">",
"      Russell C, Dodds L, Armson BA, et al. Diabetes mellitus following gestational diabetes: role of subsequent pregnancy. BJOG 2008; 115:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/136\">",
"      Ferber KM, Keller E, Albert ED, Ziegler AG. Predictive value of human leukocyte antigen class II typing for the development of islet autoantibodies and insulin-dependent diabetes postpartum in women with gestational diabetes. J Clin Endocrinol Metab 1999; 84:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/137\">",
"      Mauricio D, Balsells M, Morales J, et al. Islet cell autoimmunity in women with gestational diabetes and risk of progression to insulin-dependent diabetes mellitus. Diabetes Metab Rev 1996; 12:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/138\">",
"      J&auml;rvel&auml; IY, Juutinen J, Koskela P, et al. Gestational diabetes identifies women at risk for permanent type 1 and type 2 diabetes in fertile age: predictive role of autoantibodies. Diabetes Care 2006; 29:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/139\">",
"      Shah BR, Retnakaran R, Booth GL. Increased risk of cardiovascular disease in young women following gestational diabetes mellitus. Diabetes Care 2008; 31:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/140\">",
"      Carr DB, Utzschneider KM, Hull RL, et al. Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes. Diabetes Care 2006; 29:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/141\">",
"      Retnakaran R, Shah BR. Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study. CMAJ 2009; 181:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/142\">",
"      Committee on Obstetric Practice. ACOG Committee Opinion No. 435: postpartum screening for abnormal glucose tolerance in women who had gestational diabetes mellitus. Obstet Gynecol 2009; 113:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/143\">",
"      Gunderson EP, Crites Y, Chiang V, et al. Influence of breastfeeding during the postpartum oral glucose tolerance test on plasma glucose and insulin. Obstet Gynecol 2012; 120:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/144\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/62/37866/abstract/145\">",
"      Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; 93:4774.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6790 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37866=[""].join("\n");
var outline_f36_62_37866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NUTRITIONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nutritional therapy to decrease the risk of macrosomia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GLUCOSE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Timing and frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucose target",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glycated hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MONITORING FOR KETONURIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Type of insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Oral anti-hyperglycemic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Glyburide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18999792\">",
"      - Metformin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19000274\">",
"      - Tolbutamide and chlorpropamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PERIPARTUM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6998924\">",
"      Pregnancy issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Glucose control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      FUTURE RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Long-term risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Follow-up and prevention of type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6790|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/34/20013\" title=\"table 1\">",
"      WHO MEC for patients with endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/3/28731\" title=\"table 2\">",
"      ADA criteria for diagnosis diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/61/2011\" title=\"table 3\">",
"      Categories of increased risk for diabetes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/29/4568?source=related_link\">",
"      Anatomical and physiological changes of pregnancy and exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/29/2519?source=related_link\">",
"      Intrapartum and postpartum management of insulin and blood glucose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4313?source=related_link\">",
"      Obstetrical management of pregnancies complicated by gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/46/12002?source=related_link\">",
"      Patient information: Gestational diabetes (diabetes that starts during pregnancy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/13/32979?source=related_link\">",
"      Patient information: Gestational diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/30/7657?source=related_link\">",
"      Recommendations for exercise during pregnancy and the postpartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_62_37867="Causes subclin hypothyroid";
var content_f36_62_37867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of subclinical hypothyroidism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Chronic autoimmune thyroiditis (risk factors: family history of autoimmune thyroid disease, personal or family history of associated autoimmune disorders, Down syndrome, Turner's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent TSH increase in subacute thyroiditis, postpartum thyroiditis, painless thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid injury: partial thyroidectomy or other neck surgery, radioactive iodine therapy, external radiotherapy of the head and neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs impairing thyroid function: iodine and iodine-containing medications (amiodarone, radiographic contrast agents), lithium carbonate, cytokines (especially interferon &alpha;), aminoglutetimide, ethionamide, sulfonamides, and sulfonylureas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate replacement therapy for overt hypothyroidism (inadequate dosage, noncompliance, drug interactions [iron, calcium carbonate, cholestyramine, dietary soy, fiber, etc.], increased T",
"        <sub>",
"         4",
"        </sub>",
"        clearance [phenytoin, carbamazepine, phenobarbital, etc.], malabsorption)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid infiltration (amyloidosis, sarcoidosis, hemochromatosis, Riedel's thyroiditis, cystinosis, AIDS, primary thyroid lymphoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central hypothyroidism with impaired TSH bioactivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxic substances, industrial and environmental agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TSH receptor gene mutations; G&alpha; gene mutations",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008; 29:76. file://edrv.endojournals.org. Copyright &copy; 2008 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37867=[""].join("\n");
var outline_f36_62_37867=null;
var title_f36_62_37868="Human TCR beta chain";
var content_f36_62_37868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Organization of the human T cell receptor beta chain locus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 114px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are ~75 V beta genes, two D beta genes, six J beta 1 and seven J beta 2 genes, and two C beta genes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Leiden JM. Transcriptional regulation of T cell receptor genes. Annu Rev Immunol 1993; 11:539.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37868=[""].join("\n");
var outline_f36_62_37868=null;
var title_f36_62_37869="PCR technique";
var content_f36_62_37869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymerase chain reaction (PCR)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 609px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the polymerase chain reaction (PCR), unamplified target DNA (red and black strands at top) is separated into two single strands by heating. Next, primers (green and blue arrows) anneal to the opposite DNA strands of the desired target sequence. The complementary strand is then synthesized (longer blue and green arrows). Subsequent cycles of strand separation (denaturing), primer hybridization (annealing), and strand synthesis (extension) ensure exponential amplification of the target sequence by using the amplified sequences of the previous cycle as a new template (as shown in the Second PCR cycle). The target PCR product, which consists of approximately 10(6) copies after 30 cycles, is shown at the bottom of the figure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37869=[""].join("\n");
var outline_f36_62_37869=null;
var title_f36_62_37870="Contents: Treatment issues rheumatology";
var content_f36_62_37870=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Treatment issues rheumatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Treatment issues rheumatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Alkylating agents",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/40/16008\">",
"           General principles of the use of cyclophosphamide in rheumatic and renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/32/25098\">",
"           General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Biologic response modifying therapies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/19/3384\">",
"           Overview of biologic agents in the rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/50/10025\">",
"           Role of cytokines in rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/55/40825\">",
"           Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/4/2120\">",
"           Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/53/33624\">",
"           Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complementary and alternative therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/27/7607\">",
"           Acupuncture for rheumatic conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/21/7513\">",
"           Complementary and alternative remedies in rheumatic disorders",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disease modifying antirheumatic drugs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/9/43161\">",
"           Antimalarial drugs in the treatment of rheumatic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/22/16746\">",
"           Cytokine networks in rheumatic diseases: Implications for therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Glucocorticoids",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/61/31703\">",
"           Determinants of glucocorticoid dosing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/37/28249\">",
"           Glucocorticoid effects on the immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/37/22103\">",
"           Glucocorticoid withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/14/30951\">",
"           Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Immunosuppressive agents",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/28/457\">",
"           Effects of antiinflammatory and immunosuppressive drugs on gonadal function in men with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/40/16008\">",
"           General principles of the use of cyclophosphamide in rheumatic and renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/32/25098\">",
"           General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/50/2855\">",
"           Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/38/33382\">",
"           Overview of the use of immunosuppressive and disease-modifying drugs in the rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/63/10232\">",
"           Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/27/28090\">",
"           Pharmacology and side effects of cyclosporine and tacrolimus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/59/38842\">",
"           Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint and soft tissue injections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28564\">",
"           Joint aspiration or injection in adults: Complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/52/23368\">",
"           Joint aspiration or injection in adults: Technique and indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/31/28148\">",
"           Joint aspiration: The dry tap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/31/44536\">",
"           Musculoskeletal ultrasonography: Guided injection and aspiration of joints and related structures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint replacement surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/39/1658\">",
"           Complications of total hip arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/32/16902\">",
"           Complications of total knee arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/55/10106\">",
"           Total hip arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/6/17514\">",
"           Total knee arthroplasty",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nonpharmacologic approaches",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/27/7607\">",
"           Acupuncture for rheumatic conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28565\">",
"           Synovectomy for inflammatory arthritis of the knee",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nonsteroidal antiinflammatory drugs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/47/2807\">",
"           Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/27/39351\">",
"           COX-2 selective inhibitors: Adverse cardiovascular effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/19/1336\">",
"           NSAIDs: Mechanism of action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/36/5703\">",
"           NSAIDs: Therapeutic use and variability of response in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/4/24648\">",
"           Nonselective NSAIDs: Adverse cardiovascular effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/49/17177\">",
"           Nonselective NSAIDs: Overview of adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/48/13066\">",
"           Overview of selective COX-2 inhibitors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other pharmacologic approaches",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/35/566\">",
"           Miscellaneous novel therapies in rheumatoid arthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/59/38842\">",
"           Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychosocial factors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/19/41273\">",
"           Psychosocial factors and rheumatic disease",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-EBF5F5E4E0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f36_62_37870=[""].join("\n");
var outline_f36_62_37870=null;
var title_f36_62_37871="Uterus didelphys and hemivagina";
var content_f36_62_37871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus didelphys with obstructed hemivagina with ipsolateral renal agenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_62_37871=[""].join("\n");
var outline_f36_62_37871=null;
